var title_f39_44_40640="Mood disorders brain PI";
var content_f39_44_40640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Mood disorders caused by problems in the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mood disorders, such as depression and bipolar disorder, are caused by chemical imbalances in the brain. Treatments for these conditions work by changing the chemistry of the brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40640=[""].join("\n");
var outline_f39_44_40640=null;
var title_f39_44_40641="Vaginal discharge in adult women";
var content_f39_44_40641=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaginal discharge in adult women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40641/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40641/contributors\" id=\"au4223\">",
"       Jack D Sobel, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40641/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40641/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40641/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40641/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/44/40641?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal discharge is the term for fluid or mucus that comes from the vagina. Vaginal discharge is a common concern among women, and leads many women to see their healthcare provider. Some amount of vaginal discharge is normal, unless it occurs with itching, burning, or other bothersome symptoms. Most experts recommend an examination to determine the cause because different causes can have similar symptoms.",
"    </p>",
"    <p>",
"     This topic will review the signs of normal and abnormal vaginal discharge, including the most common causes of abnormal discharge. Topics that discuss specific conditions that cause abnormal vaginal discharge are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=see_link\">",
"      \"Patient information: Vaginal yeast infection (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=see_link\">",
"      \"Patient information: Bacterial vaginosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      \"Patient information: Chlamydia (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      \"Patient information: Gonorrhea (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FEMALE ANATOMY",
"     </span>",
"    </p>",
"    <p>",
"     Before discussing vaginal discharge, it is important to have a basic understanding of the female reproductive anatomy (",
"     <a class=\"graphic graphic_figure graphicRef53704 \" href=\"mobipreview.htm?0/10/160\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Vaginal discharge is not usually noticeable until it exits the vagina, which is the passage from the uterus to the outside of the body. At the top end (inside) of the vagina is the cervix, while the lower end (outside) leads to the vulva and labia. The vulva is the name for the skin around the vaginal opening.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      IS MY VAGINAL DISCHARGE NORMAL?",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal discharge is made by the skin cells of the vagina and cervix under the influence of the female hormone, estrogen. Women who are menopausal normally have minimal vaginal discharge as a result of lower levels of estrogen.",
"    </p>",
"    <p>",
"     In women who are premenopausal, it is normal to have about one-half to one teaspoon (2 to 5 mL) of white or clear, thick, mucus-like, and mostly odorless vaginal discharge every day. However, the amount and consistency of the discharge varies from one woman to another. The amount can also vary at different times during the menstrual cycle. It may become more noticeable at certain times, such as during pregnancy, with use of birth control",
"     <span class=\"nowrap\">",
"      pills/patch/vaginal",
"     </span>",
"     ring, near ovulation, and in the week before the menstrual period.",
"    </p>",
"    <p>",
"     Normally, discharge contains vaginal skin cells, bacteria, and mucus and fluid produced by the vagina and cervix. A normal discharge often has a slight odor and may cause mild irritation of the vulva. This discharge helps to protect the vaginal and urinary tract against infections and provides lubrication to the vaginal tissues.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP FOR VAGINAL DISCHARGE",
"     </span>",
"    </p>",
"    <p>",
"     Vaginal discharge is common and normal. However, vaginal discharge with the following signs and symptoms is not normal and should be evaluated by a healthcare provider:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Itching of the vulva, vaginal opening, or labia",
"      </li>",
"      <li>",
"       Redness, burning, soreness, or swelling of the vulvar skin",
"      </li>",
"      <li>",
"       Foamy or greenish-yellow discharge",
"      </li>",
"      <li>",
"       Bad odor",
"      </li>",
"      <li>",
"       Blood-tinged vaginal discharge",
"      </li>",
"      <li>",
"       Pain with intercourse or urination",
"      </li>",
"      <li>",
"       Abdominal or pelvic pain",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CAUSES OF ABNORMAL VAGINAL DISCHARGE",
"     </span>",
"    </p>",
"    <p>",
"     The most common causes of vaginal discharge include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A vaginal infection (yeast or bacterial infection, trichomonas)",
"      </li>",
"      <li>",
"       The body's reaction to a foreign body (such as a forgotten tampon or condom) or substance (such as spermicide, soap).",
"      </li>",
"      <li>",
"       Changes that occur after menopause can cause vaginal dryness, especially during sex, as well as a watery vaginal discharge or other symptoms. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37876?source=see_link\">",
"        \"Desquamative inflammatory vaginitis\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Do I need to be examined?",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not usually possible to know if vaginal discharge is normal or not without an examination. A physical examination is the most accurate way of determining the cause of abnormal vaginal discharge. Do not begin treatment at home before being examined because self-treatment can make it more difficult to make an accurate diagnosis.",
"    </p>",
"    <p>",
"     Before the examination, the healthcare provider may ask questions, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Do you have pain in the back, abdomen, or pelvis?",
"      </li>",
"      <li>",
"       Do you have a new sexual partner?",
"      </li>",
"      <li>",
"       When was your last menstrual period?",
"      </li>",
"      <li>",
"       Do you take any medications (prescription, herbal, non-prescription)?",
"      </li>",
"      <li>",
"       Have you recently used pads, tampons, douches, \"feminine hygiene\" products, or lubricants?",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     During the examination, the healthcare provider will examine the entire outer genital area and will perform an internal examination.",
"     <span class=\"nowrap\">",
"      He/she",
"     </span>",
"     will take a sample of the discharge to test for infection. It is useful for the provider to measure the pH or acidity of the secretions; bacterial vaginosis and trichomoniasis cause the pH to be higher than normal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, it is possible to make a diagnosis and begin treatment immediately, based upon the examination. In other cases, the provider may recommend delaying treatment until test results are available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=see_link\">",
"      \"Patient information: Vaginal yeast infection (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=see_link\">",
"      \"Patient information: Bacterial vaginosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Sexual partners of women with a sexually transmitted infection, such as chlamydia, gonorrhea, or trichomonas, need evaluation and treatment. For other infections, such as yeast or bacterial vaginosis, the sexual partner does not need treatment. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      \"Patient information: Chlamydia (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      \"Patient information: Gonorrhea (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If treatment is needed, you should avoid having intercourse until the treatment is completed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Can I treat myself?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many women would prefer to avoid seeing their healthcare provider. However, self-treatment can delay getting the correct diagnosis, be costly, or even cause worsened symptoms. In most cases, a physical examination should be performed before any treatment is used. In particular, you should not douche to get rid of the discharge because douching can make the discharge worse if it is due to an infection.",
"    </p>",
"    <p>",
"     Women who develop bacterial or yeast infections frequently may be advised to use a preventive treatment. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=see_link\">",
"      \"Patient information: Vaginal yeast infection (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=see_link\">",
"      \"Patient information: Bacterial vaginosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HEALTHY HYGIENE",
"     </span>",
"    </p>",
"    <p>",
"     Abnormal vaginal discharge may be more likely to develop in women who practice certain habits, such as those who use:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Douches",
"      </li>",
"      <li>",
"       Pantyliners every day",
"      </li>",
"      <li>",
"       \"Feminine hygiene\" sprays, powders, or rinses",
"      </li>",
"      <li>",
"       Bubble baths or other scented bath products",
"      </li>",
"      <li>",
"       Tight or restrictive synthetic clothing (eg, thongs, synthetic underwear)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Healthier practices include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use water or unscented non-soap cleanser to wash genitalia, use warm (not hot) water and the hand (not a washcloth)",
"      </li>",
"      <li>",
"       Do not douche or use feminine hygiene products; if odor or discharge is bothersome, see a healthcare provider",
"      </li>",
"      <li>",
"       Avoid hot baths with scented products; plain warm water is preferred",
"      </li>",
"      <li>",
"       Wear cotton underwear; avoid thongs and lycra underwear",
"      </li>",
"      <li>",
"       Rinse genitals with water",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       pat dry after toileting; avoid use of baby wipes or scented toilet paper",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785056738\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11566641\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33570?source=see_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/1/14354?source=see_link\">",
"      Patient information: Vaginal yeast infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/56/22402?source=see_link\">",
"      Patient information: Bacterial vaginosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/62/8162?source=see_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/2/13346?source=see_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/61/10195?source=see_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/54/33634?source=see_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/40/33411?source=see_link\">",
"      Patient information: Vaginal cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11566699\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/53/2899?source=see_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/43/36529?source=see_link\">",
"      Patient information: Bacterial vaginosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link\">",
"      Bacterial vaginosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15386?source=see_link\">",
"      Candida vulvovaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"      Acute cervicitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37876?source=see_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36633?source=see_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link\">",
"      Trichomonas vaginalis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003158.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003158.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://kidshealth.org/\">",
"        KidsHealth.org",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/teen/sexual_health/girls/vdischarge2.html\">",
"      file://kidshealth.org/teen/sexual_health/girls/vdischarge2.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/health/vaginal-discharge/MY00097\">",
"      www.mayoclinic.com/health/vaginal-discharge/MY00097",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/44/40641/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/44/40641?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40641/abstract/1\">",
"      Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40641/abstract/2\">",
"      Nyirjesy P, Peyton C, Weitz MV, et al. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol 2006; 108:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40641/abstract/3\">",
"      Anderson M, Karasz A, Friedland S. Are vaginal symptoms ever normal? a review of the literature. MedGenMed 2004; 6:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_44_40641=[""].join("\n");
var outline_f39_44_40641=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FEMALE ANATOMY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           IS MY VAGINAL DISCHARGE NORMAL?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHEN TO SEEK HELP FOR VAGINAL DISCHARGE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CAUSES OF ABNORMAL VAGINAL DISCHARGE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HEALTHY HYGIENE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/10/160\" title=\"figure 1\">",
"           Female external genitalia  PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40642="Patient information: Spinal stenosis (The Basics)";
var content_f39_44_40642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17110\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/51/4917\">",
"         Anatomy of the back",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/16/11522\">",
"         Patient information: Cauda equina syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/16/33026\">",
"         Patient information: Do I need imaging for low back pain? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/7/36978\">",
"         Patient information: Low back pain in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8950\">",
"         Patient information: Low back pain in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Spinal stenosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/spinal-stenosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27462479\">",
"      <span class=\"h1\">",
"       What is spinal stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Spinal stenosis is a back condition that can cause pain, numbness, or tingling in the back or down the legs.",
"     </p>",
"     <p>",
"      To understand more about spinal stenosis and how it causes symptoms, it&rsquo;s helpful to first know a little about the back and spine.",
"     </p>",
"     <p>",
"      The back is made up of (",
"      <a class=\"graphic graphic_figure graphicRef56246 \" href=\"mobipreview.htm?4/51/4917\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vertebrae &ndash; A stack of bones that sit on top of one another like a stack of coins. Each of these bones has a hole in the center. When stacked, the bones form a hollow tube (called the spinal canal) that protects the spinal cord.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Spinal cord and nerves &ndash; The spinal cord is the highway of nerves that connects the brain to the rest of the body. It runs through the vertebrae. Nerves branch from the spinal cord and pass in between the vertebrae. From there they connect to the arms, the legs, and the organs. (This is why problems in the back can cause leg pain or bladder problems.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Discs &ndash; Rubbery discs sit in between each of the vertebrae to add cushion and allow movement.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Muscles, tendons, and ligaments &ndash; Together the muscles, tendons, and ligaments are called the \"soft tissues\" of the back. These soft tissues support the back and help hold the different parts together.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Spinal stenosis is a narrowing of the spinal canal or of the spaces between the vertebrae where spinal nerves pass through. This narrowing is usually caused by arthritis or injury, and can happen when:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The vertebrae can form &ldquo;bone spurs.&rdquo; These are bony growths that pinch the spinal cord or the nerves branching from the spinal cord.",
"       </li>",
"       <li>",
"        The discs can shrink and make the space between the vertebrae smaller. This can cause the vertebrae to pinch the nerves that pass through them. &nbsp; &nbsp; &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      This article will only discuss spinal stenosis in the lower back. This is called &ldquo;lumbar spinal stenosis.&rdquo; Other parts of the back can have spinal stenosis, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462494\">",
"      <span class=\"h1\">",
"       What are the symptoms of a spinal stenosis in the lower back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Spinal stenosis does not always cause symptoms. When it does, the most common symptom is tingling, pain, or numbness that spreads down the legs. These symptoms usually affect both legs, but the symptoms can be worse in 1 leg than the other.",
"     </p>",
"     <p>",
"      Symptoms of spinal stenosis are usually worst when the person is walking or standing upright. Usually, they get better if the person sits down or bends forward at the waist, for example, while leaning over a shopping cart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462509\">",
"      <span class=\"h1\">",
"       Is there a test for spinal stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Imaging tests, such as an MRI or a CT scan, can show what&rsquo;s going on inside the back. These tests can show if a person has bone spurs or other changes that happen with spinal stenosis.",
"     </p>",
"     <p>",
"      In some cases, doctors also order tests called &ldquo;electromyography&rdquo; or &ldquo;nerve conduction studies.&rdquo; These tests measure how well electrical signals travel across the nerves that start in the spine. They can also show how well electrical signals travel from the spine to muscles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462524\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Back or leg pain that is so severe that you cannot find a comfortable position",
"       </li>",
"       <li>",
"        Back or leg pain plus a new problem controlling your bowels or bladder.",
"       </li>",
"       <li>",
"        Back or leg pain plus new numbness or weakness in the legs",
"       </li>",
"       <li>",
"        A problem called &ldquo;foot drop.&rdquo; This is when you have trouble holding foot up, for example, while walking",
"       </li>",
"       <li>",
"        Back or leg pain along with a fever or other symptoms that worry you",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462539\">",
"      <span class=\"h1\">",
"       How is spinal stenosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A small number of people end up needing surgery to treat a spinal stenosis. But most people do well with simpler treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain medicines that you can get without a prescription. If these do not work, doctors and nurses can prescribe stronger pain medicines.",
"       </li>",
"       <li>",
"        Medicines to relax the muscles (called muscle relaxants)",
"       </li>",
"       <li>",
"        Injections of medicines that numb the back or reduce swelling",
"       </li>",
"       <li>",
"        Physical therapy to teach you special exercises and stretches",
"       </li>",
"       <li>",
"        Spinal manipulation, which is when someone like a physical therapist or a chiropractor moves or \"adjusts\" the joints of your back",
"       </li>",
"       <li>",
"        Acupuncture, which is when someone who knows traditional Chinese medicine inserts tiny needles into your body to block pain signals",
"       </li>",
"       <li>",
"        Massage",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462554\">",
"      <span class=\"h1\">",
"       How do I know if surgery is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will tell you if surgery is likely to help you. The two of you can decide together if surgery is right for you.",
"     </p>",
"     <p>",
"      Surgery to treat a spinal stenosis involves exposing the spine and cutting away pieces of bone that are pinching the spinal cord or other nerves. The surgery can help with symptoms, but it is not usually necessary. People can often find ways to cope with their symptoms that do not involve surgery. &nbsp;",
"     </p>",
"     <p>",
"      If your doctor suggests surgery to treat a spinal stenosis, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How likely is that surgery will help my symptoms?",
"       </li>",
"       <li>",
"        How quickly will I recover from surgery?",
"       </li>",
"       <li>",
"        What are the risks of surgery?",
"       </li>",
"       <li>",
"        What happens I do not have surgery? &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, surgeons treating people with spinal stenosis will also decide to join together 2 vertebrae. This is called spinal fusion. Fusion is usually appropriate only for people who have spinal stenosis plus another condition called &ldquo;spondylolisthesis,&rdquo; which is when 2 vertebrae no longer line up with each other. Spinal fusion can involve much more risk and a longer recovery time than regular surgery. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462569\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. One of the most important things you can do to feel better is to stay as active as possible. Even if you have some pain or discomfort, you should not stay in bed or rest too long.",
"     </p>",
"     <p>",
"      People used to think that bedrest was the best treatment for a bad back. The truth is, bedrest can actually make back problems worse. That&rsquo;s because the back can get weak and stiff with too much rest.",
"     </p>",
"     <p>",
"      Find physical activities you like to do. If you have not been active for a while, start by doing just a few minutes of activity a few times a week. Then slowly do more. Also, ask your doctor if there are any activities, such as bending or lifting, that you shouldn&rsquo;t do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27462584\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=see_link\">",
"       Patient information: Low back pain in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11522?source=see_link\">",
"       Patient information: Cauda equina syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/16/33026?source=see_link\">",
"       Patient information: Do I need imaging for low back pain? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=see_link\">",
"       Patient information: Low back pain in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/44/40642?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17110 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40642=[""].join("\n");
var outline_f39_44_40642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462479\">",
"      What is spinal stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462494\">",
"      What are the symptoms of a spinal stenosis in the lower back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462509\">",
"      Is there a test for spinal stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462524\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462539\">",
"      How is spinal stenosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462554\">",
"      How do I know if surgery is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462569\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27462584\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/51/4917\">",
"      Anatomy of the back",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/16/11522?source=related_link\">",
"      Patient information: Cauda equina syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/16/33026?source=related_link\">",
"      Patient information: Do I need imaging for low back pain? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/47/8950?source=related_link\">",
"      Patient information: Low back pain in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/7/36978?source=related_link\">",
"      Patient information: Low back pain in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40643="The common cold in children";
var content_f39_44_40643=[" <h1 id=\"patTopicTitle\">",
"  Patient information: The common cold in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40643/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40643/contributors\" id=\"au6271\">",
"       Diane E Pappas, MD, JD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40643/contributors\" id=\"au6226\">",
"       J Owen Hendley, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40643/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40643/contributors\" id=\"se4583\">",
"       Morven S Edwards, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/44/40643/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40643/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/44/40643?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COMMON COLD OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The common cold is the most common illness in the United States. Infants and children are affected more often and experience more prolonged symptoms than adults. The common cold accounts for approximately 22 million missed days of school and 20 million absences from work, including time away from work caring for ill children.",
"    </p>",
"    <p>",
"     This topic review discusses the causes, symptoms, and treatment of the common cold in children. The common cold in adults is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      \"Patient information: The common cold in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COMMON COLD CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The common cold is a group of symptoms caused by a number of different viruses. There are more than 100 different varieties of rhinovirus, the type of virus responsible for the greatest number of colds. Other viruses that cause colds include enteroviruses (echovirus and coxsackieviruses) and coronavirus. Because there are so many viruses that cause the symptoms of the common cold, people may have multiple colds each year and dozens over a lifetime.",
"    </p>",
"    <p>",
"     Children under six years average six to eight colds per year (up to one per month, September through April), with symptoms lasting an average of 14 days. This means that a child could be ill with intermittent cold symptoms for nearly half of the days in this time period, without cause for concern. Young children in daycare appear to suffer from more colds than children cared for at home. However, when day-care children enter primary school, they catch fewer colds, presumably because they are already immune to a larger number.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Seasonal patterns",
"     </span>",
"     &nbsp;&mdash;&nbsp;The common cold may occur at any time of year, although most colds occur during the fall and winter months, regardless of the geographic location. Colds are not caused by cold climates or being exposed to cold air.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Transmission",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colds are transmitted from person-to-person, either by direct contact or by contact with the virus in the environment. Colds are most contagious during the first two to four days.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Direct contact",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with colds typically carry the cold virus on their hands, where it is capable of infecting another person for at least two hours. If a child with a cold touches another child or adult, who then touches their eye, nose, or mouth, the virus can later infect that person.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Infection from particles on surfaces",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some cold viruses can live on surfaces (such as countertops, door handles, or toys) for up to one day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Inhaling viral particles",
"     </span>",
"     &nbsp;&mdash;&nbsp;Droplets containing viral particles can be exhaled into the air by breathing or coughing. Rhinoviruses are not usually transmitted as a result of contact with infected droplets, although influenza virus and coronavirus can be transmitted via small droplets. Cold viruses are not usually spread through saliva.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      COMMON COLD SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The signs and symptoms of a cold usually begin one to two days after exposure. In children, nasal congestion is the most prominent symptom. Children can also have clear, yellow, or green-colored nasal discharge; fever (temperature higher than 100.4&ordm;F or 38&ordm;C) is common during the first three days of the illness. The table describes how to take a child's temperature (",
"     <a class=\"graphic graphic_table graphicRef57109 \" href=\"mobipreview.htm?7/6/7277\">",
"      table 1",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      \"Patient information: Fever in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other symptoms may include sore throat, cough, irritability, difficulty sleeping, and decreased appetite. The lining of the nose may become red and swollen, and the lymph nodes (glands) in the neck may become slightly enlarged.",
"    </p>",
"    <p>",
"     The symptoms of a cold are usually worst during the first 10 days. However, some children continue to have a runny nose, congestion, and a cough beyond 10 days. In addition, it is not unusual for a child to develop a second cold as the symptoms of the first cold are resolving; this can make it seem as if the child has a single cold that lasts for weeks or even months, especially during the fall and winter. This is not a cause for concern, unless the child has any of the more serious symptoms, discussed below. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'When to seek help'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Symptoms of allergies (allergic rhinitis) are slightly different than those of a cold, and may include bothersome itching of the nose and eyes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      COMMON COLD COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Most children who have colds do not develop complications. However, parents should be aware of the signs and symptoms of potential complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Ear infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Between 5 and 19 percent of children with a cold develop a bacterial or viral ear infection. If a child develops a fever (temperature higher than 100.4&ordm;F or 38&ordm;C) after the first three days of cold symptoms, an ear infection may be to blame. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"      \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Colds can cause wheezing in children who have not wheezed before, or worsening of asthma in children who have a history of this condition.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Sinusitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children who have nasal congestion that does not improve over the course of 10 days may have a bacterial sinus infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pneumonia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children who develop a fever after the first three days of cold symptoms may have bacterial pneumonia, especially if the child also has a cough and is breathing rapidly.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      COMMON COLD TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Symptomatic treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatment of an infant or child with a cold is different than treatment recommended for adults. Antihistamines, decongestants, cough medicines, and expectorants, alone and in combinations, are all marketed for the symptoms of a cold. However, there have been few clinical trials of these products in infants and children, and there are no studies that demonstrate any benefit in infants or children.",
"    </p>",
"    <p>",
"     The United States Food and Drug Administration (FDA) advisory panel has recommended against the use of these medications in children younger than six [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/44/40643/abstract/1\">",
"      1",
"     </a>",
"     ]. We agree with this recommendation because these medications are not proven to be effective and have the potential to cause dangerous side effects. For children older than 6 years, cold medications may have fewer risks; however, there is still no proven benefit.",
"    </p>",
"    <p>",
"     Parents may give acetaminophen (sample brand name: Tylenol&reg;) to treat a child (older than three months) who is uncomfortable because of fever during the first few days of a cold. Ibuprofen (sample brand names: Advil&reg;, Motrin&reg;,) can be given to children older than six months. Aspirin should not be given to any child under age 18 years. There is no benefit of these medications if the child is comfortable. Parents should speak with their child's healthcare provider about when and how to treat fever. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      \"Patient information: Fever in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Humidified air may improve symptoms of nasal congestion and runny nose. For infants, parents can try saline nose drops to thin the mucus, followed by bulb suction to temporarily remove nasal secretions (",
"     <a class=\"graphic graphic_table graphicRef67982 \" href=\"mobipreview.htm?24/55/25467\">",
"      table 2",
"     </a>",
"     ). An older child may try using a saline nose spray.",
"    </p>",
"    <p>",
"     Parents should encourage their child to drink an adequate amount of fluids; it is not necessary to drink extra fluids. Children often have a reduced appetite during a cold, and may eat less than usual. If an infant or child completely refuses to eat or drink for a prolonged period, the parent should contact their child's healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are not effective in treating colds. They may be necessary if the cold is complicated by a bacterial infection, like an ear infection, pneumonia, or sinusitis. Parents who think their child has developed one of these infections should contact their child's healthcare provider.",
"    </p>",
"    <p>",
"     Inappropriate use of antibiotics can lead to the development of antibiotic resistance, and can possibly lead to side effects, such as an allergic reaction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Herbal and alternative treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of alternative products, including zinc, and herbal products such as echinacea, are advertised to treat or prevent the common cold. There is some evidence that prophylactic use of vitamin C may decrease the duration of the common cold in children and adults. With the exception of vitamin C, none of these treatments have been proven to be effective in clinical trials; their use is not recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      COMMON COLD PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Simple hygiene measures can help to prevent infection with the viruses that cause colds. These measures include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hand washing is an essential and highly effective way to prevent the spread of infection. Hands should be wet with water and plain soap, and rubbed together for 15 to 30 seconds. It is not necessary to use antibacterial hand soap. Teach children to wash their hands before and after eating and after coughing or sneezing.",
"      </li>",
"      <li>",
"       Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available. Hand rubs should be spread over the entire surface of hands, fingers, and wrists until dry, and may be used several times. These rubs can be used repeatedly without skin irritation or loss of effectiveness.",
"      </li>",
"      <li>",
"       It may be difficult or impossible to completely avoid people who are ill, although parents should try to limit direct contact.",
"      </li>",
"      <li>",
"       Most children with colds need not be excluded from day care or school. It is likely that they spread the virus before they developed cold symptoms.",
"      </li>",
"      <li>",
"       Using a household cleaner that kills viruses, such as",
"       <span class=\"nowrap\">",
"        phenol/alcohol",
"       </span>",
"       (sample brand name: Lysol&reg;), may help to reduce viral transmission.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     If a child develops any of the following features, the parent should call their healthcare provider, regardless of the time of day or night.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Refusing to drink anything for a prolonged period",
"      </li>",
"      <li>",
"       Behavior changes, including irritability or lethargy (decreased responsiveness); this usually requires immediate medical attention",
"      </li>",
"      <li>",
"       Difficulty breathing, working hard to breathe, or breathing rapidly; this usually requires immediate medical attention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Parents should call the healthcare provider if the following symptoms develop, or if there are general concerns about the child:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fever greater than 101&ordm;F (38.4&ordm;C) lasts more than three days. The table describes how to take a child's temperature (",
"       <a class=\"graphic graphic_table graphicRef57109 \" href=\"mobipreview.htm?7/6/7277\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Nasal congestion does not improve or worsens over the course of 14 days.",
"      </li>",
"      <li>",
"       The eyes become red or develop yellow discharge.",
"      </li>",
"      <li>",
"       There are signs or symptoms of an ear infection (pain, ear pulling, fussiness).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The common cold is a group of symptoms caused by a number of different viruses. Children under six years average six to eight colds per year (up to one per month, September through April), with symptoms lasting an average of 14 days. This means that a child could be ill with intermittent cold symptoms for nearly half of the days in this time period, without cause for concern.",
"      </li>",
"      <li>",
"       Colds are most contagious during the first two to four days. People with colds typically carry the cold virus on their hands, where it is capable of infecting another person for at least two hours. Some cold viruses can live on surfaces (such as countertops, door handles, or toys) for as long as one day. Droplets containing viral particles can be exhaled into the air by breathing, coughing, or sneezing.",
"      </li>",
"      <li>",
"       The signs and symptoms of a cold usually begin one to two days after exposure. In children, nasal congestion is the most prominent symptom. Children can also have clear, yellow, or green-colored nasal discharge. Fever (temperature higher than 100.4&ordm;F or 38&ordm;C) is common during the first three days of the illness. Other symptoms may include sore throat, cough, irritability, difficulty sleeping, and decreased appetite.",
"      </li>",
"      <li>",
"       Most children who have colds do not develop complications. However, parents should be aware of the signs and symptoms of potential complications, including ear infections, asthma, sinusitis, and pneumonia.",
"      </li>",
"      <li>",
"       There have been few clinical trials of cold medications (antihistamines, decongestants, cough medicines, and expectorants) in infants and children, and there are no studies that demonstrate any benefit in infants or children. We do",
"       <strong>",
"        not",
"       </strong>",
"       recommend their use in infants and children because of the lack of proven efficacy and the potential risk of dangerous side effects.",
"      </li>",
"      <li>",
"       Parents may give acetaminophen (sample brand name: Tylenol&reg;) to children older than three months or ibuprofen (sample brand names: Advil&reg;, Motrin&reg;) to children older than six months to treat discomfort associated with fever. Humidified air can improve symptoms of nasal congestion and runny nose. Parents should encourage their child to drink an adequate amount of fluids; it is not necessary to drink extra fluids.",
"      </li>",
"      <li>",
"       Antibiotics are not effective in treating colds. They may be necessary if the cold is complicated by a bacterial infection, like an ear infection, pneumonia, or sinusitis. Parents who think their child has developed one of these infections should contact their child's healthcare provider. Inappropriate use of antibiotics can lead to the development of antibiotic resistance, and can possibly lead to side effects, such as an allergic reaction.",
"      </li>",
"      <li>",
"       A number of alternative products, including zinc, vitamin C, and herbal products such as echinacea, are advertised to treat or prevent the common cold. None of these treatments has been proven to be effective in clinical trials; their use is not recommended.",
"      </li>",
"      <li>",
"       Simple hygiene measures can help to prevent infection with the viruses that cause colds, including hand washing or use of an alcohol-based hand rub and limiting contact with others who are ill.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287288941\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395085\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/26/28066?source=see_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/53/17234?source=see_link\">",
"      Patient information: Sinusitis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/45/25298?source=see_link\">",
"      Patient information: Eustachian tube problems (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/17/14611?source=see_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=see_link\">",
"      Patient information: Adenovirus infections (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/44/14019?source=see_link\">",
"      Patient information: Mycoplasma pneumonia in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5395131\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/11/44210?source=see_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11273?source=see_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42921?source=see_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30458?source=see_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=see_link\">",
"      Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30537?source=see_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22281?source=see_link\">",
"      The common cold in children: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29753?source=see_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13146?source=see_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (404) 639-3534",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/44/40643/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/44/40643?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     U.S. Food and Drug Administration. Public Health Advisory. Nonprescription cough and cold medicine use in children. FDA recommends that over-the-counter (OTC) cough and cold products not be used for infants and children under 2 years of age. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM051137 (Accessed on August 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40643/abstract/2\">",
"      Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40643/abstract/3\">",
"      Heikkinen T, J&auml;rvinen A. The common cold. Lancet 2003; 361:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40643/abstract/4\">",
"      Clemens CJ, Taylor JA, Almquist JR, et al. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children? J Pediatr 1997; 130:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40643/abstract/5\">",
"      Paul IM, Yoder KE, Crowell KR, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics 2004; 114:e85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_44_40643=[""].join("\n");
var outline_f39_44_40643=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COMMON COLD OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COMMON COLD CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           COMMON COLD SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           COMMON COLD COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           COMMON COLD TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           COMMON COLD PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/6/7277\" title=\"table 1\">",
"           Measuring temperature PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/55/25467\" title=\"table 2\">",
"           Bulb syringe PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40644="Gram positive diplococci";
var content_f39_44_40644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum from pneumococcal pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    under high power magnification (1000x) in sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40644=[""].join("\n");
var outline_f39_44_40644=null;
var title_f39_44_40645="Sevelamer: Drug information";
var content_f39_44_40645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sevelamer: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/1/22548?source=see_link\">",
"    see \"Sevelamer: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/8/23684?source=see_link\">",
"    see \"Sevelamer: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;;",
"     </li>",
"     <li>",
"      Renvela&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphate Binder",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The dosing of sevelamer carbonate and sevelamer hydrochloride are similar; when switching from one product to another, the same dose (on a mg per mg basis) should be utilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Control of serum phosphorous:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients not taking a phosphate binder: 800-1600 mg 3 times/day with meals; the initial dose may be based on serum phosphorous levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;5.5 mg/dL to &lt;7.5 mg/dL: 800 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;7.5 mg/dL to &lt;9.0 mg/dL: 1200-1600 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;9.0 mg/dL: 1600 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose adjustment based on serum phosphorous concentration (goal range of 3.5-5.5 mg/dL; maximum dose studied was equivalent to 13 g/day [sevelamer hydrochloride] or 14 g/day [sevelamer carbonate]):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;5.5 mg/dL: Increase by 400-800 mg per meal at 2-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5-5.5 mg/dL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;3.5 mg/dL: Decrease by 400-800 mg per meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment when switching between phosphate-binder products:",
"     </i>",
"     667 mg of calcium acetate is equivalent to ~800 mg sevelamer (carbonate or hydrochloride)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion based on dose per meal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Calcium acetate 667 mg: Convert to 800 mg Renagel&reg; / Renvela&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcium acetate 1334 mg: Convert to 1600 mg Renagel&reg; 800 mg/ Renvela&reg;",
"     <b>",
"      or",
"     </b>",
"     1200 mg Renagel&reg; 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcium acetate 2001 mg: Convert to 2400 mg Renagel&reg; 800 mg / Renvela&reg;",
"     <b>",
"      or",
"     </b>",
"     2000 mg Renagel&reg; 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5265838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/8/23684?source=see_link\">",
"      see \"Sevelamer: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Control of serum phosphorous (unlabeled use):",
"     </b>",
"     Oral: In a pilot study of 17 pediatric patients aged 11.8 &plusmn; 3.7 years on hemodialysis (n=3) or peritoneal dialysis (n=14), initial doses of 121 &plusmn; 50 mg/kg/day (4.5 &plusmn; 5 g/day) were used. Doses were adjusted based on the serum phosphorus with final doses of 163 &plusmn; 46 mg/kg (6.7 &plusmn; 2.4 g/day) without any adverse effects (Mahdavi, 2003). In a study of 18 patients aged 0.9-18 years with chronic kidney disease, a mean dose of 140 &plusmn; 86 mg/kg/day (5.38 &plusmn; 3.24 g/day) resulted in good phosphorus control with minimal adverse effects. Initial doses were based on prior phosphate-binder dose and were adjusted based on the serum phosphorus (Pieper, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as carbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renvela&reg;: 0.8 g/packet (90s); 2.4 g/packet (90s) [contains propylene glycol; citrus-cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as carbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renvela&reg;: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renagel&reg;: 400 mg, 800 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be administered with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral suspension: Stir vigorously to suspend mixture just prior to drinking; powder does not dissolve. Drink within 30 minutes of preparing and resuspend just prior to drinking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Swallow whole; do not crush, chew, or break.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction or control of serum phosphorous in patients with chronic kidney disease on hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Renagel&reg; may be confused with Reglan&reg;, Regonol&reg;, Renvela&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Renvela&reg; may be confused with Reglan&reg;, Regonol&reg;, Renagel&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sevelamer may be confused with Savella&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Renagel [U.S., Canada, and multiple international markets] may be confused with Remegel brand name for aluminium hydroxide and magnesium carbonate [Netherlands] and for calcium carbonate [Hungary, Great Britain and Ireland] and with Remegel Wind Relief brand name for calcium carbonate and simethicone [Great Britain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9%), flatulence (8%), constipation (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Peritonitis (peritoneal dialysis: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Fecal impaction, ileus (rare), intestinal obstruction (rare), intestinal perforation (rare), pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders including dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including constipation), or major gastrointestinal surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal binding: Sevelamer may bind to some drugs in the gastrointestinal tract and decrease their absorption. When changes in absorption of oral medications may have significant clinical consequences (such as antiarrhythmic and antiseizure medications), these medications should be taken at least 1 hour before or 3 hours after a dose of sevelamer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamins: May cause reductions in vitamin D, E, K, or folic acid absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tablets: Should not be taken apart or chewed; broken or crushed tablets will rapidly expand in water/saliva and may be a choking hazard.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Sevelamer may decrease the serum concentration of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.  Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Sevelamer may decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13851538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: May cause reductions in vitamin D, E, K, or folic acid absorption. Management: Must be administered with meals. Consider vitamin supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown reduced or irregular ossification of fetal bones. Because sevelamer may cause a reduction in the absorption of some vitamins, it should be used with caution in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F220784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution (not absorbed systemically but may alter maternal nutrition)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F220769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether sevelamer is excreted in human milk. Because sevelamer may cause a reduction in the absorption of some vitamins, it should be used with caution in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1044875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals. Reduced levels of folic acid, and vitamins D, E, and K may occur; most hemodialysis patients in clinical trials received vitamin supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Renvela Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 g (1): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.4 g (1): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Renagel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (360): $720.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (180): $720.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Renvela Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (270): $864.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum chemistries, including bicarbonate and chloride",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 3: Every 6-12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 4: Every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 5 and 5D: Every 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3-12 months depending on CKD severity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus (K/DOQI, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L) (adults); maintain within age-appropriate limits (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L) (children &gt;12 years and adults); 4-6 mg/dL (1.29-1.94 mmol/L) (children 1-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &gt;12 years and adults); &lt;65 mg2/dL2 (children &le;12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Renagel (AU, CH, ES, FI, GR, IT, KP, PL, TR, TW, UY);",
"     </li>",
"     <li>",
"      Renvela (AT, BE, CN, CR, CZ, DE, DK, EE, FR, GB, GT, HK, HN, IE, IL, MY, NL, NO, PA, PT, SE, SG, SV, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Reduction in serum phosphorus has been demonstrated after 1-2 weeks (Burke, 1997; Chertow, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not systemically absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burke SK, Slatopolsky EA, and Goldberg DI, \"RenaGel, a Novel Calcium- and Aluminium-Free Phosphate Binder, Inhibits Phosphate Absorption in Normal Volunteers,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 1997, 12(8):1640-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/9269642/pubmed\" id=\"9269642\" target=\"_blank\">",
"        9269642",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chertow GM, Burke SK, Lazarus JM, et al, \"Poly[allylamine Hydrochloride] (RenaGel): A Noncalcemic Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Renal Failure,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 1997, 29(1):66-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/9002531/pubmed\" id=\"9002531\" target=\"_blank\">",
"        9002531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delmez J, Block G, Robertson J, et al, &ldquo;A Randomized, Double-Blind, Crossover Design Study of Sevelamer Hydrochloride and Sevelamer Carbonate in Patients on Hemodialysis,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 2007, 68(6):386-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/18184521/pubmed\" id=\"18184521\" target=\"_blank\">",
"        18184521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 13. Treatment of Bone Disease in Chronic Kidney Disease.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease,\" 2002. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahdavi H, Kuizon BD, Gales B, et al, &ldquo;Sevelamer Hydrochloride: An Effective Phosphate Binder in Dialyzed Children,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2003, 18(12):1260-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/14586677/pubmed\" id=\"14586677\" target=\"_blank\">",
"        14586677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pieper AK, Haffner D, Hoppe B, et al, &ldquo;A Randomized Crossover Trial Comparing Sevelamer With Calcium Acetate in Children With CKD,&rdquo;",
"      <i>",
"       Am J Kid Dis",
"      </i>",
"      , 2006, 47(4):625-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/16564940/pubmed\" id=\"16564940\" target=\"_blank\">",
"        16564940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storms LE, Chicella MF, and Dice JE, &ldquo;Sevelamer Therapy for Pediatric End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(3):410-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/44/40645/abstract-text/16503722/pubmed\" id=\"16503722\" target=\"_blank\">",
"        16503722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10261 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40645=[""].join("\n");
var outline_f39_44_40645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220777\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220778\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220795\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220780\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5265838\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220781\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220762\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220761\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220802\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220793\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220765\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220749\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300038\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220754\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13851538\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220784\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220769\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044875\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220767\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220758\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203338\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038827\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220764\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10261|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/1/22548?source=related_link\">",
"      Sevelamer: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/8/23684?source=related_link\">",
"      Sevelamer: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40646="Bicarbonate therapy in lactic acidosis";
var content_f39_44_40646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bicarbonate therapy in lactic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Michael Wiederkehr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40646/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/44/40646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25392892\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactic acidosis causes a decrease in serum bicarbonate concentration that is similar in magnitude to the increase in the lactate concentration. Lactate is a metabolizable organic anion that, when oxidized, will generate bicarbonate. Thus, if the stimulus to lactic acid production is eliminated by successful treatment of the underlying disease (eg, restoration of perfusion in a patient with shock), oxidative processes will metabolize the accumulated lactate and regenerate bicarbonate. This will correct the metabolic acidosis and reduce the anion gap.",
"   </p>",
"   <p>",
"    The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Most, but not all, experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis and acidemia (arterial pH less than 7.1). Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/1,5-10\">",
"     1,5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of bicarbonate therapy and alternative buffering agents in patients with lactic acidosis will be discussed in this topic. The causes of lactic acidosis, the approach to the adult with metabolic acidosis, and the treatment of shock in adults are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=see_link\">",
"     \"Causes of lactic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of bicarbonate dialysis to correct lactic acidosis caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21799?source=see_link\">",
"     \"Metformin poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631273\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Who should be treated &ndash; We suggest that patients with lactic acidosis and severe acidemia (pH less than 7.10, but generally not those with higher values) receive bicarbonate therapy. (See",
"      <a class=\"local\" href=\"#H12631281\">",
"       'Which patients should receive bicarbonate therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Goals of therapy &ndash; The primary aim of therapy is reversal of the underlying disease",
"      <strong>",
"      </strong>",
"      (eg, shock). When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, the aim is to maintain the arterial pH above 7.10 until the primary process causing the metabolic acidosis can be reversed. (See",
"      <a class=\"local\" href=\"#H12631289\">",
"       'Therapeutic goal'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Potential harms &ndash; Rapid infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      may increase the PCO2, accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. There is little evidence that any alternative buffering agents are superior to bicarbonate therapy. (See",
"      <a class=\"local\" href=\"#H12631806\">",
"       'Potential harms of bicarbonate, and alterative agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Approach &ndash; In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still below 7.10. (See",
"      <a class=\"local\" href=\"#H12631304\">",
"       'Approach'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631281\">",
"    <span class=\"h1\">",
"     WHICH PATIENTS SHOULD RECEIVE BICARBONATE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with lactic acidosis and severe acidemia (pH less than 7.10 and serum bicarbonate level 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less) receive bicarbonate therapy. If the patient's pH is 7.1 or lower and the serum bicarbonate level is greater than 6",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    then this indicates that the PCO2 is greater than 20 mmHg, which signifies inadequate ventilation. Inadequately ventilated patients with severe acidemia should receive artificial ventilation because administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    in this setting will likely worsen the respiratory acidosis.",
"   </p>",
"   <p>",
"    Although physiologic studies show that this degree of acidemia may produce adverse hemodynamic consequences, bicarbonate therapy was not beneficial in two randomized trials that enrolled patients with arterial pH values above 7.10. Although there is no good evidence for, or against,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy when the pH is below 7.10, we suggest its use because it may",
"    <span class=\"nowrap\">",
"     treat/prevent",
"    </span>",
"    the following adverse clinical effects of acidemia, each of which can produce hemodynamic instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/1,5-11\">",
"     1,5-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced left ventricular contractility",
"     </li>",
"     <li>",
"      Arrhythmias",
"     </li>",
"     <li>",
"      Arterial vasodilation and venoconstriction",
"     </li>",
"     <li>",
"      Impaired responsiveness to catecholamine vasopressors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, relatively small bicarbonate changes will have great pH impact when the serum bicarbonate concentration is markedly reduced.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    infusion will also expand the extracellular fluid (ECF) volume, an effect that can be beneficial or deleterious, depending on the patient's pre-infusion volume status.",
"   </p>",
"   <p>",
"    However, we do",
"    <strong>",
"     not",
"    </strong>",
"    suggest bicarbonate therapy in patients with less severe acidosis (pH 7.1 or greater). Two randomized trials failed to find a benefit of bicarbonate therapy in critically ill patients with lactic acidosis and pH values greater than 7.1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a crossover study, 14 patients with lactic acidosis (serum bicarbonate less than 17",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      and arterial lactate greater than 2.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in a single intensive care unit received, in random order, 2",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      and an equivalent dose of sodium chloride [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/12\">",
"       12",
"      </a>",
"      ]. Bicarbonate therapy produced a significant rise in arterial pH (from 7.22 to 7.36) and serum bicarbonate (from 12 to 18",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      However, the hemodynamic responses to sodium bicarbonate and sodium chloride, including cardiac output, mean arterial pressure, and pulmonary capillary wedge pressure, were identical.",
"     </li>",
"     <li>",
"      In a similarly designed trial of 10 patients with lactic acidosis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/kg)",
"      </span>",
"      and an equivalent dose of sodium chloride were administered in random order [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/10\">",
"       10",
"      </a>",
"      ]. Bicarbonate therapy significantly increased the arterial pH (from 7.16 to 7.21) and serum bicarbonate (from 16 to 19",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Again, the infusion of sodium bicarbonate and sodium chloride produced similar changes in cardiac output, mean arterial pressure, and pulmonary artery pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two trials were too small to detect a minor benefit of bicarbonate therapy; in addition, patients with severe acidemia were not represented. Thus, we and other experts continue to use bicarbonate therapy in patients who have an arterial pH less than 7.10. However, bicarbonate therapy requires adequate ventilation as discussed below. (See",
"    <a class=\"local\" href=\"#H12631806\">",
"     'Potential harms of bicarbonate, and alterative agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of bicarbonate therapy in patients with cardiac arrest is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35448?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapies of uncertain benefit in basic and advanced cardiac life support\", section on 'Sodium bicarbonate therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631289\">",
"    <span class=\"h1\">",
"     THERAPEUTIC GOAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary aim of therapy is",
"    <strong>",
"     reversal of the underlying disease",
"    </strong>",
"    (eg, shock). Tissue hypoxia may dramatically increase lactic acid production, often coupled with reduced metabolic clearance of lactate by the liver, heart, and kidneys. This combination of overproduction and underutilization can easily overwhelm any attempt to increase the serum bicarbonate with exogenously administered alkali. In fact, as discussed below, alkali therapy may accelerate lactic acid production. Thus, unless the pathologic process causing the relentless production of lactic acid can be reversed, any beneficial effect of exogenous bicarbonate will be transient. (See",
"    <a class=\"local\" href=\"#H12631806\">",
"     'Potential harms of bicarbonate, and alterative agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, we aim to maintain the arterial pH above 7.10 until the primary process causing the metabolic acidosis can be reversed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631806\">",
"    <span class=\"h1\">",
"     POTENTIAL HARMS OF BICARBONATE, AND ALTERATIVE AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632674\">",
"    <span class=\"h2\">",
"     Potential harms of bicarbonate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    have a number of potentially adverse effects:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased arterial and tissue capillary PCO2",
"     </li>",
"     <li>",
"      Acceleration of lactate generation",
"     </li>",
"     <li>",
"      Reduced ionized calcium",
"     </li>",
"     <li>",
"      Hypernatremia",
"     </li>",
"     <li>",
"      Extracellular fluid (ECF) volume expansion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632681\">",
"    <span class=\"h3\">",
"     Increased PCO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infused bicarbonate must undergo several metabolic steps to effectively raise the pH. First, it combines with a hydrogen ion to form H2CO3 (carbonic acid). Second, H2CO3 dehydrates to CO2, and H2O and CO2 must be removed from the tissue bed and the body by circulation and respiration. If the CO2 generated by infused bicarbonate is not efficiently removed, then the resulting increase in PCO2 will prevent carbonic acid dehydration and keep the pH low. Consequently, adequate perfusion and ventilation is a prerequisite to the effective use of exogenous bicarbonate.",
"   </p>",
"   <p>",
"    Even with adequate ventilation, the PCO2 is likely to rise at the local tissue level when bicarbonate is infused. Because CO2 readily penetrates cell membranes, this increase in tissue PCO2 may worsen intracellular acidosis even as arterial blood pH increases. This dissociation between tissue and systemic arterial acid-base parameters is magnified in patients with circulatory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cerebrospinal fluid (CSF) pH may also fall when bicarbonate is infused for two reasons: first, the mechanism described above increases the PCO2 locally in the brain and CSF; second, amelioration of systemic acidemia (ie, the rise in arterial blood pH) diminishes the drive for hyperventilation, causing the systemic PCO2 to increase. Any systemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local increase in PCO2 will be quickly reflected within the CSF. In contrast, an increased blood bicarbonate concentration is only slowly transmitted to the CSF. Because CSF bicarbonate concentration does not rise as rapidly as the CSF PCO2, \"paradoxical\" CSF acidemia results and may be associated with neurological deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632935\">",
"    <span class=\"h3\">",
"     Acceleration of lactate generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acidemia may act as a \"brake\" on lactic acid generation by inhibiting glycolysis, mediated by a reduction in the activity of the enzyme, phosphofructokinase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, increasing pH with exogenous bicarbonate may accelerate the production of lactate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632964\">",
"    <span class=\"h3\">",
"     Effects on calcium and sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in pH can decrease the ionized calcium concentration, which may adversely affect cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is usually infused as a hypertonic solution, a 50 mL ampule containing 50 meq of sodium bicarbonate (1000",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    will raise the serum sodium concentration of a 70 kg person by about 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and expand the ECF volume by about 250 mL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631930\">",
"    <span class=\"h2\">",
"     Alternatives to bicarbonate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations and potential deleterious effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy in patients with lactic acidosis have prompted investigation into the use of alternative buffering agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/29/43475?source=see_link\">",
"     tromethamine",
"    </a>",
"    (tris-hydroxymethyl aminomethane; also called THAM, TRIS, and trometamol), Carbicarb, and dichloroacetate (DCA). However,",
"    <strong>",
"     none",
"    </strong>",
"    of these alternative agents have shown benefit in patients with lactic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632114\">",
"    <span class=\"h3\">",
"     Tromethamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/29/43475?source=see_link\">",
"     Tromethamine",
"    </a>",
"    (tris-hydroxymethyl aminomethane; also called THAM, TRIS, and trometamol) is an amino alcohol which buffers protons by virtue of its amine (NH2) moiety (pKa = 7.7) via the following reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;THAM-NH2 &nbsp;+ &nbsp;H+ &nbsp;= &nbsp;THAM-NH3+",
"   </p>",
"   <p>",
"    Unlike bicarbonate which generates CO2, THAM consumes CO2:",
"   </p>",
"   <p>",
"    &nbsp;THAM-NH2 &nbsp;+ &nbsp;H2O &nbsp;+ &nbsp;CO2 &nbsp;= &nbsp;THAM-NH3+ &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    The urinary clearance of protonated THAM salts is slightly greater than urinary clearance of creatinine. To the extent THAM-NH3+ is excreted in the urine with chloride, this represents net acid excretion. However, if THAM-NH3+ is excreted with HCO3-, then no net acid excretion occurs. Thus, THAM can increase the buffering capacity of blood without generating CO2 but is less effective in anuric patients. Reported toxicities of THAM include hyperkalemia, hypoglycemia, and respiratory depression; the last complication may be due to the ability of THAM to rapidly increase the pH and decrease the PCO2 in the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    THAM has been used to treat severe acidemia due to sepsis, permissive hypercapnia, diabetic ketoacidosis, renal tubular acidosis, gastroenteritis, and drug intoxications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, THAM has",
"    <strong>",
"     not",
"    </strong>",
"    been evaluated in clinical trials involving patients with lactic acidosis. Thus, the efficacy and safety of THAM in such patients is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632121\">",
"    <span class=\"h3\">",
"     Carbicarb",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential and perhaps more effective alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is an equimolar mixture of sodium carbonate (Na2CO3) and sodium bicarbonate called \"Carbicarb\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/22\">",
"     22",
"    </a>",
"    ]. Sodium carbonate in the mixture reacts with carbonic acid (H2CO3) to generate bicarbonate via the following reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;CO3(2-) &nbsp;+ &nbsp;H2CO3 &nbsp;= &nbsp;2 HCO3-",
"   </p>",
"   <p>",
"    Thus, the carbonate component of Carbicarb consumes H2CO3 (or CO2) while the HCO3 component and the newly generated HCO3 will form CO2 when protons are buffered. Consequently, the total amount of CO2 which is generated is two-thirds the amount that would be generated by an equimolar amount of HCO3 alone. The mixture of sodium carbonate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is utilized instead of sodium carbonate alone because a solution of pure sodium carbonate is too caustic to be intravenously infused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/24\">",
"     24",
"    </a>",
"    ]. The risks of hypertonicity and hypervolemia are similar to those of sodium bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbicarb has been evaluated in animals, with inconsistent benefit compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. One human study of 36 surgical patients with metabolic acidosis compared the effects of sodium bicarbonate with Carbicarb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/28\">",
"     28",
"    </a>",
"    ]. No benefit was observed. Carbicarb is not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12632128\">",
"    <span class=\"h3\">",
"     Dichloroacetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dichloroacetate (DCA) is another investigational drug that has been studied in lactic acidosis. It increases the activity of the enzyme, pyruvate dehydrogenase, which accelerates mitochondrial oxidation of pyruvate and thereby also accelerates lactate metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Although several early human and animal studies were promising, a clinical trial in humans with lactic acidosis showed no mortality benefit or hemodynamic improvement despite a fall in lactic acid levels and improvement in arterial pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/31\">",
"     31",
"    </a>",
"    ]. DCA is being studied in patients with congenital mitochondrial defects associated with chronic lactic acidosis and as an anti-neoplastic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. It is not currently available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631304\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In critically ill patients with lactic acidosis and severe acidemia (pH less than 7.10 and serum bicarbonate concentration 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less), we suggest the following approach in regard to bicarbonate therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, adequate ventilation is a prerequisite to the effective use of exogenous bicarbonate in patients with lactic acidosis. In non-intubated patients with severe acidemia, an appropriate ventilatory response should reduce the PCO2 to 15 mmHg and often to 10 to 12 mmHg.",
"     </li>",
"     <li>",
"      Bicarbonate administration can reduce the ionized calcium concentration, which can have adverse hemodynamic consequences. Ideally, the ionized calcium should be measured, followed, and treated. However, in many facilities, this measurement may not be readily available within the required time frame. Under such circumstances, the ionized calcium should still be sent for measurement. If the blood pressure falls or does not improve, and the ionized calcium could be low, empiric calcium infusion should be considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40646/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If ventilation is adequate, the patient with severe lactic acidosis (pH less than 7.10) should be given 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      as an intravenous bolus. The serum electrolytes and blood pH should be measured 30 to 60 minutes later, and the dose of sodium bicarbonate can be repeated if severe lactic acidosis (pH less than 7.10) persists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12631328\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial. Most experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis and acidemia (arterial pH less than 7.1 and serum bicarbonate 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less). Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines. (See",
"      <a class=\"local\" href=\"#H25392892\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis (see",
"      <a class=\"local\" href=\"#H12631273\">",
"       'Overview of therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The primary aim of therapy for lactic acidosis is reversal of the underlying disease",
"      <strong>",
"      </strong>",
"      (eg, shock). (See",
"      <a class=\"local\" href=\"#H12631289\">",
"       'Therapeutic goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with lactic acidosis and severe acidemia (pH less than 7.10 and serum bicarbonate 6",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less) receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H12631281\">",
"       'Which patients should receive bicarbonate therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, the aim is to maintain the arterial pH above 7.10 until the primary process causing the metabolic acidosis can be reversed. (See",
"      <a class=\"local\" href=\"#H12631289\">",
"       'Therapeutic goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still less than 7.10. (See",
"      <a class=\"local\" href=\"#H12631304\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      may increase the PCO2, accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. (See",
"      <a class=\"local\" href=\"#H12631806\">",
"       'Potential harms of bicarbonate, and alterative agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little evidence that any alternative buffering agents are superior to bicarbonate therapy. (See",
"      <a class=\"local\" href=\"#H12631806\">",
"       'Potential harms of bicarbonate, and alterative agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/1\">",
"      Kraut JA, Kurtz I. Use of base in the treatment of severe acidemic states. Am J Kidney Dis 2001; 38:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/2\">",
"      Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/3\">",
"      Stacpoole PW. Lactic acidosis: the case against bicarbonate therapy. Ann Intern Med 1986; 105:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/4\">",
"      Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/5\">",
"      Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol 2012; 8:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/6\">",
"      Marsh JD, Margolis TI, Kim D. Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/7\">",
"      Mitchell JH, Wildenthal K, Johnson RL Jr. The effects of acid-base disturbances on cardiovascular and pulmonary function. Kidney Int 1972; 1:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/8\">",
"      Teplinsky K, O'Toole M, Olman M, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990; 258:H1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/9\">",
"      Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/10\">",
"      Mathieu D, Neviere R, Billard V, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991; 19:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/11\">",
"      Orchard CH, Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/12\">",
"      Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 1990; 112:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/13\">",
"      Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/14\">",
"      Adrogu&eacute; HJ, Rashad MN, Gorin AB, et al. Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood. N Engl J Med 1989; 320:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/15\">",
"      Posner JB, Plum F. Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med 1967; 277:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/16\">",
"      Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/17\">",
"      Hood VL, Tannen RL. Protection of acid-base balance by pH regulation of acid production. N Engl J Med 1998; 339:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/18\">",
"      Lang RM, Fellner SK, Neumann A, et al. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988; 108:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/19\">",
"      Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs 1998; 55:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/20\">",
"      Kallet RH, Jasmer RM, Luce JM, et al. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med 2000; 161:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/21\">",
"      Weber T, Tschernich H, Sitzwohl C, et al. Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 162:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/22\">",
"      Filley GF, Kindig NB. Carbicarb, an alkalinizing ion-generating agent of possible clinical usefulness. Trans Am Clin Climatol Assoc 1985; 96:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/23\">",
"      Shapiro JI, Elkins N, Logan J, et al. Effects of sodium bicarbonate, disodium carbonate, and a sodium bicarbonate/carbonate mixture on the PCO2 of blood in a closed system. J Lab Clin Med 1995; 126:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/24\">",
"      Gazmuri RJ, von Planta M, Weil MH, Rackow EC. Cardiac effects of carbon dioxide-consuming and carbon dioxide-generating buffers during cardiopulmonary resuscitation. J Am Coll Cardiol 1990; 15:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/25\">",
"      Bersin RM, Arieff AI. Improved hemodynamic function during hypoxia with Carbicarb, a new agent for the management of acidosis. Circulation 1988; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/26\">",
"      Blecic S, De Backer D, Deleuze M, et al. Correction of metabolic acidosis in experimental CPR: a comparative study of sodium bicarbonate, carbicarb, and dextrose. Ann Emerg Med 1991; 20:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/27\">",
"      Kette F, Weil MH, von Planta M, et al. Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation. Circulation 1990; 81:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/28\">",
"      Leung JM, Landow L, Franks M, et al. Safety and efficacy of intravenous Carbicarb in patients undergoing surgery: comparison with sodium bicarbonate in the treatment of mild metabolic acidosis. SPI Research Group. Study of Perioperative Ischemia. Crit Care Med 1994; 22:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/29\">",
"      Park R, Arieff AI. Treatment of lactic acidosis with dichloroacetate in dogs. J Clin Invest 1982; 70:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/30\">",
"      Stacpoole PW, Harman EM, Curry SH, et al. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983; 309:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/31\">",
"      Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 1992; 327:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/32\">",
"      Mori M, Yamagata T, Goto T, et al. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 2004; 26:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/33\">",
"      Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40646/abstract/34\">",
"      Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003; 43:683.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2294 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40646=[""].join("\n");
var outline_f39_44_40646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12631328\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25392892\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631273\">",
"      OVERVIEW OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631281\">",
"      WHICH PATIENTS SHOULD RECEIVE BICARBONATE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631289\">",
"      THERAPEUTIC GOAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631806\">",
"      POTENTIAL HARMS OF BICARBONATE, AND ALTERATIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12632674\">",
"      Potential harms of bicarbonate therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632681\">",
"      - Increased PCO2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632935\">",
"      - Acceleration of lactate generation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632964\">",
"      - Effects on calcium and sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12631930\">",
"      Alternatives to bicarbonate therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632114\">",
"      - Tromethamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632121\">",
"      - Carbicarb",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12632128\">",
"      - Dichloroacetate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631304\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12631328\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21799?source=related_link\">",
"      Metformin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35448?source=related_link\">",
"      Therapies of uncertain benefit in basic and advanced cardiac life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40647="Sinusoidal events";
var content_f39_44_40647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Sinusoidal events during fibrosing liver injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in the subendothelial space of Disse and sinusoid as fibrosis develops in response to liver injury include alterations in both cellular responses and extracellular matrix composition. Stellate cell activation leads to accumulation of scar (fibril-forming) matrix. This in turn contributes to the loss of hepatocyte microvilli and sinusoidal endothelial fenestrae, which result in deterioration of hepatic function. Kupffer cell (macrophage) activation accompanies liver injury and contributes to paracrine activation of stellate cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott L Friedman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40647=[""].join("\n");
var outline_f39_44_40647=null;
var title_f39_44_40648="Prevention of Rh(D) alloimmunization";
var content_f39_44_40648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of Rh(D) alloimmunization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40648/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/44/40648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of anti-D immune globulin, approximately 16 percent of Rh(D)-negative women became alloimmunized after two deliveries of Rh(D)-positive ABO compatible infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/1\">",
"     1",
"    </a>",
"    ]. This rate fell to 2 percent with routine postpartum administration of a single dose of anti-D immune globulin and was further reduced to as low as 0.1 percent with the addition of routine antenatal administration in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/2\">",
"     2",
"    </a>",
"    ]. However, Rh(D) alloimmunization has not been eliminated. Reasons for continued occurrence of sensitized pregnancies include both failure to administer anti-D immune globulin in accordance with published guidelines and sensitization early in gestation before administration of routine third trimester antenatal anti-D prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of Rh(D) alloimmunization will be reviewed here. Related topics, including a discussion of the Rhesus system, diagnosis and management of Rhesus alloimmunization in pregnancy, in utero transfusion, and neonatal issues, are reviewed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=see_link\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=see_link\">",
"       \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"       \"Intrauterine fetal transfusion of red blood cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10665?source=see_link\">",
"       \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTI-D IMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-D immune globulin is a sterile solution containing IgG anti-D (anti-Rh) manufactured from human plasma. A single 300 microgram dose (1 microgram = 5 IU) contains sufficient anti-D to suppress the immune response to 15 mL of Rh-positive red blood cells (30 mL Rh(D)-positive fetal whole blood). A single 50 microgram dose contains sufficient anti-D to suppress the immune response to 2.5 mL of Rh-positive red blood cells.",
"   </p>",
"   <p>",
"    The product is manufactured from pooled source plasma selected for high titers of antibodies to Rh(D)-positive erythrocytes. The plasma units are tested and found non-reactive for anti-hepatitis C virus, anti-human immunodeficiency viruses, anti-hepatitis B virus, and anti-parvovirus B19. Furthermore, the process used to prepare most anti-D immune globulin (Cohn cold ethanol fractionation followed by viral-clearance ultrafiltration) is highly effective for removing viral particles, such as hepatitis A and C, parvovirus B12, and the human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Anti-D immune globulin prepared by this method (eg, HyperRho",
"    <span class=\"nowrap\">",
"     S/D&reg;,",
"    </span>",
"    RhoGAM&reg;) must be administered intramuscularly because trace amounts of IgA and other plasma proteins in the product could cause anaphylaxis if they were given intravenously. By comparison, anti-D immune globulin prepared by ion-exchange chromatography isolation (eg, Rhophylac&reg;, WinRho SDF&reg;) is purer and can be given intramuscularly or intravenously. Intramuscular and intravenous preparations are equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peak serum levels are achieved faster after intravenous than intramuscular injection, but the half-life is about the same for both preparations (mean 24 days). After administration, low titer antibody (4 or less) can usually be detected in maternal serum for several weeks. In a small proportion of patients, highly sensitive assays have detected residual anti-D antibody as long as 95 days after a routine antepartum injection of anti-D immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/7\">",
"     7",
"    </a>",
"    ], and possibly as long as 180 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/8\">",
"     8",
"    </a>",
"    ]. In one study, 20 percent of infants whose mothers received Rh(D)-immune globulin at 34 weeks of gestation had a positive direct antiglobulin test, but hemoglobin and bilirubin levels were similar to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although once produced from the plasma of alloimmunized women, the decreasing prevalence of Rhesus alloimmunization has necessitated the use of male donors who undergo repeated injections of Rh(D)-positive red cells to develop high-titered polyclonal anti-D plasma. This dwindling resource has led to a search for a synthetic anti-D immune globulin, but currently none are available for clinical use.",
"   </p>",
"   <p>",
"    Two monoclonal antibodies, BRAD-3 and BRAD-5, have been derived by immortalizing B lymphocyte cell lines from hyperimmunized donors with Ebstein-Barr virus. A recombinant polyclonal human anti-D consisting of 25 different monoclonal IgG1 antibodies (Rozrolimupah&reg; [Sym001]; Symphogen) has also been developed by transfecting Chinese hamster ovary cells with human genes. Rozrolimupah&reg; is currently in phase III trials for the prevention of anti-D alloimmunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Advantages of a synthetic product over products derived from humans include greater availability and elimination of risks of pathogen transmission and adverse reactions due to impurities in plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism whereby anti-D immune globulin prevents alloimmunization remains unproven. Possibilities include rapid macrophage mediated clearance of anti-D coated red blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    down-regulation of antigen-specific B cells before an immune response occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A significant number of Rh(D) antigen sites on fetal red blood cells in the maternal circulation are not bound by passive anti-D; therefore, epitope masking is not the reason why anti-D responses are prevented by administration of prophylactic anti-D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR USE OF ANTI-D IMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-D immune globulin is not effective once alloimmunization to the Rh(D) antigen has occurred. Therefore, it is essential that it be given to any Rh(D)-negative woman whose fetus is, or may be, Rh(D)-positive whenever there is a risk of fetomaternal hemorrhage (",
"    <a class=\"graphic graphic_table graphicRef81077 \" href=\"mobipreview.htm?8/1/8219\">",
"     table 1",
"    </a>",
"    ). The Rhesus system, including weak and partial Rh(D), is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\", section on 'The Rhesus system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, a woman is \"sensibilized\" such that the indirect Coombs test may not be positive early in pregnancy, although a primary immune response has occurred and she has the capacity of producing IgG anti-D antibody later in pregnancy. This secondary immune response upon re-exposure to the D antigen cannot be prevented by maternal administration of anti-D immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antepartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical guidelines reflect practice in the United States. &nbsp;Recommendations may differ in other countries; some of these differences are indicated below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Antepartum routine",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All Rh(D)-negative pregnant women should undergo an antibody screen at the first prenatal visit of each pregnancy. The blood test is safe, accurate, and inexpensive and, if antibodies are identified, interventions are available for diagnosing severe fetal anemia and preventing fetal death in affected fetuses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=see_link\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second antibody screen may be obtained at 28 weeks of gestation to detect the rare woman who has become alloimmunized in the interval since the first screen; however, the cost-benefit of rescreening is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"       16",
"      </a>",
"      ]. The AABB recommends that an antibody screen be obtained prior to anti-D immune globulin administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/17\">",
"       17",
"      </a>",
"      ], while the American College of Obstetricians and Gynecologists (ACOG) leaves the decision to repeat an antibody screen to the discretion of the obstetrical provider [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Practice guidelines in the United States recommend that anti-D immune globulin be administered early in the third trimester, a single dose of 300 micrograms at 28 weeks of gestation. This practice reduces the incidence of antenatal alloimmunization from 2 percent to 0.1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/2,18-21\">",
"       2,18-21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the United Kingdom, 100 micrograms of anti-D immune globulin are given at 28 and 34 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In Canada, 100 to 120 micrograms are administered at 28 and 34 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patient convenience, anti-D immune globulin can be administered at the office visit when the maternal blood sample is obtained for an antibody screen. Ideally, the injection is given after the sample is drawn; however, slow absorption from an intramuscular injection site should prevent detection of passively acquired antibody in maternal serum if the injection is given shortly before blood drawing.",
"   </p>",
"   <p>",
"    Antenatal prophylaxis has no benefit if the fetus is Rh(D)-negative, but the fetal blood type is generally unknown. Antenatal prophylaxis may be omitted if the biologic father of the baby is known",
"    <strong>",
"     with certainty",
"    </strong>",
"    to be Rh(D)-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5320208\">",
"    <span class=\"h4\">",
"     Free fetal DNA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of using cell-free fetal DNA circulating in maternal serum to determine fetal",
"    <em>",
"     RHD",
"    </em>",
"    gene and guide administration of prophylaxis has been shown in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. In some European countries, fetal",
"    <em>",
"     RHD",
"    </em>",
"    gene determination is performed clinically in Rh(D)-negative women and administration of antenatal anti-D immune globulin is avoided in the case of an",
"    <em>",
"     RHD",
"    </em>",
"    negative fetus. Results from two of the largest studies are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series from the Netherlands (n = 2312 Rh(D)-negative women), fetal",
"      <em>",
"       RHD",
"      </em>",
"      gene detection sensitivity was 99.9 percent at 25 weeks of gestation using an automated system that targeted two",
"      <em>",
"       RHD",
"      </em>",
"      exons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/27\">",
"       27",
"      </a>",
"      ]. Six fetuses were falsely identified as",
"      <em>",
"       RHD",
"      </em>",
"      positive and 74 results were inconclusive due to methodologic issues or variant D types; all of these women received antenatal Rh(D) prophylaxis. Prophylaxis was unnecessary and avoided in 862 true negative cases (37.3 percent), unnecessary antenatal prophylaxis was administered to 39 women who had a false positive or inconclusive result antenatally but delivered an Rh(D)-negative newborn (1.7 percent). In two pregnancies (0.087 percent), an Rh(D)-positive fetus was not detected antenatally so antenatal prophylaxis was not given; however, the women received postnatal prophylaxis.",
"     </li>",
"     <li>",
"      In a series from Sweden, 4118 samples from Rh(D)-negative pregnant women were analyzed for cffDNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/28\">",
"       28",
"      </a>",
"      ]. Using an assay with only exon 4, sensitivity was 99.3 percent after 10 weeks of gestation and 100 percent after 22 weeks of gestation. Use of cffDNA testing allowed 38.8 percent of Rh(D)-negative women to avoid receiving Rh(D) immune globulin in the antenatal period due to the finding of an",
"      <em>",
"       RHD",
"      </em>",
"      negative fetus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Second antepartum dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experts recommend a second dose of anti-D immune globulin be given if the patient has not delivered within",
"    <span class=\"nowrap\">",
"     12",
"     <sup>",
"      3/7ths",
"     </sup>",
"    </span>",
"    weeks of the previous dose (ie, at",
"    <span class=\"nowrap\">",
"     40",
"     <sup>",
"      3/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation for patients receiving antepartum prophylaxis at",
"    <span class=\"nowrap\">",
"     28",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    weeks); this is because of rare case reports of maternal sensitization possibly due to waning levels of antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/1,29,30\">",
"     1,29,30",
"    </a>",
"    ]. There is no consensus regarding routine administration of a repeat antepartum dose of anti-D immune globulin at term; ACOG has left this decision to the physician's judgment, and in clinical practice a repeat dose is not often given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"     3",
"    </a>",
"    ]. Fifteen to 20 percent of patients who receive anti-D immune globulin at 28 weeks will have a low titer (&le;1:4) at term.",
"   </p>",
"   <p>",
"    There is an absence of evidence on the effect of induction of labor on alloimmunization in non-alloimmunized women who remain undelivered more than 12 weeks after receiving anti-D immune globulin prophylaxis at 28 weeks. In the absence of any evidence of risk or benefit, the timing and mode of delivery in these patients should be based on standard obstetrical indications.",
"   </p>",
"   <p>",
"    As discussed above, if the fetus is known to be Rh(D)-negative, then anti-D immune globulin is not indicated (see",
"    <a class=\"local\" href=\"#H5320208\">",
"     'Free fetal DNA testing'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Additional indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The D antigen is detectable on embryonic red blood cells by 38 days after conception (ie,",
"    <span class=\"nowrap\">",
"     7",
"     <sup>",
"      3/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation). A significant number of fetal red cells are detected in the maternal circulation of women exposed to the pregnancy events listed below and alloimmunization has been reported in such women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3,16,31-33\">",
"     3,16,31-33",
"    </a>",
"    ], although the precise risk of alloimmunization associated with these events is less clear than the risk after delivery. Given the possibility of alloimmunization, in the United States anti-D immune globulin is given to any Rh(D)-negative woman whose fetus is or may be Rh(D)-positive and has:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous abortion (1.5 to 2 percent risk of sensitization) or induced abortion (5 percent risk of sensitization). By comparison, the Royal College of Obstetricians and Gynaecologists has suggested that anti-D administration is unnecessary in cases of spontaneous abortions less than 12 weeks of gestation. If surgical evacuation is undertaken, however, a 250 IU (50 mcg) dose is recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/31\">",
"       31",
"      </a>",
"      ]. Few data are available on which to base a recommendation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ectopic pregnancy",
"     </li>",
"     <li>",
"      Multifetal reduction",
"     </li>",
"     <li>",
"      Invasive procedures: genetic amniocentesis; chorion villus sampling; fetal blood sampling (2 percent risk of sensitization).",
"     </li>",
"     <li>",
"      Threatened abortion (significant clinical bleeding, not just spotting)",
"     </li>",
"     <li>",
"      Fetal death in the second or third trimester",
"     </li>",
"     <li>",
"      Blunt trauma to the abdomen (including motor vehicle accidents)",
"     </li>",
"     <li>",
"      Antepartum hemorrhage in the second or third trimester (eg, placenta previa or abruption)",
"     </li>",
"     <li>",
"      External cephalic version",
"     </li>",
"     <li>",
"      Hydatidiform mole &mdash; Fetal blood is not present in a complete mole, but prophylaxis is suggested because fetal blood is present in partial molar pregnancies, sometimes it is initially difficult to distinguish between a missed abortion and molar pregnancy, and trophoblast may contain the Rh (D) antigen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A dose of 50 mcg is effective through the 12th week of gestation due to the small volume of red cells in the fetoplacental circulation (mean red cell volume at 8 and 12 weeks is 0.33 mL and 1.5 mL, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"     3",
"    </a>",
"    ], although there is no harm in giving the standard 300 microgram dose, which is more readily available. As discussed above, 50 micrograms of Rh(D) immune globulin provides protection against fetomaternal transfusion of 2.5 mL of red blood cells.",
"   </p>",
"   <p>",
"    The fetoplacental blood volume at 20 weeks of gestation is about 30 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/35\">",
"     35",
"    </a>",
"    ]. In pregnancies complicated by fetal death, blunt abdominal trauma, or antepartum hemorrhage after 20 weeks of gestation, 300 micrograms of anti-D immune globulin should be given in association with testing for fetomaternal hemorrhage, because the prevalence of excessive fetomaternal bleeding is increased under these circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"     16",
"    </a>",
"    ]. If excessive bleeding is detected, additional anti-D immune globulin is administered (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Testing for fetomaternal hemorrhage'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19876668\">",
"    <span class=\"h3\">",
"     Repeating antepartum doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence based studies to guide the use of repeat doses of anti-D immune globulin when there is persistent recurrent fetomaternal hemorrhage, such as in a pregnancy complicated by chronic placental abruption with ongoing intermittent vaginal bleeding. As discussed above, the half-life of anti-D-immune globulin is about three weeks (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Anti-d immune globulin'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Given the pharmacokinetics of anti-D-immune globulin, we agree with the ACOG recommendation to monitor the maternal indirect Coombs titer every three weeks in women with recurrent antepartum bleeding who have received a dose of this drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"     3",
"    </a>",
"    ]. If the result is positive, indicating that anti-D immune globulin from the previous dose of prophylaxis is still present, no additional treatment is necessary. If the result is negative, then the woman may not be protected. In these cases, a test to evaluate the volume of fetal red blood cells in the maternal circulation is obtained and a repeat dose of 300 micrograms of anti-D immune globulin is administered, with additional dosing if indicated by the results of testing for fetomaternal hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum administration of anti (D)-immune globulin significantly reduces the risk of maternal alloimmunization. This was illustrated in a 2000 Cochrane review of randomized trials comparing postpartum anti-D prophylaxis with no",
"    <span class=\"nowrap\">",
"     treatment/placebo",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment within 72 hours of birth dramatically lowered the incidence of Rh(D) alloimmunization in a subsequent pregnancy: relative risk 0.12, 95% CI 0.07-0.23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Postpartum routine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and others recommend administration of 300 micrograms of anti-D immune globulin within 72 hours of delivery of an Rh(D)-positive infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. This dose of immune globulin is adequate to protect against maternal sensitization from as much as 15 mL red blood cells (30 mL Rh(D)-positive fetal whole blood). The incidence of fetomaternal hemorrhage greater than 20 to 30 mL at delivery is estimated to be about 1 in 200 to 300 deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Fetomaternal hemorrhage greater than 80 mL and greater than 150 mL is estimated to occur in 1 in 1000 deliveries and 1 in 5000 deliveries, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/37\">",
"     37",
"    </a>",
"    ]. Risk factors (eg, cesarean delivery) will only identify 50 percent of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, we suggest routine testing of all women for excessive fetomaternal bleeding at the time of delivery (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Testing for fetomaternal hemorrhage'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, a lower dose of anti-D immune globulin can be given postpartum (eg, 100 to 120 micrograms), with routine testing for fetomaternal hemorrhage and administration of more drug if more than 5 to 6 mL of fetal red blood cells are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Testing for fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rosette test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/40\">",
"     40",
"    </a>",
"    ] is a qualitative, yet sensitive, test for fetomaternal hemorrhage. We suggest performing this test as an initial screen. A standard dose of anti-D immune globulin is given to patients with a negative test. The test is designed to give a negative result when the amount of fetomaternal hemorrhage is small (&lt;2 mL or 0.04 percent fetal cells) and thus will not necessitate additional doses of anti-D immune globulin; few cases require confirmatory quantitative testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive rosette test for fetomaternal hemorrhage should be evaluated further (see",
"    <a class=\"local\" href=\"#H5478312\">",
"     'Evaluation and management of large fetomaternal hemorrhages'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5478312\">",
"    <span class=\"h4\">",
"     Evaluation and management of large fetomaternal hemorrhages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the calculation for determining fetomaternal hemorrhage depends upon an estimation of the maternal blood volume, which is not directly measured, the blood bank should be consulted if there has been a large fetomaternal hemorrhage. When the College of American Pathologists evaluated laboratory accuracy of anti-D immune globulin dose calculation among laboratories participating in proficiency testing, they found that 9 percent recommended a dose of anti-D immune globulin that was too low and 11 percent recommended a dose that was too high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=see_link\">",
"     \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the rosette test is positive, a Kleihauer-Betke test or flow cytometry is recommended to determine the percentage of fetal red blood cells in the maternal blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/43\">",
"     43",
"    </a>",
"    ]. (It should be noted that women with hereditary persistence of fetal hemoglobin will have a high proportion of fetal hemoglobin that is not due to fetomaternal transfusion). The percentage of fetal red blood cells is multiplied by 50 to estimate the volume of the fetomaternal hemorrhage (50 is the factor used to represent the average maternal blood volume of 5 liters). This is then divided by 30 to determine the number of vials of anti-D immune globulin that should be administered.",
"   </p>",
"   <p>",
"    Because of the risk of underdosing, the American Association of Blood Banks standards recommend that calculation of fractional units of anti-D immune globulin &ge;0.5 be rounded up to the next higher whole number and that at least one additional vial of anti-D immune globulin be administered over the calculated amount of 300 micrograms per 15 mL fetal red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/44\">",
"     44",
"    </a>",
"    ]. In the proficiency testing study discussed above, providing one additional dose of immune globulin would have prevented underdosing in all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the American College of Pathology has provided a calculator in Microsoft Excel&reg; format that takes maternal height and weight into account when determining the maternal blood volume. This calculator provides a more accurate estimate of the correct dose of anti-D immune globulin than other methods of calculation, and can be found at",
"    <a class=\"external\" href=\"file://www.cap.org/apps/docs/committees/transfusionmedicine/rhigcale.zip\">",
"     file://www.cap.org/apps/docs/committees/transfusionmedicine/RHIGcale.zip",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    No more than five 300 microgram doses should be administered intramuscularly in a 24-hour period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/17\">",
"     17",
"    </a>",
"    ]. However, large doses, if indicated, can be given using an intravenous preparation (WinRho SDF&reg;, Rhophylac&reg;). In these cases, no more than 600 micrograms should be given every eight hours intravenously until the total calculated dose is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Additional considerations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large fetomaternal hemorrhage at delivery in the RhD-negative patient may cause a mixed field agglutination reaction and make the patient appear to be weakly RhD-positive. Having a prior typing of the mother as RhD-negative aids in the interpretation of such a result. Interpretation of these results in consultation with the blood bank is recommended. Quantitation of the volume of the fetomaternal hemorrhage should be undertaken using the Kleihauer-Betke stain or flow cytometry and the appropriate dose of Rhesus immune globulin administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/46\">",
"       46",
"      </a>",
"      ]. This dose and appropriate hematological follow-up should be determined in consultation with the blood bank.",
"     </li>",
"     <li>",
"      If anti-D immune globulin is inadvertently omitted after delivery, it should be given as soon as possible after recognition of the omission. Partial protection is afforded with administration within 13 days of the birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/47\">",
"       47",
"      </a>",
"      ], and some experts recommend giving it as late as 28 days after delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/1,48\">",
"       1,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A delivery that occurs less than three weeks from the administration of anti-D immune globulin for the usual indications does not require a repeat dose, unless a large fetomaternal hemorrhage is detected in the immediate postpartum period.",
"     </li>",
"     <li>",
"      Whether anti-D immune globulin should be administered after a postpartum tubal ligation is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/3\">",
"       3",
"      </a>",
"      ]. Some of these women will subsequently become pregnant as a result of a failed procedure, reanastomosis of the fallopian tubes, or in vitro fertilization. In addition, RhD sensitization will limit the availability of red cell units should a patient require an emergency blood transfusion later in life. These women could benefit from having received prophylaxis, but such an approach is unlikely to be cost-effective.",
"     </li>",
"     <li>",
"      In approximately 30 percent of patients whose sera contain anti-C and anti-D, an anti-RhG antibody can be detected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/49\">",
"       49",
"      </a>",
"      ]. In a typical RhD sensitized patient, the RhD titer exceeds that of RhC (example: anti-D: 64, anti-C: 4). The clinician can suspect the presence of anti-RhG if the RhC titer equals or exceeds the RhD titer (example: anti-D: 64, anti-C: 64) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/50\">",
"       50",
"      </a>",
"      ]. In this situation, consultation with a blood bank pathologist is indicated for specific testing to check for the presence of anti-D. If only anti-C and anti-G are found, the patient is at risk for RhD alloimmunization and standard indications for the administration of anti-D immune globulin should be followed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of doses of anti-D immune globulin are issued from hospital blood banks, these preparations can be purchased by private physicians for use in their offices. The recall of this product by one manufacturer warrants that careful records of lot numbers be documented in the patient's medical chart as well as a logbook so that patients can be contacted if a problem becomes known or reassured as to the product they received.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11888613\">",
"    <span class=\"h2\">",
"     Guidelines from other countries",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Canada [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.rcog.org.uk/womens-health/clinical-guidance/use-anti-d-immunoglobulin-rh-prophylaxis-green-top-22\">",
"       United Kingdom",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.ranzcog.edu.au/component/content/article/270-revised-statement-guidelines/419--guidelines-for-the-use-of-rh-d-immunoglobulin-anti-d-in-obstetrics-in-australia-c-obs-6-.html\">",
"       Australia",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2006, the FDA published an advisory that the liquid formulation of WinRho&reg; SDF contains maltose, which can give falsely high blood glucose levels in certain types of blood glucose testing systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/51\">",
"     51",
"    </a>",
"    ]. Due to the potential for falsely elevated glucose readings, only testing systems that are glucose-specific should be used to test or monitor blood glucose levels in patients recently receiving WinRho&reg; SDF Liquid.",
"   </p>",
"   <p>",
"    There is no evidence that maternal administration of anti-D immune globulin results in any significant risk of fetal anemia, enhancement of maternal primary immune response to Rh(D)-positive RBCs, adverse obstetrical outcome, reduced maternal response to postpartum rubella immunization, or short- or long-term harm to the fetal immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Serious adverse reactions are rare: from 1990 to 2000, during which time 2.9 million doses of one manufacturer's anti-D immune globulin were given, the manufacturer received only 11 reports of adverse events possibly related to the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks of hepatitis C related to anti-D immune globulin administration have been reported in Germany and Ireland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. These outbreaks were due to viral contamination of the drug, a risk that has been potentially eliminated by the inclusion of solvent detergent treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    filtration with micropore filters during the manufacturing process. Thimerosal, a mercury preservative used to prevent bacterial and fungal contamination, had been used in anti-D globulin products in the past, but the FDA mandated its removal from these products several years ago.",
"   </p>",
"   <p>",
"    There is no evidence that anti-D immune globulin administration can transmit prions associated with Creutzfeldt-Jakob disease (CJD). Available epidemiologic studies suggest that a history of preceding transfusion does not increase the risk of developing CJD. However, human-to-human transmission of prion diseases can occur under special circumstances, and low levels of infectivity have been noted when whole blood, serum, or buffy coat derived from patients with CJD is inoculated into animals. Therefore, as a precaution, all anti-D immune globulin used in the United Kingdom is manufactured from plasma from the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inadvertent administration of anti(D)-immune globulin to an Rh(D)-positive woman is not harmful. Although a positive direct Coombs may result, red cell hemolysis has not been reported. Much higher doses of anti(D)-immune globulin (50",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    are sometimes used to treat immune thrombocytopenia (ITP) in nonpregnant Rh(D)-positive patients, and can cause a fall in hemoglobin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NONPREGNANT PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of Rh(D)-positive blood to Rh(D)-negative women rarely occurs in settings other than fetomaternal hemorrhage. Units of platelets from Rh(D)-positive donors contain less than 0.1 mL of red cell contamination per adult therapeutic unit transfused. However, a study of 59 Rh(D)-negative patients who received platelets from Rh(D)-positive donors found that eight (13.5 percent) developed detectable anti-D antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/56\">",
"     56",
"    </a>",
"    ]. One to three units of platelets had been transfused to the patients for nonhematological conditions (eg, surgery, pneumonia). Prophylactic anti-D immune globulin should be considered for premenopausal women receiving Rh(D) incompatible platelet transfusions. The RCOG recommends 250 IU (50 mcgs) be administered for every 18 units of random donor platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfusion of Rh(D)-positive red blood cells into an Rh(D)-negative recipient may occur because of administrative error or emergent circumstances. Anti-D immune globulin should be administered to premenopausal women to prevent alloimmunization for small volume transfusions. In the case of transfusions of greater than 2 units, consultation with a hematologist is recommended. Exchange transfusion with Rh(D) negative red cells can be undertaken to reduce the antigenic load. Sufficient anti-D should be administered to clear circulating Rh(D) positive cells using intravenous preparations to minimize patient discomfort. Serial testing should be repeated every 48 hours with additional anti-D given as needed until the RhD cells are cleared from the circulation. Testing for RhD sensitization should be deferred for 9 to 12 months to allow for the degradation of the exogenously administered anti-D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40648/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=see_link&amp;anchor=H14#H14\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Rh blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/59/4019?source=see_link\">",
"       \"Patient information: Pregnancy in Rh-negative women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All Rh(D)-negative pregnant women should undergo an antibody screen at the first prenatal visit. If the initial screen is negative, a routine repeat screen at 28 weeks of gestation is optional. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antepartum routine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following recommendations apply to women who are Rh(D)-negative and whose fetus is, or may be, Rh(D)-positive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend routine administration of anti-D immune globulin early in the third trimester (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimum dose regimen in the United States is 300 micrograms at 28 weeks of gestation; other countries use 100 to 120 micrograms at 28 and 34 weeks. This practice reduces the incidence of antenatal alloimmunization from 2 to 0.1 percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antepartum routine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of antenatal anti-D immune globulin when there is an increased risk of fetomaternal hemorrhage (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Some examples include miscarriage, abortion, ectopic pregnancy, multifetal reduction, amniocentesis, chorionic villus sampling, blunt abdominal trauma, external cephalic version, antepartum bleeding, and fetal death. We administer 300 micrograms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Additional indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Repeat dosing for situations where there may be an ongoing risk for fetomaternal hemorrhage (such as chronic placental abruption or placenta previa with intermittent vaginal bleeding) can be managed with serial determinations of the maternal indirect Coombs every three weeks with repeat dosing if it is found to be negative.",
"     </li>",
"     <li>",
"      We recommend administration of anti-D immune globulin within 72 hours of delivery of an Rh(D)-positive infant (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We administer 300 micrograms and also test for excessive fetomaternal hemorrhage in case additional doses are needed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Postpartum routine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If anti-D immune globulin is inadvertently omitted after delivery, we recommend giving it as soon as possible after recognition of the omission (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Partial protection is afforded with administration within 13 days of the birth, and there may be an effect as late as 28 days after delivery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Additional considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In approximately 30 percent of patients whose sera contain anti-C and anti-D, an anti-RhG antibody can be detected. In a typical RhD sensitized patient, the RhD titer exceeds that of RhC (example: anti-D: 64, anti-C: 4). The clinician can suspect the presence of anti-RhG if the RhC titer equals or exceeds the RhD titer (example: anti-D: 64, anti-C: 64). In this situation, consultation with a blood bank pathologist is indicated for specific testing to check for the presence of anti-D. If only anti-C and anti-G are found, the patient is at risk for RhD alloimmunization and standard indications for the administration of anti-D immune globulin should be followed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Additional considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/1\">",
"      Bowman JM. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol 1985; 151:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/2\">",
"      Bowman JM. The prevention of Rh immunization. Transfus Med Rev 1988; 2:129.",
"     </a>",
"    </li>",
"    <li>",
"     Prevention of Rho(D) alloimmunization. American College of Obstetricians and Gynecologists Practice Bulletin No 4 . American College of Obstetricians and Gynecologists, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/4\">",
"      Centers for Disease Control (CDC). Lack of transmission of human immunodeficiency virus through Rho(D) immune globulin (human). MMWR Morb Mortal Wkly Rep 1987; 36:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/5\">",
"      Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2002; 100:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/6\">",
"      Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev 2013; 1:CD007885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/7\">",
"      Kennedy MS, McNanie J, Waheed A. Detection of anti-D following antepartum injections of Rh immune globulin. Immunohematology 1998; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/8\">",
"      Lee D, Contreras M, Robson SC, et al. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Transfus Med 1999; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/9\">",
"      Maayan-Metzger A, Schwartz T, Sulkes J, Merlob P. Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. Arch Dis Child Fetal Neonatal Ed 2001; 84:F60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/10\">",
"      Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010; 12:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/11\">",
"      Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012; 120:3670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/12\">",
"      Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006; 46:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/13\">",
"      Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 2002; 82:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/14\">",
"      de Silva M, Contreras M, Mollison PL. Failure of passively administered anti-Rh to prevent secondary Rh responses. Vox Sang 1985; 48:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/15\">",
"      Bowman JM, Pollock JM. Reversal of Rh alloimmunization. Fact or fancy? Vox Sang 1984; 47:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/16\">",
"      Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 2003; 25:765.",
"     </a>",
"    </li>",
"    <li>",
"     Silva, M (Ed). Standards for blood banks and transfusion services. 24th ed. American Association of Blood Banks. Amercian Association of Blood Banks, Bethesda, MD, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/18\">",
"      Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978; 118:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/19\">",
"      Crowther CA, Middleton P, McBain RD. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2013; 2:CD000020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/20\">",
"      Parant O. [Comparison of the efficacy of different methods for the prevention of anti-D allo-immunization during pregnancy: targeted strategy limited to risk situations or associated with systematic prevention in the 3rd trimester]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:1S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/21\">",
"      Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. Br J Obstet Gynaecol 1998; 105:129.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Guidance on the use of routine anti-D prophylaxis for RhD-negative women. Guideline #41. May be viewed at (www.nice.org.uk).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/23\">",
"      Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 2004; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/24\">",
"      Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/25\">",
"      M&uuml;ller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/26\">",
"      Van der Schoot CE, Soussan AA, Koelewijn J, et al. Non-invasive antenatal RHD typing. Transfus Clin Biol 2006; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/27\">",
"      Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/28\">",
"      Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/29\">",
"      Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/30\">",
"      Koelewijn JM, de Haas M, Vrijkotte TG, et al. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116:1307.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologist. Green top guidelines. Anti-D immunoglobulin for Rh prophylaxis. RCOG, London, 2002.",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Guidelines. Pregnancy &mdash; routine anti-D prophylaxis for rhesus negative women (no 41). NICE, London, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/33\">",
"      Fedrick J, Adelstein P. Factors associated with low birth weight of infants delivered at term. Br J Obstet Gynaecol 1978; 85:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/34\">",
"      Karanth JL, Jaafar SH, et al. Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2013; :CD009617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/35\">",
"      Wylie BJ, D'Alton ME. Fetomaternal hemorrhage. Obstet Gynecol 2010; 115:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/36\">",
"      Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000; :CD000021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/37\">",
"      de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. Obstet Gynecol 1994; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/38\">",
"      Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/39\">",
"      Rubod C, Deruelle P, Le Goueff F, et al. Long-term prognosis for infants after massive fetomaternal hemorrhage. Obstet Gynecol 2007; 110:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/40\">",
"      Stedman CM, Baudin JC, White CA, Cooper ES. Use of the erythrocyte rosette test to screen for excessive fetomaternal hemorrhage in Rh-negative women. Am J Obstet Gynecol 1986; 154:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/41\">",
"      Kim YA, Makar RS. Detection of fetomaternal hemorrhage. Am J Hematol 2012; 87:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/42\">",
"      Ramsey G, College of American Pathologists Transfusion Medicine Resource Committee. Inaccurate doses of R immune globulin after rh-incompatible fetomaternal hemorrhage: survey of laboratory practice. Arch Pathol Lab Med 2009; 133:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/43\">",
"      Kumpel BM. Analysis of factors affecting quantification of fetomaternal hemorrhage by flow cytometry. Transfusion 2000; 40:1376.",
"     </a>",
"    </li>",
"    <li>",
"     Standards for Blood Banks and Transfusion Services, 25th ed, American Association of Blood Banks, Bethesda, MD 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/45\">",
"      Lafferty J, Raby A, Keeney M, et al. Inaccurate doses of Rh immune globulin after Rh-incompatible fetomaternal hemorrhage-survey of laboratory practice. Arch Pathol Lab Med 2009; 133:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/46\">",
"      Larsen R, Berkowicz A, Lousen T, et al. Massive fetomaternal hemorrhage: clearance of fetal red blood cells after intravenous anti-D prophylaxis monitored by flow cytometry. Transfusion 2008; 48:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/47\">",
"      Samson D, Mollison PL. Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology 1975; 28:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/48\">",
"      Sandler SG, Gottschall JL. Postpartum Rh immunoprophylaxis. Obstet Gynecol 2012; 120:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/49\">",
"      Issitt PD, Tessel JA. On the incidence of antibodies to the Rh antigens G, rhi(Ce), C, and CG in sera containing anti-CD or anti-C. Transfusion 1981; 21:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/50\">",
"      Trevett TN Jr, Moise KJ Jr. Twin pregnancy complicated by severe hemolytic disease of the fetus and newborn due to anti-g and anti-C. Obstet Gynecol 2005; 106:1178.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2006/safety06.htm#WinRho (accessed January 9, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/52\">",
"      Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998; 105 Suppl 18:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/53\">",
"      Jones ML, Wray J, Wight J, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 2004; 111:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/54\">",
"      Yap PL. Viral transmission by blood products: a perspective of events covered by the recent tribunal of enquiry into the Irish Blood Transfusion Board. Ir Med J 1997; 90:84, 86, 88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/55\">",
"      Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/56\">",
"      Atoyebi W, Mundy N, Croxton T, et al. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 2000; 111:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40648/abstract/57\">",
"      Nester TA, Rumsey DM, Howell CC, et al. Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin. Transfusion 2004; 44:1720.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6773 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40648=[""].join("\n");
var outline_f39_44_40648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTI-D IMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GUIDELINES FOR USE OF ANTI-D IMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Antepartum routine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5320208\">",
"      Free fetal DNA testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Second antepartum dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Additional indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19876668\">",
"      - Repeating antepartum doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postpartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Postpartum routine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Testing for fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5478312\">",
"      Evaluation and management of large fetomaternal hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Additional considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11888613\">",
"      Guidelines from other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NONPREGNANT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/1/8219\" title=\"table 1\">",
"      Indications for anti-(D) immune globulin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/59/4019?source=related_link\">",
"      Patient information: Pregnancy in Rh-negative women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40649="Overview of the outcome of acute lymphoblastic leukemia in children";
var content_f39_44_40649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the outcome of acute lymphoblastic leukemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Terzah M Horton, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     C Philip Steuber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40649/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/44/40649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the acute leukemias, acute lymphoblastic leukemia (ALL) occurs five times more commonly than does acute myeloid leukemia (AML). Survival rates for ALL have improved dramatically since the 1980s, with a current five-year overall survival rates estimated at greater than 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This improvement in survival is due to treatment of a large number of children on sequential standardized research protocols. Approximately 75 to 80 percent of children with newly diagnosed ALL participate in such trials, the goals of which are to improve clinical outcomes while minimizing acute toxicities and late-occurring adverse events.",
"   </p>",
"   <p>",
"    The outcome of ALL in children is reviewed here. Presentation, classification, risk group stratification, and treatment of childhood ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29268309\">",
"    <span class=\"h2\">",
"     Event free survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Event-free survival (EFS) rates for ALL have steadily improved since the 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The overall five-year EFS for childhood ALL currently approaches 80 percent in the developed world, and the 10-year EFS is about 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/5\">",
"     5",
"    </a>",
"    ]. The five- and estimated 10-year survival rates for patients diagnosed from 2000 to 2004 were 88 and 84 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/6\">",
"     6",
"    </a>",
"    ]. The 10-year survival rate for children diagnosed in the 2005 to 2009 period is estimated to be 88 percent.",
"   </p>",
"   <p>",
"    In contrast, in the developing world, cure rates are less than 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/8\">",
"     8",
"    </a>",
"    ], in part because of abandonment of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/9\">",
"     9",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of dedicated, multidisciplinary pediatric oncology units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/10\">",
"     10",
"    </a>",
"    ]. Individual prognosis in the developed world varies according to risk group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five-year EFS rates are highest (&gt;90 percent) for patients with low- or standard-risk B-precursor ALL who have a good response to induction chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/11-17\">",
"       11-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with high-risk features at presentation and a good early response to induction chemotherapy have a &gt;80 percent five-year EFS with intensive chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/11-17\">",
"       11-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subset of very-high-risk patients, such as those with hypodiploid karyotype (less than 44 chromosomes) or slow response to induction chemotherapy, have a poor prognosis, with expected five-year EFS of less than 45 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with T cell ALL have variable outcomes. Those without high-risk features do relatively well. However, the majority (70 percent in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/21\">",
"       21",
"      </a>",
"      ]) have high-risk features at presentation (eg, unfavorable age or high WBC count). In one study of 694 children with ALL, overall six-year EFS among the 371 patients with T cell ALL was 62 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The outcome for children with mature B cell ALL has improved over the past several years. In one study, seven-year EFS for 151 patients with Burkitt-type lymphomas, including mature B cell ALL, was 81 percent. Patients with mature B cell ALL were treated using highly aggressive B cell lymphoma treatment protocols [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients with B cell ALL who relapse tend to have early recurrences. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37753?source=see_link&amp;anchor=H12#H12\">",
"       \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\", section on 'Mature B cell ALL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The outcome for children with Philadelphia chromosome (Ph+) ALL has had a significant increase in EFS with the introduction of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35352?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/24\">",
"       24",
"      </a>",
"      ]. One study of 65 patients with Ph+ ALL reported the addition of imatinib to an intensive chemotherapy resulted in an increase in three-year FS from 35 to 80 percent.",
"     </li>",
"     <li>",
"      The prognosis for infant ALL is poor, with an EFS of 10 to 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Aggressive treatment protocols have resulted in improved outcome in some studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/27-30\">",
"       27-30",
"      </a>",
"      ]. The outcome for infants less than 90 days at diagnosis who have the t(4;11) MLL translocation is substantially worse than for older infants without this translocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the length of time from completion of therapy to recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A majority (60 to 75 percent) of patients who relapse after successful completion of an initial therapy regimen do so within the first year of completion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk of relapse decreases by 7 to 10 percent per year in the second through fourth years after treatment cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/35\">",
"     35",
"    </a>",
"    ]. Recurrences after four years are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As survival from childhood leukemia increases, there has also been an increase in the proportion of children who are \"cured\" from their disease, defined as the proportion of survivors for whom, as a group, there is no excess mortality compared to the general population. In one study, data on children diagnosed with leukemia during 1971 to 2000 in Great Britain demonstrated an increase in the cure rate from 25 to 68 percent by 1995 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, the estimated cumulative risk of leukemic relapse 30 years after the induction of remission for those with 10 years of event-free survival was 0.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/37\">",
"     37",
"    </a>",
"    ]. For the subgroup of children not receiving radiation therapy, long-term survival (98.3 percent at 30 years) was similar to that of the general United States population matched for age, sex, and race.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment-related mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the vast majority of children with ALL enjoy long-term",
"    <span class=\"nowrap\">",
"     survival/cure,",
"    </span>",
"    the serious nature of the disease, as well as the aggressiveness of the treatment programs employed in obtaining such results (eg, use of corticosteroids, central lines, antibiotics, chemotherapy, hematopoietic cell transplantation), have resulted in significant treatment-related mortality (TRM).",
"   </p>",
"   <p>",
"    Much of the TRM occurs during the first year of ALL treatment, often during induction or shortly thereafter. Estimates of overall TRM (ie, deaths during induction plus during first complete remission) have ranged from 2.6 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. As an example, in a study from the Nordic countries covering 1652 children with ALL diagnosed between 1992 through 2001, TRM during induction and TRM while in first CR were 1.2 and 2.2 percent, respectively, with infection being the most frequent cause of death (68 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/41\">",
"     41",
"    </a>",
"    ]. The presence of Down syndrome (RR 4.5, 95% CI 2.0-10) significantly increases the risk for TRM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Down syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with trisomy 21 are at increased risk for development of several hematopoietic disorders, including transient myeloproliferative disease during the newborn period, acute myeloid leukemia (most commonly the FAB M7 subtype) later in infancy, and both myeloid and lymphoid leukemias in childhood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    B-precursor ALL is the most common type of leukemia among patients with Down syndrome (DS). Children with DS who develop ALL are usually younger than 10 years of age and often respond to chemotherapy as well as do children without DS. However, children with DS are more likely to experience severe toxicity with standard chemotherapy regimens, particularly those requiring",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and often require reduced doses of chemotherapy. Because children with DS have a higher incidence of treatment-related toxicity, their survival rate is generally inferior to that of children without DS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, children with DS had an increased number of deaths caused by infection (11 versus 2 percent), a decreased five-year survival (73 versus 82 percent), and decreased EFS (53 versus 63 percent) when compared to ALL children without DS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/42\">",
"     42",
"    </a>",
"    ]. These findings emphasize the need for providing aggressive supportive care for patients with DS and ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the frequency of genetic abnormalities seen in ALL that develops in children with DS is different from that of ALL that develops in children without DS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. While ETV6-RUNX1 (30 percent) and trisomies (30 percent) are the most common genetic abnormalities seen in common B cell precursor ALL in children without DS, these mutations were much less frequent in patients with DS (ETV6-RUNX1: 2.5 percent and trisomies 4 and 10: 7.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/46\">",
"     46",
"    </a>",
"    ]. Instead, the most common genetic abnormality seen in ALL that develops in children with DS is the overexpression of CRLF2 and JAK2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Although JAK2 mutations and CRLF2 overexpression have clearly been associated with poor prognosis in patients with non-DS ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/48\">",
"     48",
"    </a>",
"    ], the prognostic significance of these molecular changes in DS-ALL remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LATE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long-term survival in ALL improves, more children experience late adverse effects including CNS impairment, decreased linear growth, cardiotoxicity, infertility, and an increased incidence of secondary cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/51\">",
"     51",
"    </a>",
"    ], as well as an overall decreased health status due to such factors as neurocognitive dysfunction, depression, fatigue, and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of specific complications depends upon the patient's age and the type and intensity of therapy with which they were treated. As an example, neurocognitive decline is more likely to occur in children younger than six years who received CNS radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/54\">",
"     54",
"    </a>",
"    ], whereas decreased fertility is more common among adolescents who received alkylating agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CNS and cognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of leukemia treatment on CNS development are variable. Decline in cognitive function in children treated for ALL has historically been a common finding, particularly in those who received cranial radiation or triple intrathecal chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/54,56,57\">",
"     54,56,57",
"    </a>",
"    ]. As an example, in one report, Finnish patients with ALL who received cranial radiation at an early age were compared with matched controls and had lower ninth-grade school reports in all school subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/58\">",
"     58",
"    </a>",
"    ]. Current therapy regimens have reduced or eliminated cranial radiation from the CNS preventive therapy for the majority of patients with ALL in an attempt to minimize the incidence and severity of cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Initial reports suggest that these measures have decreased the incidence and severity of cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children younger than six years of age who received high-dose cranial radiotherapy (&ge;24 Gy) in combination with intrathecal chemotherapy are at the greatest risk for incurring subsequent CNS impairment. In one study of long-term toxicity in 150 ALL survivors, intellectual performance was evaluated with standardized neuropsychological tests (age-adapted versions of the Wechsler test) for a median follow-up time of 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/56\">",
"       56",
"      </a>",
"      ]. Eighty-three percent had minimal or no impairment, 14 percent had moderate deficiencies, and 3 percent had severe cognitive dysfunction.",
"     </li>",
"     <li>",
"      Another study demonstrated that patients (age range 4 to 12.3 years) treated only with intrathecal and systemic chemotherapy had similar neurophysiologic performance compared to control siblings at a mean follow-up of 4.5 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/63\">",
"       63",
"      </a>",
"      ]. The one exception was poorer fine-motor functioning in patients.",
"     </li>",
"     <li>",
"      Another study evaluated the cognitive function of children treated on a protocol that omitted prophylactic cranial irradiation in all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/62\">",
"       62",
"      </a>",
"      ]. This study used standardized testing at 120 weeks after completion of consolidation therapy. Children with ALL had preserved functioning on global measures of intellectual functioning, academic abilities, learning, and memory. However, measures of sustained attention were lower than those in the control group. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies support the current trend towards limiting cranial irradiation and suggest that all patients with ALL should be monitored for the development of both early attention deficits and late cognitive deficits. CNS preventative therapy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'CNS preventive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link&amp;anchor=H27#H27\">",
"     \"Complications of cranial irradiation\", section on 'Acute lymphoblastic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of childhood leukemia are also at increased risk for late-occurring stroke. This was illustrated in a report from the Childhood Cancer Survivor Study that demonstrated an increased incidence of stroke in &ge;5-year survivors of childhood leukemia compared to their siblings (RR 6.4, 95% CI 3 to 13.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/64\">",
"     64",
"    </a>",
"    ]. The risk of developing stroke in patients who received chemotherapy only or low dose radiation (&lt;30 Gy) did not differ from age-matched siblings. However, patients who received previous cranial radiation greater than 30 Gy compared to those who only received chemotherapy were more likely to have late-occurring stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult survivors of childhood leukemia are at risk for late-onset auditory-vestibular-visual sensory deficits, coordination and motor problems, seizures, and headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/65\">",
"     65",
"    </a>",
"    ]. These neurological findings were more likely to occur in patients who relapsed or had received either intracranial radiation or high dose intrathecal chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neurologic follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging with computed tomography (CT) or magnetic resonance imaging (MRI) and frequent neurocognitive testing are recommended for children who survive ALL, particularly those who received high-dose radiotherapy and intrathecal chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/66\">",
"     66",
"    </a>",
"    ]. CT scanning is used to detect intracranial calcifications and MRI to detect subtle abnormalities in myelinization. A standard interval for CT monitoring has not been determined. However, we recommend that ALL survivors have a CT scan performed at the end of treatment and at three-year intervals if CT abnormalities are noted.",
"   </p>",
"   <p>",
"    Similarly, the optimal interval for neurocognitive testing has yet to be determined. We recommend neurocognitive testing before beginning school and every three to four years thereafter. More frequent testing is recommended (eg, every two years) if neurocognitive abnormalities are noted. Subtle behavioral and educational sequelae may also be noted in survivors of childhood ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Height",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, but not all, children with ALL experience \"catch-up\" growth after completion of chemotherapy. However, some children have permanent short stature, the cause of which is not entirely clear.",
"   </p>",
"   <p>",
"    This was best illustrated in a study from the Childhood Cancer Survivor Study that determined adult height for 2434 ALL survivors and 3009 of their siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/68\">",
"     68",
"    </a>",
"    ]. Height comparisons for ALL survivors and their siblings were based upon the patients' treatment exposure, which included chemotherapy alone, chemotherapy and cranial radiation, or chemotherapy and craniospinal radiation. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to their siblings, all three ALL treatment exposure groups had decreased adult height and an increased risk of adult short stature (height standard deviation scores less than -2), (OR 12.5, 95% 8.1-19.2).",
"     </li>",
"     <li>",
"      Patients treated only with chemotherapy had a threefold increased risk of short stature compared to their siblings (OR 3.4, 95% CI 1.9-6). No specific chemotherapy agent was identified as increasing the risk of short stature.",
"     </li>",
"     <li>",
"      Identified risk factors for short stature included diagnosis of ALL before puberty, higher-dose cranial radiotherapy (&ge;20 Gy versus &lt;20 Gy), any radiotherapy to the spine, and female sex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with ALL may have low growth hormone (GH) levels possibly due to abnormal hypothalamic-pituitary function from cranial radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Others may have undiagnosed mild primary or central hypothyroidism. In addition, children with ALL are at increased risk for developing osteoporosis, which can result in vertebral compression fractures and loss of height [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/70\">",
"     70",
"    </a>",
"    ]. A more general discussion of growth failure and bone problems in childhood cancer patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4538?source=see_link&amp;anchor=H13#H13\">",
"     \"Bone problems in childhood cancer patients\", section on 'Reduced bone mineral density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term survivors of childhood ALL may have an increased incidence of obesity and other cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/71-76\">",
"     71-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, an increased risk for obesity was found in a large retrospective cohort analysis from the Childhood Cancer Survivor Study (CCSS) of 1765 adult survivors of childhood ALL and 2565 adult siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/73\">",
"     73",
"    </a>",
"    ]. The following findings were noted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age- and race-adjusted risk for being obese (body mass index [BMI] &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      in survivors treated with cranial radiation doses &ge;20 Gy, in comparison with siblings, was 2.6 for females (95% CI 1.9-3.6) and 1.9 for males (95% CI 1.3-2.6).",
"     </li>",
"     <li>",
"      The risk was greatest for females diagnosed at birth to four years of age and treated with cranial radiation doses &ge;20 Gy (OR 3.8, 95% CI 2.3-6.0).",
"     </li>",
"     <li>",
"      There was no difference in the rate of obesity between patients treated with chemotherapy alone, or chemotherapy and cranial radiation doses of 10 to 19 Gy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report from the CCSS, adult survivors treated with cranial radiation compared to control adult siblings had a significantly greater increase in BMI, especially among female survivors treated with cranial radiation during the first decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study from the CCSS suggested that leptin receptor (LEPR) gene polymorphism, which is associated with leptin insensitivity, was more commonly found among female survivors of childhood ALL, particularly those who were treated with cranial irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/74\">",
"     74",
"    </a>",
"    ]. In a study of 273 young adults from a single center, cranial radiation increased the risk of adiposity, insulin resistance, dyslipidemia, and higher leptin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a single center study of 165 children of which only 19 percent were exposed to cranial radiotherapy of 18 Gy, 21 percent of patients were obese (BMI &gt; 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and 17 percent were overweight (BMI between 25 and 29",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    at a median follow-up of 5.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/75\">",
"     75",
"    </a>",
"    ]. In multivariate analysis, increasing BMI was associated with higher level of corticosteroid exposure but not exposure to cranial radiotherapy.",
"   </p>",
"   <p>",
"    In contrast, a prospective study from a single center of 456 children who were treated under a single protocol found that the prevalence of obesity in the 248 ALL survivors who attained adult height was comparable to that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/78\">",
"     78",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of obesity was 16 percent in adolescent survivors (13 to 19 years of age) compared to a rate of 15.5 percent of adolescents (12 to 19 years of age) from a national survey. In survivors older than 20 years of age, the rate of obesity or overweight was 46 percent compared to a rate of 55 percent in the general population.",
"     </li>",
"     <li>",
"      Risk factors for obesity in ALL survivors included a young age (younger than six years of age) and being overweight or obese at the time of diagnosis.",
"     </li>",
"     <li>",
"      There was no difference in the rate of obesity between patients treated with radiation and those who did not receive radiation. In addition, the dose of cranial radiation (18 versus 24 Gy) did not affect the rate of obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survivors who are obese compared to those who are not obese may have a greater risk of relapse. This was illustrated in a report that analyzed data from the Children's Cancer Group from 1995 to 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients who were obese compared to nonobese survivors had a lower five-year EFS rate (72 versus 77 percent) and a higher risk of relapse (26 versus 20 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with anthracyclines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31029?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) may cause cardiovascular complications, including irreversible and fatal cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/80\">",
"     80",
"    </a>",
"    ]. However, with the doses of anthracyclines used in current regimens, cardiotoxicity is an infrequent occurrence. Strategies for preventing anthracycline cardiotoxicity and monitoring children for acute and late manifestations of cardiotoxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H36#H36\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Issues in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Second neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 2 to 3 percent of childhood ALL survivors develop a second malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The risk is greatest among patients who received cranial radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/83,84\">",
"     83,84",
"    </a>",
"    ] or intensive therapy for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/85\">",
"     85",
"    </a>",
"    ]. Brain tumors and hematologic malignancies, such as acute myeloid leukemia (AML), are the most common secondary malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/81,83\">",
"     81,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 856 patients with childhood ALL who had at least 10 years of event-free survival, 44 developed second malignancies, 41 of which were radiation related. The estimated rates for second malignancy 30 years after remission induction were 20.9 and 0.95 percent for those receiving or not receiving radiation therapy, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/37\">",
"     37",
"    </a>",
"    ]. Virtually all of the tumors in the former group were located in the field of irradiation, and most were either benign or low-grade. The most common tumors in the radiated group were basal cell carcinomas (10), meningiomas (10), malignant brain tumors (5), and thyroid carcinoma (4).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Brain tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one review of almost 10,000 children treated for ALL, the risk of developing a primary brain tumor, particularly an astrocytoma, was increased by 22-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/86\">",
"     86",
"    </a>",
"    ]. This corresponds to a 10- to 20-year cumulative incidence of 1 to 2 percent. Brain tumors were seen only in children who had previously undergone cranial irradiation. Similar findings were noted in another, smaller series of children with ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/87\">",
"     87",
"    </a>",
"    ]. Children treated with cranial irradiation for ALL also may develop glioblastoma multiforme. In one series of 37 such children, three of these tumors were multifocal, an unusual finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of prophylactic cranial irradiation and orally administered 6-mercaptopurine (6MP) has resulted in a much higher than expected incidence of brain tumors in survivors of ALL who have genetic defects in 6MP metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult survivors of childhood ALL who received cranial radiation are also at high-risk of developing subsequent meningiomas. In a case series of 49 cranially irradiated adult survivors, 11 (22 percent) developed meningiomas at a mean follow-up of 25 years (range 14 to 34 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/89\">",
"     89",
"    </a>",
"    ]. No other brain tumors were detected. Meningiomas occurred only in patients who received cranial irradiation doses &ge;21 Gy. The incidence of meningioma was higher in patients (47 percent) treated by 1980 (greater than 20 year follow-up) who received irradiation doses between 21 and 25 Gy. Although no meningioma had been detected in patients treated with lower radiation dose (18 Gy) after 1980, it remains unknown whether these patients will develop a meningioma over time as the latency period was shorter for these patients. These results suggest periodic brain imagining in cranially irradiated adult survivors of ALL, particularly if they are symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of childhood ALL are at risk for the development of a secondary hematologic malignancy. One study evaluated the risk of developing acute myeloid leukemia (AML) during initial remission in 733 children with ALL who were treated with intensive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/90\">",
"     90",
"    </a>",
"    ]. At six years of follow-up, the cumulative risk of development of secondary AML was 5 percent (95% CI: 2-10 percent). The risk was greater among patients with T cell ALL (cumulative risk at six years of follow-up: 19 percent, 95% CI: 6-47 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic beta cell function and glucose metabolism may be altered during the acute phase of ALL therapy by L-asparaginase,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , or the leukemic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. A retrospective study of 167 children with ALL reported that hyperglycemia during induction was associated with an increase in mortality and relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/93\">",
"     93",
"    </a>",
"    ]. Prospective studies are needed to confirm this observation, and if there is an association between hyperglycemia during induction and outcome, further investigations will be needed to see if treatment of hyperglycemia improves outcome.",
"   </p>",
"   <p>",
"    In some patients, abnormal glucose metabolism may persist after completion of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/94\">",
"     94",
"    </a>",
"    ]. Glucose metabolism was studied in 32 children with ALL who were off of therapy for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/95\">",
"     95",
"    </a>",
"    ]. Among these children, 22 (69 percent) had an impaired insulin response, 9 had impaired glucose tolerance, and 1 had overt diabetes. Abnormal glucose metabolism was indirectly related to duration of time off of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reproductive health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproductive capacity and sexual function of ALL survivors are affected by age at time of therapy and treatment regimen. Postpubescent males with ALL can have treatment-related declines in reproductive function, particularly if they were treated with high-dose alkylating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/55\">",
"     55",
"    </a>",
"    ]. The gonadal function and fertility of prepubescent ALL patients, however, are relatively unaffected by current treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both males and females are more likely to have decreased fertility if treated with high-dose (24 Gy) cranial radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/96\">",
"     96",
"    </a>",
"    ]. Women are more likely to have decreased fertility if they received cranial radiotherapy around the time of menarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital abnormalities are no more common among the offspring of ALL survivors than the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40649/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/40/24194?source=see_link\">",
"       \"Patient information: Leukemia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although cure rates for childhood acute lymphoblastic leukemia approach 90 percent in many studies, children with adverse prognostic indicators (eg, hypodiploidy, slow response to induction therapy, or relapsed ALL) continue to have poor outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term complications are related to the type and intensity of the treatment regimen. Patients with high-risk ALL receive more aggressive chemotherapy and are at greater risk for acute and chronic adverse effects. Late effects include neurodevelopmental impairment, growth retardation, cardiotoxicity, risk for second malignancies, impaired glucose and insulin metabolism, and infertility. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Late effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because they are at risk for long-term complications, it is crucial that survivors of childhood ALL continue regular follow-up with their oncologists after the cessation of chemotherapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Long-term follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Cancer Statistic Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/2\">",
"      Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/3\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/4\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/5\">",
"      Trigg ME, Sather HN, Reaman GH, et al. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 2008; 49:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/6\">",
"      Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008; 100:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/7\">",
"      Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/8\">",
"      Nandakumar A, Anantha N, Venugopal T, et al. Descriptive epidemiology of lymphoid and haemopoietic malignancies in Bangalore, India. Int J Cancer 1995; 63:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/9\">",
"      Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet 2003; 362:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/10\">",
"      Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA 2004; 291:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/11\">",
"      Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002; 99:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/12\">",
"      Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-M&uuml;nster. Leukemia 2000; 14:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/13\">",
"      LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002; 20:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/14\">",
"      Kamps WA, Veerman AJ, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000; 14:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/15\">",
"      Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/16\">",
"      Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/17\">",
"      Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/18\">",
"      Aric&ograve; M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/19\">",
"      Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/20\">",
"      Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/21\">",
"      Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/22\">",
"      Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/23\">",
"      Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-M&uuml;nster Group. J Clin Oncol 1995; 13:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/24\">",
"      Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27:5175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/25\">",
"      Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/26\">",
"      Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/27\">",
"      Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/28\">",
"      Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/29\">",
"      Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Espa&ntilde;ol de Trasplante de M&eacute;dula Osea en Ni&ntilde;os. J Clin Oncol 2000; 18:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/30\">",
"      Chessells JM, Harrison CJ, Kempski H, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002; 16:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/31\">",
"      Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/32\">",
"      Isoyama K, Eguchi M, Hibi S, et al. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 2002; 118:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/33\">",
"      Chessells JM, Leiper AD, Tiedemann K, et al. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child 1987; 62:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/34\">",
"      George SL, Aur RJ, Mauer AM, Simone JV. A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med 1979; 300:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/35\">",
"      Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer 1998; 82:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/36\">",
"      Shah A, Stiller CA, Kenward MG, et al. Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer 2008; 99:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/37\">",
"      Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003; 349:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/38\">",
"      Conter V, Aric&ograve; M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 1998; 83:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/39\">",
"      Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/40\">",
"      Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/41\">",
"      Christensen MS, Heyman M, M&ouml;tt&ouml;nen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005; 131:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/42\">",
"      Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001; 85:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/43\">",
"      Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006; 135:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/44\">",
"      Maloney KW. Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br J Haematol 2011; 155:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/45\">",
"      Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008; 111:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/46\">",
"      Maloney KW, Carroll WL, Carroll AJ, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010; 116:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/47\">",
"      Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/48\">",
"      Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/49\">",
"      Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010; 107:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/50\">",
"      Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/51\">",
"      Robison LL, Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/52\">",
"      Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/53\">",
"      Meeske KA, Siegel SE, Globe DR, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol 2005; 23:5501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/54\">",
"      Moore IM, Espy KA, Kaufmann P, et al. Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Semin Oncol Nurs 2000; 16:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/55\">",
"      Ise T, Kishi K, Imashuku S, et al. Testicular histology and function following long-term chemotherapy of acute leukemia in children and outcome of the patients who received testicular biopsy. Am J Pediatr Hematol Oncol 1986; 8:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/56\">",
"      von der Weid N, Swiss Pediatric Oncology Group (SPOG). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med Wkly 2001; 131:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/57\">",
"      Paolucci G, Vecchi V, Favre C, et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica 2001; 86:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/58\">",
"      Harila-Saari AH, L&auml;hteenm&auml;ki PM, Pukkala E, et al. Scholastic achievements of childhood leukemia patients: a nationwide, register-based study. J Clin Oncol 2007; 25:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/59\">",
"      Waber DP, Shapiro BL, Carpentieri SC, et al. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 2001; 92:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/60\">",
"      von der Weid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer 2003; 39:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/61\">",
"      Jansen NC, Kingma A, Schuitema A, et al. Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study. Eur J Cancer 2006; 42:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/62\">",
"      Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst 2012; 104:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/63\">",
"      Jansen NC, Kingma A, Schuitema A, et al. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. J Clin Oncol 2008; 26:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/64\">",
"      Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24:5277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/65\">",
"      Goldsby RE, Liu Q, Nathan PC, et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/66\">",
"      Iuvone L, Mariotti P, Colosimo C, et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 2002; 95:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/67\">",
"      Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ. Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor. Cancer 2006; 106:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/68\">",
"      Chow EJ, Friedman DL, Yasui Y, et al. Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr 2007; 150:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/69\">",
"      Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol 1995; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/70\">",
"      Alos N, Grant RM, Ramsay T, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 2012; 30:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/71\">",
"      Oeffinger KC, Buchanan GR, Eshelman DA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2001; 23:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/72\">",
"      Warner JT, Evans WD, Webb DK, Gregory JW. Body composition of long-term survivors of acute lymphoblastic leukaemia. Med Pediatr Oncol 2002; 38:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/73\">",
"      Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/74\">",
"      Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004; 22:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/75\">",
"      Chow EJ, Pihoker C, Hunt K, et al. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 2007; 110:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/76\">",
"      Janiszewski PM, Oeffinger KC, Church TS, et al. Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 2007; 92:3816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/77\">",
"      Garmey EG, Liu Q, Sklar CA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008; 26:4639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/78\">",
"      Razzouk BI, Rose SR, Hongeng S, et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2007; 25:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/79\">",
"      Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/80\">",
"      Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/81\">",
"      Kimball Dalton VM, Gelber RD, Li F, et al. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:2848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/82\">",
"      Maule M, Sc&eacute;lo G, Pastore G, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J Natl Cancer Inst 2007; 99:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/83\">",
"      L&ouml;ning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-M&uuml;nster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/84\">",
"      Kadan-Lottick N, Neglia JP. Pediatric acute lymphoblastic leukemia: redefining outcomes. J Pediatr Hematol Oncol 2002; 24:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/85\">",
"      Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer 2008; 44:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/86\">",
"      Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/87\">",
"      Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/88\">",
"      Fontana M, Stanton C, Pompili A, et al. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia. Cancer 1987; 60:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/89\">",
"      Banerjee J, P&auml;&auml;kk&ouml; E, Harila M, et al. Radiation-induced meningiomas: a shadow in the success story of childhood leukemia. Neuro Oncol 2009; 11:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/90\">",
"      Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/91\">",
"      Pastore G, Saracco P, Brach del Prever A, et al. Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Acta Haematol 1984; 72:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/92\">",
"      Dacou-Voutetakis C, Palis J, Haidas S, et al. Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase. Am J Pediatr Hematol Oncol 1983; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/93\">",
"      Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr 2009; 155:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/94\">",
"      Oudin C, Simeoni MC, Sirvent N, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/95\">",
"      Mohn A, Di Marzio A, Capanna R, et al. Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet 2004; 363:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/96\">",
"      Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40649/abstract/97\">",
"      Nygaard R, Clausen N, Siimes MA, et al. Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med Pediatr Oncol 1991; 19:459.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6247 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40649=[""].join("\n");
var outline_f39_44_40649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29268309\">",
"      Event free survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment-related mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LATE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CNS and cognition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neurologic follow-up care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Height",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Second neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Brain tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reproductive health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4538?source=related_link\">",
"      Bone problems in childhood cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37753?source=related_link\">",
"      Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40650="Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults";
var content_f39_44_40650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Detlef Schuppan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Walburga Dieterich, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/44/40650/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/44/40650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease (also called gluten-sensitive enteropathy and nontropical sprue) was first described by Samuel Gee in 1888 in a report entitled \"On the Coeliac Affection\", although a similar description of a chronic, malabsorptive disorder by Aretaeus from Cappadocia (now Turkey) reaches as far back as the second century AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of celiac disease was unexplained until the Dutch pediatrician Willem K Dicke recognized an association between the consumption of bread and cereals and relapsing diarrhea. This observation was corroborated when, during periods of food shortage in the Second World War, the symptoms of his patients improved once bread was replaced by unconventional, non-cereal containing foods; this finding confirmed the usefulness of earlier, empirical diets that used pure fruit, potatoes, banana, milk, or meat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since symptoms reoccurred when bread was reintroduced after the war, Dicke and van de Kamer initiated controlled experiments exposing children with celiac disease to defined diets and then determined fecal weight and fecal fat as a measure of malabsorption. Wheat, barley, rye, and (to a minor degree) oats triggered malabsorption, which could be reversed after exclusion of these \"toxic\" cereals from the diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/4\">",
"     4",
"    </a>",
"    ]. Shortly after, the toxic agents were found to be present in gluten, the alcohol-soluble fraction of wheat protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The celiac lesion in the proximal small intestine was first described in 1954. The primary findings were mucosal inflammation, crypt hyperplasia, and villous atrophy (",
"    <a class=\"graphic graphic_picture graphicRef76680 \" href=\"mobipreview.htm?23/30/24041\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/6\">",
"     6",
"    </a>",
"    ]. With the development of peroral biopsy, it became apparent that celiac disease and adult nontropical sprue shared the same features and pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/7\">",
"     7",
"    </a>",
"    ]. When unrecognized and untreated, celiac disease is associated with increased mortality. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Risk of malignancy and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical manifestations of celiac disease will be reviewed here. Its management and the use of antibodies for diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .) This topic is also discussed in an official position statement issued by the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent intrafamilial occurrence and the remarkably close association with the HLA-DQ2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DQ8 gene loci provide the basis of our current understanding of celiac disease as an immune disorder that is triggered by an environmental agent (the gliadin component of gluten) in genetically predisposed individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It has been estimated that the HLA contribution to the development of celiac disease among siblings is 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, another gene or genes at an HLA-unlinked locus must also participate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. A particular association was found with chromosome 15q26, which contains a type 1 diabetes susceptibility locus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/13\">",
"     13",
"    </a>",
"    ], and with chromosome 5q and possibly 11q [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA typing for DQ2 (DQA1*05; DQB1*02) and DQ8 (DQA1*03; DQB1*0302) may be useful in individuals with equivocal small bowel histologic findings since celiac disease is unlikely if neither is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/17\">",
"     17",
"    </a>",
"    ]. Homozygosity for HLA DQ2 has been associated with an increased risk for celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and enteropathy-associated T-cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-HLA locus genes conferring risk for celiac disease have also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and an increasing number of non-HLA risk alleles has been associated with an increased risk of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genome wide association study in large numbers of patients with celiac disease and matched controls from the United Kingdom, Italy, and Ireland identified a number of genes involved in controlling immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, type 1 diabetes and celiac disease share common genetic risk regions (including HLA-DQ). However, the new polymorphisms, even when taken together, contribute only 3 to 4 percent to the genetic risk for celiac disease, as compared with 30 to 40 percent for HLA-DQ2 or -DQ8.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serum autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic studies are now used to further confirm the diagnosis of celiac disease. These include the ELISA for IgA antibodies to gliadin and the immunofluorescence test for IgA antibodies to endomysium, a structure of the smooth muscle connective tissue, the presence of which is virtually pathognomonic for celiac disease (",
"    <a class=\"graphic graphic_table graphicRef80588 \" href=\"mobipreview.htm?5/38/5739\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/21\">",
"     21",
"    </a>",
"    ]. The target autoantigen contained within the endomysium was identified as tissue transglutaminase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/22\">",
"     22",
"    </a>",
"    ]. IgA-antibodies against endomysium and the endomysial autoantigen tissue transglutaminase are highly sensitive and specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Some studies also revealed a high sensitivity and specificity for IgG antibodies against deamidated gluten peptides, almost reaching that of IgA anti-transglutaminase antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Widespread use of these serologic tests has allowed earlier diagnosis, large scale population screening and thereby an improved understanding of its epidemiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gliadin reactive T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue transglutaminase is a ubiquitous intracellular enzyme that is released by inflammatory and endothelial cells and fibroblasts in response to mechanical irritation or inflammation. Once it has been secreted, it crosslinks glutamine-rich proteins such as gluten proteins from wheat. However, it can also deamidate glutamine residues in gluten to glutamic acid. Deamidation produces a negative charge in gluten peptides that increases their binding to HLA-DQ2 and DQ8, which potentiates their capacity to stimulate T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies suggested that, in adult patients, the dominant epitope responsible for the T-cell response appeared to be a deamidated glutamine residue (Q65E) of alpha gliadin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, younger patients appeared to have a less restricted T-cell response with reactivity to a diverse set of gliadin and glutenin peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/31\">",
"     31",
"    </a>",
"    ]. This suggested that there may be a broad group of different gluten peptides that activate celiac disease in children, while with advancing age the T-cell response narrows to only a few deamidated peptides. However, a later study suggests that there is a broader range of gliadin peptides recognized by T cells in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common feature is the recognition of epitopes in gliadins that are located in regions rich in proline residues. A 33 amino acid peptide (A-gliadin, peptide 56-89) that is particularly resistant to gastrointestinal peptidases has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/33\">",
"     33",
"    </a>",
"    ]. One study demonstrated that this peptide can be completely degraded by enterocytes in controls but only partly in celiac patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/34\">",
"     34",
"    </a>",
"    ]. Enterocytes from patients with celiac disease also showed only limited digestion of peptide 31-49 of A-gliadin, a peptide that is not recognized by",
"    <span class=\"nowrap\">",
"     HLA-DQ2/DQ8.",
"    </span>",
"    The high stability against proteolysis or the incomplete degradation of these gliadin peptides favors them as important initiators of the inflammatory response and toxic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate responses to wheat proteins (in addition to gluten-mediated activation of pathogenic T cells) are also involved in the immune response, and perhaps even necessary to trigger the gliadin specific (adaptive) T cell response in genetically predisposed individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/35\">",
"     35",
"    </a>",
"    ]. The innate immune system uses \"pattern recognition receptors\" to provide an early response to stimuli such as RNA, DNA, lipopolysaccharide, or viral proteins in contrast to the adaptive immune system, which depends upon HLA-presentation of antigen, its T-cell recognition and T-cell expansion. In celiac disease, gluten peptides have been implicated as triggers of innate immune responses in intestinal epithelial but also in mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this was not confirmed in a study which identified a family of non-gluten proteins, the wheat amylase-trypsin inhibitors (ATIs), as activators of innate immunity in macrophages, monocytes and dendritic cells via toll-like receptor 4, the receptor for bacterial lipopolysaccharide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/42\">",
"     42",
"    </a>",
"    ]. Notably, these ATIs are pest resistance proteins of gluten containing cereals, whose content has increased in the last few decades. ATIs are highly resistant to intestinal degradation and induce low level intestinal inflammation after oral ingestion. They are possibly the major cause of nonceliac &ldquo;gluten sensitivity&rdquo;, which is defined as dose-dependent intolerance to gluten containing cereals after exclusion of celiac disease or wheat allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of celiac disease\", section on 'Suggestive clinical features but negative serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autoantibodies and intraepithelial lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative pathogenic importance of humoral versus the established role of cellular immunity in the pathogenesis of celiac disease is uncertain. In a cell culture system, autoantibodies to tissue transglutaminase blocked intestinal epithelial differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/28,45\">",
"     28,45",
"    </a>",
"    ]. Tissue transglutaminase may support the bioactivation of transforming growth factor beta 1, which is required for epithelial differentiation, a process that is impaired in celiac disease. Some inhibitory effect of isolated autoantibodies on tissue transglutaminase activity was also demonstrated in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/46\">",
"     46",
"    </a>",
"    ]. However, residual enzymatic activity appears to be sufficient for protein crosslinking and (gliadin) deamidation reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/47\">",
"     47",
"    </a>",
"    ]. Therefore, the mucosal tTG activity in celiac disease, which cannot be completely blocked by the locally produced autoantibodies, may have a role in the pathogenesis of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/27,48\">",
"     27,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of intraepithelial lymphocytes, which mainly bear the unusual gamma-delta T cell receptor, is increased in patients with active, gluten-sensitive sprue compared with normal subjects, while patients with refractory sprue (which is of uncertain relationship to celiac disease) also have aberrant lymphocytes with restricted gene rearrangements. The intraepithelial T lymphocytes show increased expression of interferon gamma and IL-10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the pathogenetic role of these lymphocytes, compared with the lamina propria lymphocytes, is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/50\">",
"     50",
"    </a>",
"    ], and several inflammatory conditions, such as enteric infections and drug and food allergies that are unrelated to celiac disease can cause intraepithelial lymphocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gliadin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gliadin receptor(s) on intestinal epithelial cells may mediate the transport of gliadin peptides to the lamina propria where T cell activation occurs. Identification of the receptors could lead to non-dietary therapies of celiac disease by creating drugs that interfere with receptor function. A study found that CD71 (the transferrin receptor) was increased in patients with celiac disease and was also expressed at the apical pole of enterocytes, in contrast to its usual location at the basolateral pole of enterocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/52\">",
"     52",
"    </a>",
"    ]. CD71 colocalized with secretory IgA and seemed to be responsible for the apical to basal retrotransport of secretory IgA. The authors concluded gluten peptides that are bound to secretory IgA (ie, IgA anti-gliadin antibodies) may be protected from degradation by the enterocytes, leading to accumulation in the lamina propria where T cell stimulation occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study showed the colocalization of gliadin with the chemokine receptor CXCR3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/53\">",
"     53",
"    </a>",
"    ]. CXCR3 is usually expressed on T cells where it mediates their recruitment to sites of inflammation. Somewhat unexpectedly, CXCR3 was found on enterocytes, and increased levels were detected in intestinal tissue of patients with active celiac disease. The increased levels returned to baseline after introduction of a gluten-free diet. In cell lines, binding of gliadin to CXCR3 was followed by the recruitment of MyD88, which led to enhanced intestinal permeability.",
"   </p>",
"   <p>",
"    Several questions remain unanswered and final proof of a central and specific gliadin (gluten) receptor on intestinal epithelial cells remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease occurs primarily in whites of northern European ancestry. Reports in the 1950s suggested that the prevalence of celiac disease among Europeans ranged between 1:4000 and 1:8000. However, this diagnosis was based upon a clinical presentation with classic symptoms of malabsorption.",
"   </p>",
"   <p>",
"    The picture changed in the 1970s with rising awareness of the often oligosymptomatic form of celiac disease and the advent of sensitive and specific serologic assays for IgA antibodies to gliadin and endomysium. In a report from Denmark, screening assays increased the estimated prevalence of celiac disease from 1:10,000 to 1:300 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/54\">",
"     54",
"    </a>",
"    ]. In another cross-sectional study of 7798 individuals ages six years and older conducted in the United States, 1:141 individuals had either previously been diagnosed with celiac disease or had positive IgA antibodies to tissue transglutaminase and endomysium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/55\">",
"     55",
"    </a>",
"    ]. Epidemiological studies using these tests with biopsy verification have reported prevalences of 1:70 to 1:300 in most countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of screening for asymptomatic celiac disease has not yet been established. Screening could result in the recognition and treatment of unrecognized nutritional deficiency states, resolution of mild symptoms, and a potential reduction in the risk for malignancy. However, these benefits require compliance of asymptomatic patients with a difficult dietary regimen which can reduce quality of life.",
"   </p>",
"   <p>",
"    Screening programs based upon antibody testing have demonstrated a high prevalence of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/21,22,57-62\">",
"     21,22,57-62",
"    </a>",
"    ]. In a screening study of 4615 adults from northern Italy, for example, IgA endomysial antibodies had a positive predictive value of 100 percent; comparable values for IgG and IgA antigliadin antibodies were only 2 and 12 percent, respectively, because of their lower specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Population-based studies have suggested that recognized cases of celiac disease may only represent the tip of the celiac iceberg. One of the largest screening investigations of celiac disease was performed in 17,201 school children, aged 6 to 15 years, who were recruited from several regions of Italy and represented 69 percent of the eligible population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/57\">",
"     57",
"    </a>",
"    ]. The prevalence was 1:184 and the ratio of undiagnosed to diagnosed celiac disease was a remarkable 7:1 (",
"    <a class=\"graphic graphic_table graphicRef57975 \" href=\"mobipreview.htm?21/31/22011\">",
"     table 2",
"    </a>",
"    ); most children had minor but significant nonspecific symptoms. Based upon these data, it was estimated that the number of affected persons in Italy alone was 220,000, three-quarters of whom were unidentified and only about 5 percent of whom were in an organized celiac society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening investigation of 1,823 participants of the Belfast MONICA project for coronary risk factors detected 10 biopsy-proven new celiacs between 36 and 61 years of age, most of whom had iron or folate deficiency or nonspecific intestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/64\">",
"     64",
"    </a>",
"    ]. Together with the two known cases, the prevalence was 1:152. A similar prevalence (1:256) was noted in a screening study of 1866 Swedish blood donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/58\">",
"     58",
"    </a>",
"    ] and even higher prevalences (1:99 and 1:96, respectively) were observed in studies of 3654 Finnish students and 3188 Italian school children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/22,59\">",
"     22,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies describe an increasing prevalence of celiac disease with age. An Italian survey documented that approximately 15 percent of newly diagnosed patients are older than 65 years and these patients very often suffer from symptoms for 11&plusmn;19 years prior to correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/65\">",
"     65",
"    </a>",
"    ]. A study from Finland showed a prevalence of biopsy proven celiac disease of 2 percent for individuals aged between 52 and 74 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest studies in the United States included 13,145 subjects (4508 first-degree relatives of patients with celiac disease, 1275 second-degree relatives, 3236 symptomatic patients, and 4126 not-at-risk individuals) who underwent screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/60\">",
"     60",
"    </a>",
"    ]. In the at-risk groups, the prevalence of celiac disease was 1:22 in first-degree relatives, 1:39 in second-degree relatives, 1:56 in symptomatic patients, and 1:133 in the not-at-risk groups. These estimates are similar to those found in the European studies described above.",
"   </p>",
"   <p>",
"    Even those not ethnically derived from European populations can develop celiac disease if they have an appropriate genetic background. Punjabis and Gujaratis from India who lived in England developed this disorder 2.7 times as often as Europeans when on a gluten-rich diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years, celiac disease was defined by a set of classic standards for diagnosis. However, the combination of serologic, genetic, and histologic data has led to the identification of two other classes of celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Classic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic definition of celiac disease or gluten-sensitive enteropathy includes the following three features: villous atrophy; symptoms of malabsorption such as steatorrhea, weight loss, or other signs of nutrient or vitamin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/7\">",
"     7",
"    </a>",
"    ]; and resolution of the mucosal lesions and symptoms upon withdrawal of gluten-containing foods, usually within a few weeks to months. Patients with classic disease present with diarrhea, weight loss, or malabsorption, and possess antibodies against gliadin and especially tissue transglutaminase.",
"   </p>",
"   <p>",
"    The severity of histologic changes in the small bowel does not necessarily correlate with the severity of clinical manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/67\">",
"     67",
"    </a>",
"    ]. Although there is a gradient of decreasing severity from the proximal to the distal small intestine, correlating with the higher proximal concentration of dietary gluten, sampling error can occur due to spotty features of mucosal inflammation. The histologic severity ranges from a mild alteration characterized by increased intraepithelial lymphocytes (type 0 lesion) to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis and crypt hyperplasia (type 3 lesion) (",
"    <a class=\"graphic graphic_picture graphicRef76680 \" href=\"mobipreview.htm?23/30/24041\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/7,68-72\">",
"     7,68-72",
"    </a>",
"    ]. The type 4 lesion has the same histologic features seen in the type 3 lesion, except that lamina propria hyperplasia becomes hypoplasia. The type 4 lesion is characteristic of T cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of celiac disease\", section on 'Small bowel biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to improve on a gluten-free diet is mostly due to poor dietary compliance or other underlying malabsorptive disorders. However, in rare cases diet-refractory celiac disease may be related to sprue-associated, enteropathy-associated T-cell lymphoma (EATL) or extremely seldom to collagenous sprue, a related but little understood disorder, which is characterized by subepithelial collagen depositions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/73\">",
"     73",
"    </a>",
"    ]. As noted above, some patients with refractory disease have aberrant intraepithelial lymphocytes with restricted gene rearrangements; the relation of this finding to the resistance to gluten restriction is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1149418263\">",
"    <span class=\"h2\">",
"     Atypical celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atypical disease exhibit only minor gastrointestinal complaints. They can display anemia, dental enamel defects, osteoporosis, arthritis, increased transaminases, neurological symptoms, or infertility. However, most of these patients show severe mucosal damage and possess the celiac specific antibody pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1149418271\">",
"    <span class=\"h2\">",
"     Asymptomatic (silent) celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are often recognized incidentally based upon screenings for antibodies against gliadin or tissue transglutaminase. Although these patients very often display the characteristic architectural remodelling of the intestinal mucosa seen in celiac disease (ie, crypt hyperplasia and villous atrophy), they do not show clinical symptoms. Often minor symptoms (eg, fatigue) are only realized after introduction of a gluten free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Latent celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some patients who have normal jejunal mucosa and minor symptoms or no symptoms at one or more time points while on a normal, gluten-containing diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/72\">",
"     72",
"    </a>",
"    ]. Two variants of what has been called latent celiac disease have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac disease was present before, usually in childhood; the patient recovered completely with a gluten-free diet, remaining \"silent\" even when a normal diet was reintroduced. About 20 percent of such patients continue to have latent disease (asymptomatic with normal villous architecture) into adulthood, while the others re-develop variable degrees of villous atrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/74\">",
"       74",
"      </a>",
"      ]. Latency may be transient and thus regular follow up of such patients is warranted.",
"     </li>",
"     <li>",
"      A normal mucosa was diagnosed at an earlier occasion while ingesting a normal diet, but celiac disease developed later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although classically a disease of infants, celiac disease now often presents later, between the ages of 10 and 40 years. Thus, the impressive clinical picture of a child with life-threatening malabsorption is often replaced by the mostly atypical presentation of adult celiac disease. This is in part due to longer periods of breast-feeding and the later introduction of gluten in the infant diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23610802\">",
"    <span class=\"h2\">",
"     Gastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present with classic signs, including diarrhea with bulky, foul-smelling, floating stools due to steatorrhea and flatulence. These symptoms are paralleled by the consequences of malabsorption, such as growth failure in children, weight loss, severe anemia, neurologic disorders from deficiencies of B vitamins, and osteopenia from deficiency of vitamin D and calcium.",
"   </p>",
"   <p>",
"    However, there is a shift from patients presenting with classic celiac disease to more patients with atypical symptoms or an asymptomatic presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/75\">",
"     75",
"    </a>",
"    ]. In one meta-analysis that included 3383 individuals with celiac disease, the pooled prevalence of irritable bowel syndrome-type symptoms was 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult patients with undiagnosed celiac disease rarely present with profuse diarrhea and severe metabolic disturbances (celiac crisis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Subclinical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and widespread availability of serologic screening has led to the understanding that celiac disease can exist in a very mild form and may go largely undetected, since most patients have mild and unspecific symptoms, such as fatigue, borderline iron deficiency (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Iron deficiency'",
"    </a>",
"    below), or otherwise unexplained elevations in serum aminotransferases, or no symptoms at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/78\">",
"     78",
"    </a>",
"    ]. Some patients are identified because of the physician's increased awareness. Those without any specific complaints may be diagnosed during screening programs or during endoscopy performed for other reasons (",
"    <a class=\"graphic graphic_picture graphicRef65969 \" href=\"mobipreview.htm?11/1/11281\">",
"     picture 2",
"    </a>",
"    ). Thus, celiac disease may represent a continuum with variable degrees of severity. One study suggested that the severity of disease correlated with the concentration of tissue transglutaminase antibody levels, but this correlation is weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing the diagnosis of subclinical celiac disease is of potential importance for four reasons: the danger of malignancy, the presence of unsuspected nutritional deficiencies, the association with low-birth weight infants in affected mothers, and the occurrence of autoimmune disorders. The risk of malignancy in patients with subclinical celiac disease is not known, although (as discussed above) it appears to be lower than in patients who present with malabsorption symptoms. However, once the disease is in remission with a gluten-free diet, the risk approaches that of the normal population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/80\">",
"     80",
"    </a>",
"    ]. Some studies have found that the prevalence of autoimmune diseases (eg, Type 1 diabetes mellitus, collagen vascular disease, autoimmune thyroiditis) is related to the duration of undetected celiac disease, and may reach more than 30 percent of patients diagnosed after age 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/81\">",
"     81",
"    </a>",
"    ]. However, this is likely to be related to common genetic predispositions, and the relationship between the duration of gluten exposure and the risk of autoimmune disorders remains unsettled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oligosymptomatic patients with celiac disease may have significant nutritional deficiencies. The 82 patients with celiac disease, mostly oligosymptomatic, detected by screening of the adolescent Italian population described above exhibited a number of important clinical and laboratory findings such as iron deficiency, recurrent abdominal pain, and mood changes (",
"    <a class=\"graphic graphic_table graphicRef77895 \" href=\"mobipreview.htm?40/38/41579\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/57\">",
"     57",
"    </a>",
"    ]. In another study, 31 percent of patients with subclinical disease (versus 67 percent with classic symptoms) were malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/83\">",
"     83",
"    </a>",
"    ]. Once on a gluten-free diet, all reported objective and subjective improvement of well-being, realizing symptoms that they had not recognized before.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nongastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nongastrointestinal manifestations of celiac disease have been described (",
"    <a class=\"graphic graphic_table graphicRef76981 \" href=\"mobipreview.htm?20/10/20651\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/84\">",
"     84",
"    </a>",
"    ]. In some patients, they are the presenting symptom and should prompt the consideration of serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neuropsychiatric disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described an association between celiac disease and neurologic or psychiatric symptoms such as headache, peripheral neuropathy, ataxia, depression, dysthymia, anxiety, and epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/85-99\">",
"     85-99",
"    </a>",
"    ]. One retrospective study also noted that patients with established celiac disease referred for neurological opinion had significant structural and functional brain deficits on MRI as compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/100\">",
"     100",
"    </a>",
"    ]. However, these studies are limited by small sample size, retrospective acquisition of data, tertiary referral bias, and potential misclassification of celiac disease as the diagnosis in some studies was based on the presence of gliadin antibodies rather than duodenal histology or more specific autoantibodies.",
"   </p>",
"   <p>",
"    Peripheral neuropathies, characterized by burning, tingling, and numbness in hands and feet, have been described in up to 50 percent of patients with celiac disease and may precede its diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/86\">",
"     86",
"    </a>",
"    ]. In a large population-based study from Sweden that included 14,000 celiac patients and 70,000 controls, celiac disease was associated with an increased risk of polyneuropathy (hazard ratio 3.4), but not with other neurologic outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with celiac disease, neuropathies may also be associated with lymphoma and deficiencies of vitamins B1 (thiamine), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B12 (cobalamine), and E. However, vitamin deficiency syndromes are uncommon in the absence of severe and extensive small bowel involvement. While a gluten-free diet has been shown to have a favorable effect on headache and dysthymia, it has not been demonstrated to improve peripheral neuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/85,102\">",
"     85,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between celiac disease with depression and epilepsy is still unclear as studies have yielded contradictory results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A higher prevalence of osteoarthritis has been described in celiac disease, but whether there is a causal relationship is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25289?source=see_link&amp;anchor=H21#H21\">",
"     \"Arthritis associated with gastrointestinal disease\", section on 'Celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease may be a surprisingly frequent cause of iron deficiency anemia. One study of 93 patients presenting for evaluation of iron deficiency anemia found 11 (12 percent) with small bowel biopsy findings compatible with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/106\">",
"     106",
"    </a>",
"    ]. Some had other mucosal abnormalities, such as esophagitis and gastritis, which could have been taken as the cause of the anemia and delayed the discovery of celiac disease. Similar findings were noted in another report in which 6 percent of 85 patients with iron deficiency anemia had celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/107\">",
"     107",
"    </a>",
"    ]. The incidence was 20 percent in the subgroup of nonresponders to supplemental iron.",
"   </p>",
"   <p>",
"    Some reports have suggested that celiac disease can be associated with occult gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/108\">",
"     108",
"    </a>",
"    ]. However, the positive results with colorimetric tests may have been due to excess loss of intestinal cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malabsorption of peroxidase-containing foods rather than loss of red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/109\">",
"     109",
"    </a>",
"    ]. Furthermore, one study found that occult bleeding was no more common in patients with celiac disease compared with a control population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/110\">",
"     110",
"    </a>",
"    ]. Thus, occult gastrointestinal bleeding may not be a major contributor to iron deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Metabolic bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic bone disease is common in celiac disease and can occur in patients without gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/111-113\">",
"     111-113",
"    </a>",
"    ]. In one study, for example, bone mineral density (BMD) and the prevalence of osteopenia and osteoporosis in 77 patients with celiac disease were compared with 157 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/78\">",
"     78",
"    </a>",
"    ]. Patients with celiac disease had significantly decreased BMD in the lumbar spine and femoral neck compared with controls (-6 and -5 percent, respectively). They were also significantly more likely to have osteoporosis of the lumbar spine (26 versus 5 percent). Osteoporosis of the femoral neck was uncommon in both groups. These patients have secondary hyperparathyroidism that is probably due to vitamin D deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/114\">",
"     114",
"    </a>",
"    ]. Osteomalacia due to vitamin D deficiency is also sometimes seen, although its exact prevalence is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, loss of bone density in the peripheral skeleton may persist despite apparent normalization at axial skeletal sites after patients are on a gluten free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/114\">",
"     114",
"    </a>",
"    ]. In contrast, in a study of 30 children and adolescents maintained on a long-term gluten-free diet (average 10.7 years), bone mineral density and serum markers of bone metabolism completely normalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/116\">",
"     116",
"    </a>",
"    ]. These parameters improved but did not reach normal levels in adults with late diagnosis and institution of a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/117\">",
"     117",
"    </a>",
"    ]. In another report, a gluten-free diet for only one year significantly improved spinal and femoral neck bone density in 19 newly diagnosed adult patients with clinically silent celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/113\">",
"     113",
"    </a>",
"    ]. The American Gastroenterological Association (AGA) guideline for osteoporosis in gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/118\">",
"     118",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The degree to which bone loss translates into an increased fracture risk in patients with celiac disease was investigated in a population-based cohort study that focused on 4732 patients with celiac disease who were compared with 23,620 age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/119\">",
"     119",
"    </a>",
"    ]. The overall hazard ratio for any fracture was 1.3 (95% CI 1.16-1.46). The absolute difference in the overall fracture rate was 3.2 per 1000 person-years. These data suggest that the risk of fractures is only slightly increased in patients with celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hyposplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have described hyposplenism in association with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/120-123\">",
"     120-123",
"    </a>",
"    ], the pathogenesis of which is unknown. Prophylactic pneumococcal vaccination has been suggested. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Hyposplenism and asplenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular IgA deposition is common, occurring in as many as one-third of patients. The great majority of affected patients have no clinical manifestations of renal disease, perhaps because there is no associated activation of complement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=see_link\">",
"     \"Pathogenesis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Idiopathic pulmonary hemosiderosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexistence of celiac disease and idiopathic pulmonary hemosiderosis, also known as Lane-Hamilton syndrome, has been reported in a number of cases, and introduction of a gluten-free diet has been associated with remission of pulmonary symptoms in several patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RISK OF MALIGNANCY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies have noted a small absolute increase in overall mortality in patients with celiac disease compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/124-134\">",
"     124-134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The magnitude of mortality risk and its relation to small bowel histopathology was evaluated in a retrospective cohort study from Sweden that included approximately 29,000 individuals with celiac disease (diagnosed by villous atrophy on small bowel biopsy), 13,000 individuals with only inflammation on biopsy, and 3700 individuals with normal mucosal histology but positive celiac disease serology (called latent celiac disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/124\">",
"       124",
"      </a>",
"      ]. At a median follow-up of seven to nine years, there was a significant absolute increase in mortality in all three groups (2.9, 10.8, and 1.7 per 1000 person-years, respectively). The higher absolute mortality among patients with inflammation is partly explained by their older age at study entry. The increase in mortality was largely due to cardiovascular disease and malignancy.",
"     </li>",
"     <li>",
"      A study of 9133 healthy adults who were in the United States Air Force evaluated stored sera collected between 1948 and 1954 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/125\">",
"       125",
"      </a>",
"      ]. A total of 14 patients (0.2 percent) were found to have undiagnosed celiac disease. Compared with an age-and sex-matched cohort who were seronegative, undiagnosed celiac disease was associated with an approximate fourfold increase in all-cause mortality.",
"     </li>",
"     <li>",
"      Population-based studies have found an association between celiac disease and cancer risk. The association appears to be strongest for lymphoma and gastrointestinal cancer. Estimates of the magnitude of risk have differed in various reports, many of which were small, based upon referral populations, and had several methodologic limitations. The increase in some studies was limited to non-Hodgkin's lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/132-134\">",
"       132-134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One of the largest population-based studies to address this issue included 12,000 patients with celiac disease or dermatitis herpetiformis identified from a Swedish registry between 1964 and 1994 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/129\">",
"       129",
"      </a>",
"      ]. Cancer was diagnosed in 249 patients during follow-up (standardized incidence ratio [SIR] 1.3, 95% CI 1.2-1.5), suggesting that the overall increase in cancer risk was modest, especially compared with previous reports. Furthermore, the risk declined with increasing length of follow-up and was not increased in children or adolescents. The most common malignancy was lymphoma (SIR 5.9), which accounted for 18 percent of all cancers (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67338 \" href=\"mobipreview.htm?0/44/704\">",
"       image 1",
"      </a>",
"      ). The risk of lymphoma was considerably lower than in several earlier reports, in which the risk was estimated to be increased 15- to 100-fold. The risk of other digestive tract cancers was also increased, including oropharyngeal (mostly esophageal squamous cell), small intestinal adenocarcinoma, colorectal, and hepatocellular. In contrast, there was a significantly reduced risk of breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another population-based study from the United Kingdom compared 4732 people with celiac disease with 23,620 matched controls who were included in a database between 1987 and 2002 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/135\">",
"       135",
"      </a>",
"      ]. There were a total of 134 malignancies in the celiac group (2.8 percent) The overall risk of malignancy was increased by approximately 30 percent (hazard ratio [HR] 1.29, 95% CI 1.06-1.55). The risk was highest for lymphoproliferative disease (HR 4.80) and gastrointestinal (GI) cancer (HR 1.85). Most cancers were detected in the first year after diagnosis. The study also confirmed a reduced risk of breast cancer (HR 0.35) and, in addition, found a reduced risk of lung cancer (0.34), the mechanisms for which are unclear.",
"     </li>",
"     <li>",
"      In a large Swedish cohort study which evaluated the risk of GI cancers in 28,882 patients with celiac disease (villous atrophy, Marsh score = 3), 12,860 with mild inflammation (Marsh score 1 to 2), and 3705 individuals with latent celiac disease (normal mucosa but positive serology), the risk of incident GI cancers was increased in all three groups in the first year of diagnosis (HR 5.95, 9.13, 8.10, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/136\">",
"       136",
"      </a>",
"      ]. Although the high incident cancer risk in the first year of diagnosis may be due to ascertainment bias, after the first year of diagnosis, the site-specific risk for small intestinal cancer and hepatocellular carcinoma was increased in patients with celiac disease (HR 2.22 and 1.78) and inflammation (HR 2.49 and 2.17).",
"     </li>",
"     <li>",
"      Furthermore, the same Swedish cohort revealed a significantly increased risk of lymphoproliferative malignancy in patients with villous atrophy (HR 2.82) compared with patients with intestinal inflammation but without villous atrophy (HR 1.81), but not in individuals with latent celiac disease (HR 0.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/137\">",
"       137",
"      </a>",
"      ]. This risk remained increased for five years or more after diagnosis. Individuals mainly suffered from Hodgkin lymphoma and T-cell or B-cell non-Hodgkin lymphomas. The risk for any solid cancer was increased in patients with villous atrophy in the first year after diagnosis but vanished in the follow-up period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether the degree of compliance with a gluten-free diet influences the rates of cancers is uncertain. In one study, the increased risk of non-Hodgkin lymphoma persisted for five years after diagnosis despite adherence to a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is frequently associated with dermatitis herpetiformis, Down syndrome, selective IgA deficiency, and other conditions which have autoimmune features such as type 1 diabetes mellitus, thyroid disease, and liver disease. Patients with celiac disease (and their families) may also be more likely to have atopic dermatitis compared with the general population, although the prevalence of other allergies is not increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dermatitis herpetiformis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical finding in dermatitis herpetiformis is the development of multiple intensely pruritic papules and vesicles that occur in grouped (&ldquo;herpetiform&rdquo;) arrangements. The elbows, dorsal forearms, knees, scalp, back, and buttocks are among the most common sites for lesion development (",
"    <a class=\"graphic graphic_picture graphicRef86749 graphicRef86750 graphicRef86751 graphicRef86752 graphicRef86768 graphicRef78315 \" href=\"mobipreview.htm?40/39/41594\">",
"     picture 3A-F",
"    </a>",
"    ). The face and groin are less frequent sites of involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H1643384077#H1643384077\">",
"     \"Dermatitis herpetiformis\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed histologically by the demonstration of granular IgA deposits along the nonaffected subepidermal basement membrane. Similar to celiac disease, antibodies against tissue transglutaminase (anti-tTG) are elevated in patients with the disease. The autoantibodies are directed mainly against epidermal transglutaminase, which shows high sequence homology to tTG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/139\">",
"     139",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H1643388880#H1643388880\">",
"     \"Dermatitis herpetiformis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dermatitis herpetiformis is common among patients with celiac disease. In an illustrative study, celiac disease was diagnosed in 398 of 147,000 people (prevalence of 1:369) in a population-based study in Finland, of whom 24 percent had dermatitis herpetiformis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/140\">",
"     140",
"    </a>",
"    ]. However, the prevalence of dermatitis among celiac patients may have been overestimated since the prevalence of celiac disease was lower than has been described in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/22\">",
"     22",
"    </a>",
"    ]. Precise estimates of the converse (ie, the proportion of patients with dermatitis herpetiformis who have celiac disease) are uncertain, but are probably in the range of 85 percent when the diagnosis of celiac disease has been based upon a mucosal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermatitis herpetiformis and celiac disease are associated with the same HLA-DQ alpha beta heterodimers, and dermatitis herpetiformis shares an association with other autoimmune conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/142-144\">",
"     142-144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H23341200#H23341200\">",
"     \"Dermatitis herpetiformis\", section on 'Associated diseases'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dermatitis herpetiformis responds to gluten withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/145\">",
"     145",
"    </a>",
"    ]. However, this may take several months or years without additional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. The treatment of dermatitis herpetiformis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H1643384165#H1643384165\">",
"     \"Dermatitis herpetiformis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is closely associated with type 1 diabetes mellitus and polyglandular autoimmune syndrome type III characterized by autoimmune thyroiditis combined with immune mediated diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/148-151\">",
"     148-151",
"    </a>",
"    ]. In several reports, between 2.6 and 7.8 percent of adults with type 1 diabetes had IgA autoantibodies to endomysium or to tissue transglutaminase; most such patients were proven to have celiac disease with small bowel biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Many such patients had no overt clinical manifestations of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/152\">",
"     152",
"    </a>",
"    ]. Other reports have demonstrated that as many as 3.5 percent of children of parents with type 1 diabetes have celiac disease, the prevalence of which increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 1 diabetes and celiac disease share multiple genetic loci such as HLA-DR3, HLA-DQ2 (HLA-DQ8) and several genetic variations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/13,127,155\">",
"     13,127,155",
"    </a>",
"    ]. This suggests that type 1 diabetes and celiac disease have common features in their pathogenesis such as tissue damage from autoimmunity or intolerance to dietary antigens. Approximately one-third of type 1 diabetics who have the celiac disease-predisposing haplotype HLA-DQ2 (which is found in 20 to 25 percent of the general Western population) have raised IgA autoantibodies to tissue transglutaminase and are therefore likely to have celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/156\">",
"     156",
"    </a>",
"    ]. This is in comparison to a prevalence of tissue transglutaminase autoantibodies in only 2 percent of those without HLA-DQ2.",
"   </p>",
"   <p>",
"    The age of onset and the severity of diabetes do not appear to be influenced by the presence of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/152\">",
"     152",
"    </a>",
"    ]. Furthermore, celiac disease does not appear to trigger autoimmunity leading to diabetes as suggested in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/157\">",
"     157",
"    </a>",
"    ] since celiac autoantibodies usually develop after the onset of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether a gluten-free diet improves diabetes in diabetic patients with celiac disease is unclear. Only two small studies, one retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/159\">",
"     159",
"    </a>",
"    ] and one short-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/149\">",
"     149",
"    </a>",
"    ], investigated the effect of a strict gluten-free diet on type 1 diabetics with silent celiac disease. Patients showed at best a trend toward an increased body mass index, but no change in folate or hemoglobin levels or insulin requirements. However, animal studies suggest that the interplay between gluten exposure and the intestinal immune system can modulate the development of type 1 diabetes. Substitutions of hydrolyzed casein instead of gluten in the diet delayed the onset of type 1 diabetes in BB rats, which spontaneously develop diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/160\">",
"     160",
"    </a>",
"    ], and a gluten-free diet reduced the incidence of type 1 diabetes in non-obese diabetic (NOD) mice from 64 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/161\">",
"     161",
"    </a>",
"    ]. Furthermore, the very early supplementation of newborns diet with gluten (&lt;3 months) showed an increased risk for islet autoantibodies, which precede type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/162\">",
"     162",
"    </a>",
"    ]. Thus, larger and prospective clinical studies are required to clarify the relationship between celiac disease, type 1 diabetes, and other secondary autoimmunities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Selective IgA deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between selective IgA deficiency and celiac disease appears to be well-established as screening programs have detected celiac disease in up to 8 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/163\">",
"     163",
"    </a>",
"    ]. On the other hand, selective IgA deficiency occurs in 1 to 2 percent of patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/164\">",
"     164",
"    </a>",
"    ]. Screening for celiac disease in patients with IgA deficiency is best done using an IgG test for tissue transglutaminase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a strong association between Down syndrome and celiac disease. The prevalence of biopsy proven celiac disease has been reported to be as high as 16 percent, representing a 20-fold increase compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/165,166\">",
"     165,166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, celiac disease may be associated with nonspecific mild chronic elevation in serum aminotransferase levels (AST ranging from 29 to 80, and ALT ranging from 60 to 130 with the ALT usually slightly greater than AST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/167,168\">",
"     167,168",
"    </a>",
"    ]). A meta-analysis found that in patients with cryptogenic hypertransaminasemia, celiac serologies were positive in six percent and duodenal biopsies suggested celiac disease in four percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/169\">",
"     169",
"    </a>",
"    ]. In addition, the meta-analysis found abnormal serum transaminases in 27 percent of patients with newly diagnosed celiac disease. When a gluten free diet was followed, serum transaminases normalized in 63 to 90 percent of patients within a year.",
"   </p>",
"   <p>",
"    Celiac disease has also been associated with advanced liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/170-172\">",
"     170-172",
"    </a>",
"    ]. One report, for example, focused on four patients with severe liver disease (due to congenital liver fibrosis, massive steatosis, and progressive hepatitis of unclear origin) and untreated celiac disease. Hepatic dysfunction reversed in all patients following a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/173\">",
"     173",
"    </a>",
"    ]. Celiac disease was also identified in 8 of 185 adult patients who had undergone liver transplantation. In six, celiac disease had been identified preoperatively; liver disease was due to primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, or congenital liver fibrosis. Two additional patients with celiac disease were identified through screening (one with autoimmune hepatitis and one with primary sclerosing cholangitis). Although the number of patients studied is small, these data suggest that celiac disease may contribute to or be the cause of serious liver disease, which may improve following a gluten-free diet.",
"   </p>",
"   <p>",
"    The association between celiac disease and primary biliary cirrhosis (PBC) has also been described in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/171\">",
"     171",
"    </a>",
"    ]. Two studies suggested a prevalence of 6 to 11 percent in patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/174,175\">",
"     174,175",
"    </a>",
"    ], although these may be overestimates. No cases of celiac disease were detected in 65 patients with PBC in a study from Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/176\">",
"     176",
"    </a>",
"    ]. Recognition of celiac disease in patients with PBC may be important since both diseases impact negatively upon bone mineralization and are risk factors for osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study evaluated the risk of liver disease in 13,818 patients with celiac disease from 1964 to 2003, with 66,584 age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/172\">",
"     172",
"    </a>",
"    ]. Celiac disease was associated with an increased risk of acute hepatitis, chronic hepatitis and primary sclerosing cholangitis. Adjustment for socioeconomic index or diabetes mellitus had no notable effect on the risk estimates. In addition, prior liver disease was associated with a statistically significant four- to six-fold increased risk of later celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased incidence of autoimmune thyroid disease among patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/177,178\">",
"     177,178",
"    </a>",
"    ]. Hypothyroidism is more frequent than hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23610960\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association of celiac disease with gastroesophageal reflux disease (GERD) has been reported. In a study of 133 patients with celiac disease and 70 healthy controls, patients with celiac disease had significantly higher GERD symptom scores when compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/179\">",
"     179",
"    </a>",
"    ]. Prior to treatment, 30 percent of patients with celiac disease reported moderate to severe symptoms compared with 6 percent of controls. Fifteen percent of patients with atypical or silent cases of celiac disease reported moderate to severe GERD. Three months after initiating a gluten-free diet, GERD symptom scores in patients with celiac disease were comparable to those in the healthy controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109822400\">",
"    <span class=\"h2\">",
"     Eosinophilic esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of eosinophilic esophagitis is increased in both children and adults with celiac disease (age-adjusted and sex-adjusted SIR 16.0, 95% CI 8.7-25.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/180-184\">",
"     180-184",
"    </a>",
"    ]. A diagnosis of eosinophilic esophagitis should be considered in patients with celiac disease and dysphagia or persistent reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1190789757\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have demonstrated an association between celiac disease and inflammatory bowel disease, more frequently with ulcerative colitis than Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. In one case-control study, the risk of IBD in patients with celiac disease was elevated 10-fold while the risk of celiac disease in patients with IBD was comparable to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/187\">",
"     187",
"    </a>",
"    ]. Of note, two independent studies have found a common proinflammatory polymorphism of the IL-23 receptor gene in both ulcerative colitis and celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/188,189\">",
"     188,189",
"    </a>",
"    ]. One study demonstrated that first-degree relatives of patients with celiac disease may be at a fivefold increased risk of developing ulcerative colitis as compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/190\">",
"     190",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Menstrual and reproductive issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with untreated celiac disease may have later menarche, earlier menopause, secondary amenorrhea, recurrent miscarriage, infertility, preterm delivery, and low birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/191-199\">",
"     191-199",
"    </a>",
"    ]. However, on a population basis, women with celiac disease have similar overall fertility to the general female population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/200\">",
"     200",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared 588 women with poor reproductive performance with 305 women with normal obstetrical histories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/194\">",
"     194",
"    </a>",
"    ]. None of the women in the study had classic gastrointestinal symptoms of celiac disease. Reproductive problems included were idiopathic recurrent abortion (104 women), unexplained stillbirth (104 women), unexplained infertility (230 women), and idiopathic intrauterine growth restriction (150 women). Women with poor reproductive performance were more likely to have positive serologic testing for celiac disease (IgA tTG).",
"   </p>",
"   <p>",
"    The prevalence of celiac disease in the various groups was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent spontaneous abortion: 6.7 percent",
"     </li>",
"     <li>",
"      Stillbirth: 5.7 percent",
"     </li>",
"     <li>",
"      Infertility: 5.6 percent",
"     </li>",
"     <li>",
"      Intrauterine growth restriction: 9.3 percent",
"     </li>",
"     <li>",
"      Control group: 1.3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the diagnosis of celiac disease was only based on serological testing and not further proven by duodenal histology, these data may be an overestimation.",
"   </p>",
"   <p>",
"    In addition, a cohort study that included 211 newborns found a threefold higher risk of intrauterine growth retardation among infants of mothers with undiagnosed celiac disease compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/201\">",
"     201",
"    </a>",
"    ]. Treatment of celiac disease appears to prevent these problems.",
"   </p>",
"   <p>",
"    Male infertility, characterized by abnormalities in sperm motility and morphology as well as a biochemical picture of androgen resistance (high serum testosterone and high LH concentrations), has been reported in celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/202,203\">",
"     202,203",
"    </a>",
"    ]. In one study of 41 men with celiac disease and high testosterone and LH concentrations, dietary modification led to normalization of the biochemical abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/203\">",
"     203",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11114?source=see_link\">",
"     \"Causes of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Myocarditis and cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reports from Italy suggest that celiac disease, which is often clinically unsuspected, accounts for as many as 5 percent of patients with autoimmune myocarditis or idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/204,205\">",
"     204,205",
"    </a>",
"    ]. In one report of nine such patients, none had classic gastrointestinal symptoms of celiac disease (recurrent abdominal pain, diarrhea, and weight loss), but all had iron deficiency anemia refractory to oral iron replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/204\">",
"     204",
"    </a>",
"    ]. Cardiac function improved following a gluten-free diet with or without immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Atrophic glossitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral lesions (erythema or atrophy) and a soreness or burning sensation of the tongue have been described in association with celiac disease and respond to a gluten free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/206\">",
"     206",
"    </a>",
"    ]. Oral symptoms are frequent in patients with classical celiac disease, thus the involvement of the oral cavity is a helpful tool in diagnosis of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/207\">",
"     207",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large database studies have described an increased risk of pancreatitis (both acute and chronic) in patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/208,209\">",
"     208,209",
"    </a>",
"    ]. Further studies are needed to clarify the strength of the association and potential mechanisms that underlie it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2894837\">",
"    <span class=\"h2\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that patients with celiac disease are at increased risk for ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/44/40650/abstract/124,210-213\">",
"     124,210-213",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/6/13410?source=see_link\">",
"       \"Patient information: Celiac disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/31/36339?source=see_link\">",
"       \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23610989\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac disease has been described primarily in individuals of European ancestry, but is increasingly found in populations of Northern Africa, the Middle East, India, and Northern China. Anti-tissue transglutaminase based screening programs have revealed a high prevalence of undiagnosed celiac disease, reaching 1 percent or more. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First degree relatives of patients with celiac disease have a 10 to 15 percent risk of celiac disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of (serologic screening detected) celiac disease correlates with the carrier state of the major genetic predisposition (HLA-DQ2&gt;HLA-DQ8) and a high wheat consumption. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with celiac disease may present with classic symptoms related to malabsorption, including diarrhea, steatorrhea, weight loss, and nutrient or vitamin deficiencies. However, the majority of patients with celiac disease exhibit only minor gastrointestinal complaints, have nongastrointestinal manifestations, or are asymptomatic. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Classic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23610802\">",
"       'Gastrointestinal manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Numerous autoimmune conditions are frequently associated with celiac disease including dermatitis herpetiformis, type 1 diabetes mellitus, and autoimmune thyroiditis. Patients with celiac disease should therefore be screened for these conditions. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serological screening for celiac disease is indicated in patients with autoimmune conditions associated with celiac disease and in first degree relatives of patients with celiac disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/1\">",
"      Booth CC. History of celiac disease. BMJ 1989; 298:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/2\">",
"      Haas SV. Celiac disease, its specific treatment and cure without nutritional relapse. JAMA 1932; 99:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/3\">",
"      Dicke WK. Simple dietary treatment for the syndrome of GheeHerter. Ned Tijdschr Geneeskd 1941; 85:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/4\">",
"      DICKE WK, WEIJERS HA, VAN DE KAMER JH. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 1953; 42:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/5\">",
"      VAN DE KAMER JH, WEIJERS HA, DICKE WK. Coeliac disease. IV. An investigation into the injurious constituents of wheat in connection with their action on patients with coeliac disease. Acta Paediatr 1953; 42:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/6\">",
"      PAULLEY JW. Observation on the aetiology of idiopathic steatorrhoea; jejunal and lymph-node biopsies. Br Med J 1954; 2:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/7\">",
"      RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC Jr. Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue. Gastroenterology 1960; 38:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/8\">",
"      AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/9\">",
"      Kagnoff MF. Celiac disease. A gastrointestinal disease with environmental, genetic, and immunologic components. Gastroenterol Clin North Am 1992; 21:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/10\">",
"      Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000; 119:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/11\">",
"      Petronzelli F, Bonamico M, Ferrante P, et al. Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann Hum Genet 1997; 61:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/12\">",
"      Houlston RS, Ford D. Genetics of coeliac disease. QJM 1996; 89:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/13\">",
"      Houlston RS, Tomlinson IP, Ford D, et al. Linkage analysis of candidate regions for coeliac disease genes. Hum Mol Genet 1997; 6:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/14\">",
"      Greco L, Corazza G, Babron MC, et al. Genome search in celiac disease. Am J Hum Genet 1998; 62:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/15\">",
"      Romanos J, van Diemen CC, Nolte IM, et al. Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. Gastroenterology 2009; 137:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/16\">",
"      Trynka G, Zhernakova A, Romanos J, et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 2009; 58:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/17\">",
"      Kaukinen K, Partanen J, M&auml;ki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002; 97:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/18\">",
"      Al-Toma A, Goerres MS, Meijer JW, et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006; 4:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/19\">",
"      Pietzak MM, Schofield TC, McGinniss MJ, Nakamura RM. Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. Clin Gastroenterol Hepatol 2009; 7:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/20\">",
"      Hunt KA, Zhernakova A, Turner G, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/21\">",
"      Pittschieler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Paediatr Suppl 1996; 412:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/22\">",
"      M&auml;ki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med 2003; 348:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/23\">",
"      Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/24\">",
"      Dieterich W, Laag E, Sch&ouml;pper H, et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 1998; 115:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/25\">",
"      Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998; 115:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/26\">",
"      Volta U, Granito A, Parisi C, et al. Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. J Clin Gastroenterol 2010; 44:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/27\">",
"      Molberg O, Mcadam SN, K&ouml;rner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/28\">",
"      Schuppan D, Dieterich W, Riecken EO. Exposing gliadin as a tasty food for lymphocytes. Nat Med 1998; 4:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/29\">",
"      van de Wal Y, Kooy Y, van Veelen P, et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998; 161:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/30\">",
"      Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/31\">",
"      Vader W, Kooy Y, Van Veelen P, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002; 122:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/32\">",
"      Arentz-Hansen H, McAdam SN, Molberg &Oslash;, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002; 123:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/33\">",
"      Shan L, Molberg &Oslash;, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/34\">",
"      Matysiak-Budnik T, Candalh C, Dugave C, et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 2003; 125:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/35\">",
"      Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003; 362:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/36\">",
"      Schuppan D, Esslinger B, Dieterich W. Innate immunity and coeliac disease. Lancet 2003; 362:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/37\">",
"      Jabri B, Kasarda DD, Green PH. Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 2005; 206:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/38\">",
"      Londei M, Ciacci C, Ricciardelli I, et al. Gliadin as a stimulator of innate responses in celiac disease. Mol Immunol 2005; 42:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/39\">",
"      Nikulina M, Habich C, Floh&eacute; SB, et al. Wheat gluten causes dendritic cell maturation and chemokine secretion. J Immunol 2004; 173:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/40\">",
"      Palov&aacute;-Jel&iacute;nkov&aacute; L, Rozkov&aacute; D, Pecharov&aacute; B, et al. Gliadin fragments induce phenotypic and functional maturation of human dendritic cells. J Immunol 2005; 175:7038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/41\">",
"      Cinova J, Palov&aacute;-Jel&iacute;nkov&aacute; L, Smythies LE, et al. Gliadin peptides activate blood monocytes from patients with celiac disease. J Clin Immunol 2007; 27:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/42\">",
"      Junker Y, Zeissig S, Kim SJ, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med 2012; 209:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/43\">",
"      Sapone A, Bai JC, Ciacci C, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med 2012; 10:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/44\">",
"      Volta U, De Giorgio R. New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol 2012; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/45\">",
"      Halttunen T, M&auml;ki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology 1999; 116:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/46\">",
"      Esposito C, Paparo F, Caputo I, et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut 2002; 51:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/47\">",
"      Dieterich W, Trapp D, Esslinger B, et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut 2003; 52:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/48\">",
"      Esposito C, Paparo F, Caputo I, et al. Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 2003; 98:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/49\">",
"      Forsberg G, Hernell O, Melgar S, et al. Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002; 123:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/50\">",
"      Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/51\">",
"      Brown I, Mino-Kenudson M, Deshpande V, Lauwers GY. Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. Arch Pathol Lab Med 2006; 130:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/52\">",
"      Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008; 205:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/53\">",
"      Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008; 135:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/54\">",
"      Ascher H, Kristiansson B. Childhood coeliac disease in Sweden. Lancet 1994; 344:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/55\">",
"      Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012; 107:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/56\">",
"      Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012; 18:6036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/57\">",
"      Catassi C, Fabiani E, R&auml;tsch IM, et al. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl 1996; 412:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/58\">",
"      Grodzinsky E. Screening for coeliac disease in apparently healthy blood donors. Acta Paediatr Suppl 1996; 412:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/59\">",
"      Tommasini A, Not T, Kiren V, et al. Mass screening for coeliac disease using antihuman transglutaminase antibody assay. Arch Dis Child 2004; 89:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/60\">",
"      Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/61\">",
"      Sher KS, Fraser RC, Wicks AC, Mayberry JF. High risk of coeliac disease in Punjabis. Epidemiological study in the south Asian and European populations of Leicestershire. Digestion 1993; 54:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/62\">",
"      Catassi C, Kryszak D, Louis-Jacques O, et al. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol 2007; 102:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/63\">",
"      Greco L, Percopo S. The coeliac disease task force \" Free from Gluten,\" \" Improved knowledge to cure coeliac disease\". Acta Paediatr Suppl 1996; 412:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/64\">",
"      Johnston SD, Watson RG, McMillan SA, et al. Preliminary results from follow-up of a large-scale population survey of antibodies to gliadin, reticulin and endomysium. Acta Paediatr Suppl 1996; 412:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/65\">",
"      Patel D, Kalkat P, Baisch D, Zipser R. Celiac disease in the elderly. Gerontology 2005; 51:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/66\">",
"      Vilppula A, Collin P, M&auml;ki M, et al. Undetected coeliac disease in the elderly: a biopsy-proven population-based study. Dig Liver Dis 2008; 40:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/67\">",
"      Zanini B, Caselani F, Magni A, et al. Celiac disease with mild enteropathy is not mild disease. Clin Gastroenterol Hepatol 2013; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/68\">",
"      Fry L, Seah PP, McMinn RM, Hoffbrand AV. Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. Br Med J 1972; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/69\">",
"      Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/70\">",
"      Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/71\">",
"      Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential. Gut 1993; 34:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/72\">",
"      Troncone R, Greco L, Mayer M, et al. Latent and potential coeliac disease. Acta Paediatr Suppl 1996; 412:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/73\">",
"      Gopal P, McKenna BJ. The collagenous gastroenteritides: similarities and differences. Arch Pathol Lab Med 2010; 134:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/74\">",
"      Matysiak-Budnik T, Malamut G, de Serre NP, et al. Long-term follow-up of 61 coeliac patients diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut 2007; 56:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/75\">",
"      Rampertab SD, Pooran N, Brar P, et al. Trends in the presentation of celiac disease. Am J Med 2006; 119:355.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/76\">",
"      Sainsbury A, Sanders DS, Ford AC. Prevalence of Irritable Bowel Syndrome-type Symptoms in Patients With Celiac Disease: A Meta-analysis. Clin Gastroenterol Hepatol 2013; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/77\">",
"      Jamma S, Rubio-Tapia A, Kelly CP, et al. Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol 2010; 8:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/78\">",
"      Bottaro G, Cataldo F, Rotolo N, et al. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 1999; 94:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/79\">",
"      West J, Logan RF, Hill PG, Khaw KT. The iceberg of celiac disease: what is below the waterline? Clin Gastroenterol Hepatol 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/80\">",
"      Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/81\">",
"      Ventura A, Magazz&ugrave; G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/82\">",
"      Sategna Guidetti C, Solerio E, Scaglione N, et al. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 2001; 49:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/83\">",
"      Corazza GR, Di Sario A, Sacco G, et al. Subclinical coeliac disease: an anthropometric assessment. J Intern Med 1994; 236:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/84\">",
"      Holmes GK. Non-malignant complications of coeliac disease. Acta Paediatr Suppl 1996; 412:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/85\">",
"      Cicarelli G, Della Rocca G, Amboni M, et al. Clinical and neurological abnormalities in adult celiac disease. Neurol Sci 2003; 24:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/86\">",
"      Chin RL, Sander HW, Brannagan TH, et al. Celiac neuropathy. Neurology 2003; 60:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/87\">",
"      Addolorato G, Stefanini GF, Capristo E, et al. Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality \"trait\" or a reactive illness? Hepatogastroenterology 1996; 43:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/88\">",
"      Hadjivassiliou M, Chattopadhyay AK, Davies-Jones GA, et al. Neuromuscular disorder as a presenting feature of coeliac disease. J Neurol Neurosurg Psychiatry 1997; 63:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/89\">",
"      Cronin CC, Jackson LM, Feighery C, et al. Coeliac disease and epilepsy. QJM 1998; 91:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/90\">",
"      Hu WT, Murray JA, Greenaway MC, et al. Cognitive impairment and celiac disease. Arch Neurol 2006; 63:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/91\">",
"      Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996; 347:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/92\">",
"      Hadjivassiliou M, Gr&uuml;newald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998; 352:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/93\">",
"      Hadjivassiliou M, Gr&uuml;newald RA, Lawden M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology 2001; 56:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/94\">",
"      Addolorato G, Di Giuda D, De Rossi G, et al. Regional cerebral hypoperfusion in patients with celiac disease. Am J Med 2004; 116:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/95\">",
"      Hadjivassiliou M, M&auml;ki M, Sanders DS, et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006; 66:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/96\">",
"      Banerji NK, Hurwitz LJ. Neurological manifestations in adult steatorrhoea (probable Gluten enteropathy). J Neurol Sci 1971; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/97\">",
"      Kaplan JG, Pack D, Horoupian D, et al. Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 1988; 38:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/98\">",
"      Usai P, Usai Satta P, Lai M, et al. Autonomic dysfunction and upper digestive functional disorders in untreated adult coeliac disease. Eur J Clin Invest 1997; 27:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/99\">",
"      Ludvigsson JF, Zingone F, Tomson T, et al. Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study. Neurology 2012; 78:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/100\">",
"      Currie S, Hadjivassiliou M, Clark MJ, et al. Should we be 'nervous' about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurological opinion. J Neurol Neurosurg Psychiatry 2012; 83:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/101\">",
"      Ludvigsson JF, Olsson T, Ekbom A, Montgomery SM. A population-based study of coeliac disease, neurodegenerative and neuroinflammatory diseases. Aliment Pharmacol Ther 2007; 25:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/102\">",
"      Luostarinen L, Himanen SL, Luostarinen M, et al. Neuromuscular and sensory disturbances in patients with well treated coeliac disease. J Neurol Neurosurg Psychiatry 2003; 74:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/103\">",
"      Ludvigsson JF, Reutfors J, Osby U, et al. Coeliac disease and risk of mood disorders--a general population-based cohort study. J Affect Disord 2007; 99:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/104\">",
"      Garud S, Leffler D, Dennis M, et al. Interaction between psychiatric and autoimmune disorders in coeliac disease patients in the Northeastern United States. Aliment Pharmacol Ther 2009; 29:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/105\">",
"      Lubrano E, Ciacci C, Ames PR, et al. The arthritis of coeliac disease: prevalence and pattern in 200 adult patients. Br J Rheumatol 1996; 35:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/106\">",
"      Ackerman Z, Eliakim R, Stalnikowicz R, Rachmilewitz D. Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. Am J Gastroenterol 1996; 91:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/107\">",
"      Carroccio A, Iannitto E, Cavataio F, et al. Sideropenic anemia and celiac disease: one study, two points of view. Dig Dis Sci 1998; 43:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/108\">",
"      Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996; 334:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/109\">",
"      Mant MJ, Bain VG, Maguire CG, et al. Prevalence of occult gastrointestinal bleeding in celiac disease. Clin Gastroenterol Hepatol 2006; 4:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/110\">",
"      Logan RF, Howarth GF, West J, et al. How often is a positive faecal occult blood test the result of coeliac disease? Eur J Gastroenterol Hepatol 2003; 15:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/111\">",
"      Kemppainen T, Kr&ouml;ger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone 1999; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/112\">",
"      Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/113\">",
"      Mustalahti K, Collin P, Siev&auml;nen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/114\">",
"      Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/115\">",
"      Fickling WE, McFarlane XA, Bhalla AK, Robertson DA. The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J 2001; 77:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/116\">",
"      Mora S, Barera G, Beccio S, et al. Bone density and bone metabolism are normal after long-term gluten-free diet in young celiac patients. Am J Gastroenterol 1999; 94:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/117\">",
"      Mora S, Weber G, Barera G, et al. Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr 1993; 57:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/118\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/119\">",
"      West J, Logan RF, Card TR, et al. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 2003; 125:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/120\">",
"      Carroccio A, Giannitrapani L, Di Prima L, et al. Extreme thrombocytosis as a sign of coeliac disease in the elderly: case report. Eur J Gastroenterol Hepatol 2002; 14:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/121\">",
"      Schmitz F, Herzig KH, St&uuml;ber E, et al. On the pathogenesis and clinical course of mesenteric lymph node cavitation and hyposplenism in coeliac disease. Int J Colorectal Dis 2002; 17:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/122\">",
"      Johnston SD, Robinson J. Fatal pneumococcal septicaemia in a coeliac patient. Eur J Gastroenterol Hepatol 1998; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/123\">",
"      McKinley M, Leibowitz S, Bronzo R, et al. Appropriate response to pneumococcal vaccine in celiac sprue. J Clin Gastroenterol 1995; 20:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/124\">",
"      Ludvigsson JF, Montgomery SM, Ekbom A, et al. Small-intestinal histopathology and mortality risk in celiac disease. JAMA 2009; 302:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/125\">",
"      Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009; 137:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/126\">",
"      Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology 1989; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/127\">",
"      Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001; 358:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/128\">",
"      Nielsen OH, Jacobsen O, Pedersen ER, et al. Non-tropical sprue. Malignant diseases and mortality rate. Scand J Gastroenterol 1985; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/129\">",
"      Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/130\">",
"      Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002; 287:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/131\">",
"      Anderson LA, McMillan SA, Watson RG, et al. Malignancy and mortality in a population-based cohort of patients with coeliac disease or \"gluten sensitivity\". World J Gastroenterol 2007; 13:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/132\">",
"      Green PH, Fleischauer AT, Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003; 115:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/133\">",
"      Card TR, West J, Holmes GK. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004; 20:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/134\">",
"      Grainge MJ, West J, Solaymani-Dodaran M, et al. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2012; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/135\">",
"      West J, Logan RF, Smith CJ, et al. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004; 329:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/136\">",
"      Elfstr&ouml;m P, Granath F, Ye W, Ludvigsson JF. Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease. Clin Gastroenterol Hepatol 2012; 10:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/137\">",
"      Elfstr&ouml;m P, Granath F, Ekstr&ouml;m Smedby K, et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst 2011; 103:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/138\">",
"      Ciacci C, Cavallaro R, Iovino P, et al. Allergy prevalence in adult celiac disease. J Allergy Clin Immunol 2004; 113:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/139\">",
"      S&aacute;rdy M, K&aacute;rp&aacute;ti S, Merkl B, et al. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/140\">",
"      Collin P, Reunala T, Rasmussen M, et al. High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J Gastroenterol 1997; 32:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/141\">",
"      Reunala T, Kosnai I, Karpati S, et al. Dermatitis herpetiformis: jejunal findings and skin response to gluten free diet. Arch Dis Child 1984; 59:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/142\">",
"      Balas A, Vicario JL, Zambrano A, et al. Absolute linkage of celiac disease and dermatitis herpetiformis to HLA-DQ. Tissue Antigens 1997; 50:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/143\">",
"      Spurkland A, Ingvarsson G, Falk ES, et al. Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 1997; 49:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/144\">",
"      Reunala T, Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997; 136:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/145\">",
"      Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/146\">",
"      Fry L, Leonard JN, Swain F, et al. Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/147\">",
"      Ermacora E, Prampolini L, Tribbia G, et al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol 1986; 15:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/148\">",
"      Schuppan D, Hahn EG. Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14 Suppl 1:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/149\">",
"      Acerini CL, Ahmed ML, Ross KM, et al. Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. Diabet Med 1998; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/150\">",
"      Cronin CC, Feighery A, Ferriss JB, et al. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am J Gastroenterol 1997; 92:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/151\">",
"      Talal AH, Murray JA, Goeken JA, Sivitz WI. Celiac disease in an adult population with insulin-dependent diabetes mellitus: use of endomysial antibody testing. Am J Gastroenterol 1997; 92:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/152\">",
"      Seissler J, Schott M, Boms S, et al. Autoantibodies to human tissue transgutaminase identify silent coeliac disease in Type I diabetes. Diabetologia 1999; 42:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/153\">",
"      Kordonouri O, Dieterich W, Schuppan D, et al. Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/154\">",
"      Hummel M, Bonifacio E, Stern M, et al. Development of celiac disease-associated antibodies in offspring of parents with type I diabetes. Diabetologia 2000; 43:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/155\">",
"      Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/156\">",
"      Bao F, Yu L, Babu S, et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies. J Autoimmun 1999; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/157\">",
"      Galli-Tsinopoulou A, Nousia-Arvanitakis S, Dracoulacos D, et al. Autoantibodies predicting diabetes mellitus type I in celiac disease. Horm Res 1999; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/158\">",
"      Saukkonen T, Savilahti E, Reijonen H, et al. Coeliac disease: frequent occurrence after clinical onset of insulin-dependent diabetes mellitus. Childhood Diabetes in Finland Study Group. Diabet Med 1996; 13:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/159\">",
"      Westman E, Ambler GR, Royle M, et al. Children with coeliac disease and insulin dependent diabetes mellitus--growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999; 12:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/160\">",
"      Meddings JB, Jarand J, Urbanski SJ, et al. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 1999; 276:G951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/161\">",
"      Funda DP, Kaas A, Bock T, et al. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999; 15:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/162\">",
"      Ziegler AG, Schmid S, Huber D, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003; 290:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/163\">",
"      Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/164\">",
"      Cataldo F, Marino V, Bottaro G, et al. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997; 131:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/165\">",
"      Gale L, Wimalaratna H, Brotodiharjo A, Duggan JM. Down's syndrome is strongly associated with coeliac disease. Gut 1997; 40:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/166\">",
"      Carlsson A, Axelsson I, Borulf S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antiendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics 1998; 101:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/167\">",
"      Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/168\">",
"      Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/169\">",
"      Sainsbury A, Sanders DS, Ford AC. Meta-analysis: Coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2011; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/170\">",
"      Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/171\">",
"      Duggan JM, Duggan AE. Systematic review: the liver in coeliac disease. Aliment Pharmacol Ther 2005; 21:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/172\">",
"      Ludvigsson JF, Elfstr&ouml;m P, Broom&eacute; U, et al. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/173\">",
"      Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002; 122:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/174\">",
"      Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998; 42:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/175\">",
"      Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol 1997; 25:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/176\">",
"      Bardella MT, Quatrini M, Zuin M, et al. Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J Gastroenterol 1997; 92:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/177\">",
"      Counsell CE, Taha A, Ruddell WS. Coeliac disease and autoimmune thyroid disease. Gut 1994; 35:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/178\">",
"      Badenhoop K, Dieterich W, Segni M, et al. HLA DQ2 and/or DQ8 is associated with celiac disease-specific autoantibodies to tissue transglutaminase in families with thyroid autoimmunity. Am J Gastroenterol 2001; 96:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/179\">",
"      Nachman F, V&aacute;zquez H, Gonz&aacute;lez A, et al. Gastroesophageal reflux symptoms in patients with celiac disease and the effects of a gluten-free diet. Clin Gastroenterol Hepatol 2011; 9:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/180\">",
"      Thompson JS, Lebwohl B, Reilly NR, et al. Increased incidence of eosinophilic esophagitis in children and adults with celiac disease. J Clin Gastroenterol 2012; 46:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/181\">",
"      Verzegnassi F, Bua J, De Angelis P, et al. Eosinophilic oesophagitis and coeliac disease: is it just a casual association? Gut 2007; 56:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/182\">",
"      Quaglietta L, Coccorullo P, Miele E, et al. Eosinophilic oesophagitis and coeliac disease: is there an association? Aliment Pharmacol Ther 2007; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/183\">",
"      Ooi CY, Day AS, Jackson R, et al. Eosinophilic esophagitis in children with celiac disease. J Gastroenterol Hepatol 2008; 23:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/184\">",
"      Leslie C, Mews C, Charles A, Ravikumara M. Celiac disease and eosinophilic esophagitis: a true association. J Pediatr Gastroenterol Nutr 2010; 50:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/185\">",
"      Breen EG, Coghlan G, Connolly EC, et al. Increased association of ulcerative colitis and coeliac disease. Ir J Med Sci 1987; 156:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/186\">",
"      Falchuk KR, Falchuk ZM. Selective immunoglobulin a deficiency, ulcerative colitis, and gluten-sensitive enteropathy--a unique association. Gastroenterology 1975; 69:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/187\">",
"      Leeds JS, H&ouml;roldt BS, Sidhu R, et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol 2007; 42:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/188\">",
"      Einarsdottir E, Koskinen LL, Dukes E, et al. IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet 2009; 10:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/189\">",
"      Glas J, Stallhofer J, Ripke S, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009; 104:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/190\">",
"      Shah A, Mayberry JF, Williams G, et al. Epidemiological survey of coeliac disease and inflammatory bowel disease in first-degree relatives of coeliac patients. Q J Med 1990; 74:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/191\">",
"      Rujner J. [Age at menarche in girls with celiac disease]. Ginekol Pol 1999; 70:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/192\">",
"      Ferguson R, Holmes GK, Cooke WT. Coeliac disease, fertility, and pregnancy. Scand J Gastroenterol 1982; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/193\">",
"      Gasbarrini A, Torre ES, Trivellini C, et al. Recurrent spontaneous abortion and intrauterine fetal growth retardation as symptoms of coeliac disease. Lancet 2000; 356:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/194\">",
"      Kumar A, Meena M, Begum N, et al. Latent celiac disease in reproductive performance of women. Fertil Steril 2011; 95:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/195\">",
"      Sher KS, Mayberry JF. Female fertility, obstetric and gynaecological history in coeliac disease: a case control study. Acta Paediatr Suppl 1996; 412:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/196\">",
"      Meloni GF, Dessole S, Vargiu N, et al. The prevalence of coeliac disease in infertility. Hum Reprod 1999; 14:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/197\">",
"      Collin P, Vilska S, Heinonen PK, et al. Infertility and coeliac disease. Gut 1996; 39:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/198\">",
"      Soni S, Badawy SZ. Celiac disease and its effect on human reproduction: a review. J Reprod Med 2010; 55:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/199\">",
"      Kiefte-de Jong JC, Jaddoe VW, Uitterlinden AG, et al. Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. Gastroenterology 2013; 144:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/200\">",
"      Tata LJ, Card TR, Logan RF, et al. Fertility and pregnancy-related events in women with celiac disease: a population-based cohort study. Gastroenterology 2005; 128:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/201\">",
"      N&oslash;rg&aring;rd B, Fonager K, S&oslash;rensen HT, Olsen J. Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/202\">",
"      Sher KS, Jayanthi V, Probert CS, et al. Infertility, obstetric and gynaecological problems in coeliac sprue. Dig Dis 1994; 12:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/203\">",
"      Farthing MJ, Rees LH, Edwards CR, Dawson AM. Male gonadal function in coeliac disease: 2. Sex hormones. Gut 1983; 24:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/204\">",
"      Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/205\">",
"      Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Lancet 1999; 354:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/206\">",
"      Pastore L, Lo Muzio L, Serpico R. Atrophic glossitis leading to the diagnosis of celiac disease. N Engl J Med 2007; 356:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/207\">",
"      L&auml;hteenoja H, Toivanen A, Viander M, et al. Oral mucosal changes in coeliac patients on a gluten-free diet. Eur J Oral Sci 1998; 106:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/208\">",
"      Ludvigsson JF, Montgomery SM, Ekbom A. Risk of pancreatitis in 14,000 individuals with celiac disease. Clin Gastroenterol Hepatol 2007; 5:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/209\">",
"      Sadr-Azodi O, Sanders DS, Murray JA, Ludvigsson JF. Patients with celiac disease have an increased risk for pancreatitis. Clin Gastroenterol Hepatol 2012; 10:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/210\">",
"      Ludvigsson JF, James S, Askling J, et al. Nationwide cohort study of risk of ischemic heart disease in patients with celiac disease. Circulation 2011; 123:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/211\">",
"      Ludvigsson JF, de Faire U, Ekbom A, Montgomery SM. Vascular disease in a population-based cohort of individuals hospitalised with coeliac disease. Heart 2007; 93:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/212\">",
"      Peters U, Askling J, Gridley G, et al. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 2003; 163:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/44/40650/abstract/213\">",
"      Wei L, Spiers E, Reynolds N, et al. The association between coeliac disease and cardiovascular disease. Aliment Pharmacol Ther 2008; 27:514.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4774 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-B3AA2FA6DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40650=[""].join("\n");
var outline_f39_44_40650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23610989\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serum autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gliadin reactive T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Innate immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autoantibodies and intraepithelial lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gliadin receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Classic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1149418263\">",
"      Atypical celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1149418271\">",
"      Asymptomatic (silent) celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Latent celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23610802\">",
"      Gastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Subclinical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nongastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neuropsychiatric disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Metabolic bone disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hyposplenism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RISK OF MALIGNANCY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Selective IgA deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23610960\">",
"      Gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109822400\">",
"      Eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1190789757\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Menstrual and reproductive issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Myocarditis and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Atrophic glossitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2894837\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610989\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4774|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/44/704\" title=\"diagnostic image 1\">",
"      Celiac lymphoma UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4774|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/30/24041\" title=\"picture 1\">",
"      Celiac disease Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/1/11281\" title=\"picture 2\">",
"      Celiac disease Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35155\" title=\"picture 3A\">",
"      Dermatitis herpetiformis knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/27/26032\" title=\"picture 3B\">",
"      Dermatitis herpetiformis buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/32/37377\" title=\"picture 3C\">",
"      Dermatitis herpetiformis knees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/24/32128\" title=\"picture 3D\">",
"      Dermatitis herpetiformis vesicles on elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/3/42032\" title=\"picture 3E\">",
"      Dermatitis herpetiformis papules and vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/38/24163\" title=\"picture 3F\">",
"      Dermatitis herpetiformis elbows",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/38/5739\" title=\"table 1\">",
"      Antibody screening for celiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/31/22011\" title=\"table 2\">",
"      Celiac screening in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/38/41579\" title=\"table 3\">",
"      Oligosymptomatic celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/10/20651\" title=\"table 4\">",
"      Nongastrointestinal sx celiac",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20233?source=related_link\">",
"      Pathogenesis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/6/13410?source=related_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_44_40651="Types of inborn errors of metabolism";
var content_f39_44_40651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of inborn errors of metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of intermediary metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amino acid metabolism and transport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatty acid oxidation and ketogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate metabolism and transport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin-related (cobalamin, folate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mineral metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial energy metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of biosynthesis and breakdown of complex molecules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purine and pyrimidine metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lysosomal storage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peroxisomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoprenoid and sterol metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile acid and heme metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycosylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipoprotein metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of neurotransmitter metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycine and serine metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pterin and biogenic amine metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gamma-aminobutyrate metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other (eg, pyridoxine-dependent or folinic acid-dependent seizures, sulfite oxidase deficiency)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Hoffman GF, Nyhan WL, Zschocke J, et al. Inherited metabolic diseases, Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40651=[""].join("\n");
var outline_f39_44_40651=null;
var title_f39_44_40652="Chronic eosinophilic leukemia WHO criteria";
var content_f39_44_40652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent peripheral blood eosinophilia (&ge;1500/microL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased numbers of bone marrow eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myeloblasts &lt;20 percent in peripheral blood or bone marrow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Conditions to be excluded",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Reactive eosinophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parasitic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infectious diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary disease (eg, hypersensitivity pneumonia, Loeffler's pneumonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Collagen vascular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neoplastic disorders with secondary reactive eosinophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T cell lymphomas (eg, mycosis fungoides, S&eacute;zary syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute lymphoblastic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neoplastic disorders in which eosinophils are part of the neoplastic clone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic myeloid leukemia (Ph1 + or BCR/ABL positive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute myeloid leukemia [eg, FAB M5Eo with inv(16), t(16;16)(p13;q22)]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other myeloproliferative disorders (eg, polycythemia vera, essential thrombocytosis, chronic idiopathic myelofibrosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        T cell population with aberrant phenotype and abnormal cytokine production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hypereosinophilic syndrome:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        This diagnosis is made if there is no demonstrable disease that could cause the eosinophilia, no abnormal T cell population, and no evidence for a clonal myeloid malignancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Chronic eosinophilic leukemia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        This diagnosis is made if all of the above exclusions have been met and if the myeloid cells demonstrate a clonal chromosomal abnormality, or are shown to be clonal by other means, or blast cells are present in the peripheral blood (&gt; 2 percent) or are increased in the bone marrow (&gt;5 to &lt;19 percent of nucleated cells).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bain B, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2001. p.49. Permission granted from Harris NL and Vardiman JW.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40652=[""].join("\n");
var outline_f39_44_40652=null;
var title_f39_44_40653="Contents: Pulmonology calculators";
var content_f39_44_40653=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pulmonology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/8/3205\">",
"           Calculator: APACHE II scoring system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/50/23329\">",
"           Calculator: BODE Index for COPD survival prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/29/17874\">",
"           Calculator: Epworth Sleepiness Scale (ESS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/35/40496\">",
"           Calculator: Pulmonary embolism Wells score",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/51/31539\">",
"           Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/31/24049\">",
"           Calculator: Diffusing capacity for carbon monoxide (DLCO) corrected for anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14497\">",
"           Calculator: Epoprostenol (Flolan) Infusion Rate Calculator",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/47/22257\">",
"           Calculator: In-Flight PaO2 Estimation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/13/12497\">",
"           Calculator: In-Flight PaO2 Estimation (using PFT's)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/7/34928\">",
"           Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/49/14098\">",
"           Calculator: Oxygenation index",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14481\">",
"           Calculator: Peak Expiratory Flow Prediction",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F31F6076E4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f39_44_40653=[""].join("\n");
var outline_f39_44_40653=null;
var title_f39_44_40654="History incompatible crossmatch";
var content_f39_44_40654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Clinical evaluation of patients with incompatible crossmatch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40654=[""].join("\n");
var outline_f39_44_40654=null;
var title_f39_44_40655="Steroid modifications";
var content_f39_44_40655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Steroid structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Structures of cortisol, cortisone, and several of the more commonly prescribed synthetic glucocorticoids, and the mineralo-corticoid fludrocortisone. Triamcinolone, a topical glucocorticoid, is identical to dexamethasone except for a 16 alpha hydroxyl group in place of the 16 alpha methyl group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_44_40655=[""].join("\n");
var outline_f39_44_40655=null;
